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This thesis deals with the use of Schiff base, amyloid peptide and benzotriazole scaffolds 
to synthesise 3d-4f and copper complexes and hybrid materials, investigate their catalytic 
properties and develop novel cost-, time- and step-efficient methodologies for the domino 
ring-opening/electrocyclization reaction of furfural and amines for the synthesis of trans-
4,5-diaminocyclopentenones and the corresponding Stenhouse salts, as well as the 
coupling of aldehyde, amine and alkyne for the synthesis of propargylamines, to replace 
existing catalytic protocols.   
 
Chapter 1 serves as a general introduction to the chemistry discussed in the thesis. The 
first part emphasises on the synthetic aspects of coordination complexes. A rationale 
regarding the selection of the employed ligands is presented. The second part presents an 
overview of methodologies in catalysis, related to the methodologies developed in the 
present thesis, towards the synthesis of the organic derivatives.  
 
Chapter 2 focuses on the synthesis and characterisation of a new bimetallic tetranuclear 
complex Ni2Dy2 and its use as a catalyst towards the domino ring-
opening/electrocyclization reaction of furfural and amines. The present catalytic system 
surpasses the efficiency of other reported systems, and the scope and limitations are 
described.  
 
Chapter 3 describes the first amyloid fibril core decorated by a heterometallic entity. The 
tetranuclear 3d-4f entity is of the type Zn2Dy2. The functionalized assembly behaves as a 
Lewis acid and catalyses the ring-opening/electrocyclization reaction of furfural and 
amines at a nanoscale level.  
 
Chapters 4 describes the synthesis and characterisation of a CuII complex with the use 
of a Schiff Base ligand, and its use as a catalyst towards the A3 coupling reaction. Control 
experiments, cyclic voltammetry and theoretical studies shed light on the mechanism of 
the reaction, suggesting the formation of an in situ radical specie.  
 
Chapter 5 reports the synthesis and characterisation of a relatively unexplored, in 
coordination chemistry and catalysis, hybrid pyridine-benzotriazole based CuII complex 
vii 
 
and its use towards the A3 coupling reaction. Control experiments, cyclic voltammetry 
and theoretical calculations account for a detailed mechanistic pathway and the 
development of an efficient methodology.  
 
Chapter 6 provides an overall conclusion of this thesis while highlighting the 
contributions of this work to the reported literature and discusses some potential future 
directions. Finally, experimental and synthetic details, as well as crystallographic data, 
are presented in Chapter 7 and Chapter 8, respectively. The bibliography is presented 
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1 Chapter 1: General introduction  
 
1.1 Coordination Complexes and Catalysis - a Broad Introduction  
Inorganic Chemistry is the chemistry of metals, which in the broadest sense is true, but 
also overlaps with other branches of Chemistry. An example is the chemistry of 
fullerenes, e.g. C60 and C70, which was the topic of the 1996 Nobel Prize in Chemistry to 
Harrold Kroto, Robert Curl and Richard Smalley. An understanding of the properties of 
fullerenes and related molecules and their multiple applications required studies by 
inorganic, organic and physical chemists, as well as by physicists and materials scientists. 
Nowadays, there is a significant overlap between Organic, Physical and Inorganic 
chemistry for the synthesis and characterisation of molecular materials, their behaviour 
in the solid-state and solution, their features and applications.   
 
Alfred Werner’s conceptual firepower of complexes and his explanation as regards to 
their behaviour - comparable to the tetrahedral carbon atom theory in Organic Chemistry 
- was the basis for the development of other dominant concepts and approaches in 
Inorganic Chemistry.1 Evolutionary developments for complexes involve their structural 
characterisation, thermodynamic and kinetic studies, as well as investigation of electronic 
properties. Revolutionary developments include bioinorganic chemistry, organometallic 
chemistry of elements such as transition metals, lanthanides and actinides, the catalytic 
activity of metals, stereochemical nonrigidity or fluxionality, metal-metal bonding, solid-
state chemistry and supramolecular chemistry.1 Topics related to the revolutionary 
developments mentioned above seem to be the ‘hottest’ research areas of Inorganic 
Chemistry in the first years of the third millennium. It is believed that there will be much 
intellectual satisfaction, scientific profit, practical assets and fun from advancing 
Inorganic Chemistry in the future.  
 
3d and 4f complexes attract the intense interest of the chemical community due to their 
relevance in many interdisciplinary scientific fields. They consist of discrete neutral 
entities or charged ions. The presence of metal ions gives rise to multiple properties and 
enables these compounds to control reactivity and function as catalysts. For example, 




cytochromes are Fe-based complexes and transfer electrons in many biological processes 
in the cells. In the field of homogeneous catalysis, a variety of 3d metal complexes in 
different oxidation states has been used, involving chemical bond activation and 
formation events.2 Due to the electrophilic nature of the metal centre, and the ligand’s 
versatility, complexes with tunable electronic properties and geometries, which permit 
control of reactivity can serve as ideal materials. The multiple properties and potential 
applications of complexes continuously generate the need for an arsenal in synthetic 
methods.  
 
In catalysis, various new concepts and strategies have been introduced to facilitate the 
formation of organic synthons. For example, recently, the methodologies of “multi-
functionalization” and “self-assembly” have been widely employed for the development 
of new catalysts. “Multifunctionalization” employs metal-metal and/or metal-ligand 
cooperations to realize chemical transformations as a natural enzyme does, providing the 
asset of rational catalyst design and reactivity control.3,4 The “self-assembly” strategy 
uses non-covalent interactions instead of covalent bonds to connect different units to 
generate supramolecular ligands and/or catalysts in situ. The later strategy is simple as 
regards to the catalyst synthesis but expands the variability of ligand and catalyst 
diversities.5  
 
Many cases have been reported in which the reaction mechanism indicates that the 
reactions take place solely on the metal centre in the form of reductive eliminations, 
oxidative additions, ligand substitutions, etc.2 Examples in which the ligand and the metal 
synergistically interact for the activation of substrates have also received much attention. 
These cooperating ligands are involved in a bond-breaking or/and forming step of the 
substrate or product through reversible chemical processes. There is cooperative 
interaction of the ligand, and the metal centre with the substrate(s) and such interactions 
promote the chemical transformation that cannot be independently achieved by the metal 
or the ligand. In most cases, metal-ligand cooperation events are observed only between 






1.2 3d-4f and Cu Coordination Complexes  
 
1.2.1 Classification 
Complexes ensemble of metal ion(s) in a positive oxidation state (electron-pair acceptors) 
linked to moieties of electron-pair donors (usually N, O, S and P), known as ligands, with 
the essential feature that coordination bonds are formed between them. The number of 
atoms coordinated to the metal is known as its coordination number (usually varying 
from 2 to 8). Ligands with several donor atoms can act as a linker for two to six metal 
centres to form discrete molecular entities known as Polymetallic Complexes (PMCs).7 
The metal core of PMCs can be either comprised of a single metal (homometallic) or 
combine two or more different metals (heterometallic). During the last few decades, the 
interest and rate of discovery of these molecules have increased exponentially due to 
advances in single-crystal X-ray crystallography, which has allowed the characterisation 












   
Scheme 1.1. (top) Classifcation of 0D coordination complexes. (bottom) Schematic 




nature of the ligand: (A) mononuclear complexes with monodentate ligands, (B) 
mononuclear complexes with multidentate (chelate/ pincer/ pocket-type/ macrocyclic) 
ligand(s), (C) PMCs with a covalently linked macrocyclic ligand, (D) PMCs with 
multidentate ligands forming a macrocyclic skeleton, (E) PMCs with multidentate ligands 
as molecular cages with a vacant inner space. The blue dots represent the metal centres 
and the black lines represent the ligands.8 
 
1.2.2 Metal selection   
The choice of metal sources in the design of complexes requires multiple parameters to 
be taken into consideration. These parameters include:  
 
(i) the coordination affinity to the donor atoms of the ligand, which determines the 
complex stability. Ligand prerequisites for the stabilization of discrete species should 
include multiple donor atoms to preferentially isolate or bridge metal ions, as well as 
bulky groups to isolate molecules from each other.9 According to the “Hard and Soft 
Acids and Bases” (HSAB) theory,10 3d and 4f metal ions have priority to coordinate with 
different donor atoms, such as nitrogen and oxygen, respectively. Therefore, by simply 
mixing 3d ions, 4f ions, and organic ligands it is possible to preferentially produce pure 
3d or 4f PMCs over 3d-4f PMCs.  
 
(ii) the coordination numbers. The oxidation state and the coordination number of a 3d 
ion can vary; for example, the oxidation state of manganese varies (from minus three to 
plus seven) while the coordination numbers vary from two up to seven.11 On the contrary, 
zinc has a limited number of oxidation states (Zn, ZnII), yet possesses coordination 
numbers ranging from two up to eight. The coordination patterns met in zinc-based 
metalloproteins are those with 4, 5 or 6 heteroatoms fulfilling the zinc coordination 
sphere, depending on the ligand nature.  The small size of the ZnII cation (~74 pm for four 
coordinate and ~88 pm for six-coordinate ion) prevents higher coordination numbers due 
to molecular repulsion and higher energy orbitals.12  “Soft” donor ligands such as 
imidazole/thiolate/chloride, yield complexes with coordination numbers up to four, 
whereas “hard” donors, like oxygen containing ligands, impose coordination numbers 





(iii) the preferred geometries. For example, copper in oxidation state I prefers a tetrahedral 
geometry, while in oxidation state II adopts an octahedral or square planar geometry.  
 
(iv) The electronic properties of the metals are one more important parameter. This allows 
the formation of unprecedented coordination modes and a range of reactivity to be 
explored. ZnII has filled d-orbitals (electronic configuration [Ar]3d10), thus is diamagnetic 
and permits monitoring by NMR. Zinc is estimated to be one of the most dominant co-
factors in biology, present in one-third of proteins in the human genome.13 The inherent 
“inertness” of this non-toxic metal, along with the coordination compatibility with many 
amino acid functional groups, both soft and hard base donors, are the main reasons of the 
multifunctional role of zinc in biological processes. Distinctive functions are the 
stabilization of the crystal or packing formation of biological oligomers and catalytic or 
co-catalytic role in essential enzyme reactions.13  
 
v) The intended, resulting application with cost-economical sources and environmentally 
benign procedures are also vital factors. In this trend of eco-friendly development, the 
chemistry of earth-abundant metals is primarily explored, as it offers a sustainable 
alternative to precious metals in the chemical synthesis. Low-cost transition metals like 
copper, iron, cobalt, nickel and manganese may exist in multiple oxidation states and are 
thus ideal for the design of complexes, with potential catalytic activity in redox reactions.  
Copper-based catalysts have attracted arising interest because of the abundance and low 
price of this element, contrary to noble-metals. Copper is present in earth crust in a 
proportion of 50 ppm (6982 USD per ton, January 2018).14 The variety of valence states 
(zero to plus three) leads to extensive redox properties, and potential applications in the 
development of in situ formed or well-characterised complexes.15,16 Copper ions are 
known to perform as cross-coupling agents, Lewis acids and oxidizing agents.17,18 The 
high affinity for π-bonds, for instance with triple alkyne bonds,19 enable copper to 
promote a variety of cycloadditions and other transformations.20 
 
Heterometallic 3d-4f PMCs have attracted attention since the first report in 1977 due to 
the inherent contribution of their d and f electrons and their unique exchange 
interactions.21 The topological arrangement of these molecular compounds can be diverse 
and strongly dependent on the geometrical preferences of the metal ions, the symmetries 




The main focus in d-f chemistry is the cluster-based molecular magnetic materials due to 
their great potential in high-density information-storage devices, quantum computers, 
spintronics and magnetocaloric materials.22–27 In catalysis, the presence of 3d and 4f with 
significantly different binding selectivity (3d vs 4f) will facilitate selective substrate-
binding; this feature is not feasible with monometallic catalysts. The 4f centres retain their 
catalytic activity in the presence of Lewis basic N-groups allowing their use with 
unprotected amines,28 whereas the 3d centres can be redox-active.29,30 Finally, cases of 
cooperative heterobimetallic catalysts have also been described in the literature.31 
 
1.2.3 Ligand Selection  
 





















Scheme 1.2. Representative examples of ligand types used for 3d and 4f PMC synthesis. 
 
Two broad synthetic routes are used for the preparation of new complexes. The first route 
is the “designed assembly”, characterized by the use of rigid ligands with predictable and 
controllable bridging modes, and metal ions with preferred coordination geometries. The 
second route is named “serendipitous assembly”, traditionally employed for the synthesis 
of PMCs,32 and uses poly-functional ligands that do not exhibit consistent ways of 
binding. The “designed assembly” has yielded a wide variety of complexes including 
Schiff base ligands,33,34  oximate-based ligands,35 ethanolamines,36 phosphonates,37 
carboxylates,38 pyridine-based,39 benzotriazoles40 and many other varying groups 




1.2.3.2 Schiff Base Ligands in 3d/4f Chemistry  
Schiff bases are named after Hugo Schiff who first reported the synthesis of the first 
members of this compound family in 1864. Since then, Schiff bases meet the continuous 
interest of chemical community due to their existence as intermediates in various organic 
transformations43 and the direct applications of their metal complexes in the fields of 
catalysis, supramolecular chemistry, magnetism, electrochemistry, nanoscience, and 
biology.44,45 The first synthesis of these compounds, containing azomethine (–HC=N–) 
or imine (–RC=N–) group, involved the condensation of a carbonyl compound (aldehyde 
or ketone) with a primary amine in refluxing conditions under azeotropic distillation.46 
The formation of Schiff bases, which is sometimes acid-catalysed, is a reversible reaction 
that proceeds via a carbinolamine intermediate; thus, removal of water is required.47 
Schiff bases that contain a phenyl group may show tautomerism between enol-imine and 
keto-amine in solution. This phenomenon of proton intake and abstraction in the nitrogen 
moiety is strongly dependent on the solvent and the carbonyl precursor and not in the 
stereochemistry or the N-substitution.47 Phenol-imine and keto-amine can also be present 
in the solid-state and X-Ray crystallography is the most reliable technique to determine 
the dominant species in the solid-state.48 For example, a shortening in the carbon-oxygen 
bond length (from 1.28 to 1.26 Å) and the lengthening of the imine carbon-nitrogen bond 
distance (from ca. 1.31 to 1.33 Å) indicate the predominance of the quinoidal structure 
(keto-amine form).47 Moreover, Schiff base imines can be reduced to amines using 
appropriate reducing agents.49 The appropriate selection of the carbonyl and amine 
precursors defines the structure-property relationship over a wide range of easily 
accessible azomethine materials. The structural and electronic fine-tunability with the use 
of bulky groups, the nature of the functional groups, the donor-atoms, the coordination 
“pockets” and the chelating moieties of the ligand provides control over the nature and 
properties of the resulting complexes.50–52  
 
The most commonly reported keto precursors used to synthesise Schiff base ligands in 
3d/4f PMCs are either o-vanillin (o-van) or salicylaldehyde (HSal) (Scheme 1.3). 
Whereas the choice of amine precursor varies, with two main broad categories which are 
designed either to bridge between metal ions (amino alcohol, amal) or to form a selective 






Scheme 1.3. (upper) The two main classes of reactions to form Schiff base ligands. 
(lower) Commonly used aldehydes and amines. 
  
Schiff base ligands have been designed for 3d-4f PMCs with low nuclearity (2, 3 or 4) 
and with a fixed number of metal ions in a specific arrangement. When 3d-4f PMCs are 
desired, the ligand compartments must be dissimilar and have a different set of donor 
ions. Specifically, LnIII metal ions are hard Lewis acids with high oxophilicity, and 3d 
metal ions are less oxophilic and have a higher preference for N donors; therefore, pockets 
can be designed accordingly.  
 
In early ’90s Jacobsen and Katsuki made an outstanding contribution in the fields of 
coordination chemistry and catalysis by independently reporting the catalytic asymmetric 
epoxidation of olefins using chiral mononuclear MnIII‒salen complexes, employing 
ligands with {N2O2} “pockets”.
53,54 This type of ligands contains four donor-atoms in 
such an array that promotes the coordination of only one metal. Since then, numerous 
reports have been published regarding well-characterized 3d-based complexes, supported 






























R1, R2: - 
tBu
            - CH3
            - H
            - F/ Cl/ Br
 
Scheme 1.4. (upper left) Common ligand of salen type for the synthesis of mononuclear 
complexes. (upper right) Common dinucleating salen-type ligand for the synthesis of 
dinuclear, trinuclear and tetranuclear 3d-4f PMCs.  Colour code: {N2O2} compartment, 
green; {O2O2} compartment, light blue.  
 
The use of a bi-compartmental/dinucleating Schiff base ligand for the synthesis of ZnII-
4f PMCs, which in turn were tested towards the Friedel–Crafts alkylation of 2-acyl 
imidazoles with indoles, has been recently reported by Kostakis and co-workers.62 In this 
example, the inner compartment {N2O2} hosts the Zn
II ion, while the outer compartment 
{O2O2} hosts the 4f ion (Y
III or DyIII) (Scheme 1.4).62 Many bimetallic complexes with 
bi-compartmental Schiff base ligands have been reported including MII-LnIII (selected 




invariant and tuning the other, it has been shown that valuable mechanistic information 
can be extracted by correlating product distributions and selectivity versus metal 
properties. Bi-compartmental Schiff base ligands have also been reported to construct 
crystallographically characterized PMCs with nuclearities higher than two, and the 
resulting PMCs have been employed in catalysis.67,68  
 
Another approach has applied amino alcohol (amal) (Scheme 1.5) derived Schiff base 
ligands which have been proven successful in synthesising high nuclearity 3d-4f PMCs. 
While these ligands have quite predictable coordination behaviour, with compartments 
for specific metal ion coordination (Scheme 1.5), the resultant structures cannot always 












Scheme 1.5. Amino-alcohol based Schiff base ligands with specific compartments for 














Scheme 1.6. Diastereoselective Michael addition of nitrostyrenes with barbituric acid as 




Hydrogen atoms and solvent molecules are omitted for clarity. Colour code: Zn (grey), Y 
(turquoise), C (grey), N (light blue), O (red).69  
 
Consequently, this type of Schiff base ligand has generated an array of 3d-4f PMCs, 




69,72  and NiII2Ln
III
2.
73,74 An example reported by 
Kostakis et al.  was the heterometallic PMC formulated as [Zn2Y2L
1
4(NO3)2(DMF)2] 
(1.1), and constructed using the amal-based ligand H2L1 = (E)-2-(2-hydroxy-3-
methoxybenzylideneamino)-5-nitrophenol (Scheme 1.6). The PMC was found to 
function as a 3d-4f cooperative catalyst for diastereoselective Michael addition of 









































Scheme 1.7. Ligands employed for the synthesis of complexes 1.1-1.8. 
 
1.2.3.3 Self-assembling Amyloid Peptide Ligands in 3d and 4f Chemistry.  
 
1.2.3.3.1 Binding Preferences 
The region of a protein molecule that participates in a metalloenzyme (ME) catalytic 
reaction is relatively small. The generation of artificial miniature enzymes has long been 




at low cost and provide mechanistic information. These enzymes aim to mimic the active 
sites without the additional architecture contributed by the protein fold.75 The need 
persists for metal catalysts with well-defined secondary coordination environments that 
can be readily and extensively fine-tuned for particular applications.  
 
Most protein chains fold correctly into a defined native structure. However, some proteins 
and peptides are capable of self-assembling to form amyloid fibrils, which are 
characterized by a regular cross-β architecture. Amyloid fibrils are known for their 
association with diseases, such as Alzheimer’s, Parkinson’s, type-II diabetes,76 as well as 
for their use as nanomaterials.77 The Amyloid-β (Αβ),78 and other amyloidogenic peptides 
form highly ordered supramolecular structures that assemble via hydrogen bonding, 
hydrophobic and electrostatic interactions, resulting in the formation of extremely stable 
fibrils. The fibrils have diameter 7-10 nm and lengths often exceeding several 
micrometers, regardless of their precursor protein.79  
 
 
Figure 1.1. (A) Schematic representation of the fibrillation process of Aβ peptide and 
metal ion/complex interactions on the fibril. (B) Ribbon representation of the lowest 
energy structure showing the alignment of the dimers along the fibril axis. Only residues 
15−42 are shown, PDB ID 5KK3.78  
 
Characteristic cross-β X-ray fibre diffraction (XRFD) from the amyloid core provides a 
characteristic 4.7-4.8 Å reflection on the meridian, which arises from the hydrogen-




the equator arises from the spacing between the β-sheets.80 Several prediction algorithms, 
like Maurer-Stroh,81 along with  experimental data, suggest that aromatic residues, such 
as phenylalanine (Phe) and tyrosine (Tyr) are important for amyloidogenicity as they are 
found to drive self-assembly within numerous sequences through π-π stacking 
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Scheme 1.8. Proposed coordination sites of CuII (A), CuI (B), FeII (C), and ZnII (D) ions 
to the soluble forms of Aβ peptide.83 
 
The amphiphilic peptide backbone containing both hydrophobic and hydrophilic groups 
facilitate self-assembly, fibrillar stability and intersheet stability, as well as further 
functionalization. Cysteine (Cys) and histidine (His) with S and N donor-atoms 
respectively are known for their dominant presence in the first coordination sphere of 
many natural and artificial metalloproteins containing 3d metals. Strong coordination is 
also observed between metal ions and the peptidic moieties of aspartic acid (Asp), 
glutamic acid (Glu) and tryptophan (Trp). The fluorescence signal of the  Tyr10 residue 
has been beneficial for monitoring the metal-induced conformational changes of Aβ 
peptides, and for studying metal-peptide complexes.3,95  The number of 
crystallographically characterized Zn-His bonds were calculated to be three orders of 
magnitude higher than the number of molecules that contain -OH groups, such as serine 
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Scheme 1.9. Coordination dynamics of: (upper) zinc (grey sphere) in Cys, His, Glu;86 
(lower)  3d ions (green sphere)  in Phe, Tyr and Trp.87 
 
Metal ion coordination or combination of different metals can induce changes in the 
peptide tertiary structure, inhibit fibril formation or evoke aggregation by initiating 
protein misfolding.88 Characteristic is the example of the Aβ complexes of CuII which 





•– .89 Faller and co-workers showed that 3d ions affect the kinetics of the Aβ 
aggregations of the sequences Aβ1-16, Aβ1-28, Aβ1-40 and Aβ1-42, with the most significant 
metal-specific impact on the nucleation phase.83  The study highlighted the selectivity of 
ZnII to His moiety and terminal carboxyl groups over other binding sites. Unlike ZnII, FeII 
and CuII ions exhibited a broad range of coordination preferences with the main peptide 
backbone as well as side chain donor-atoms, in various conditions (Scheme 1.8 and 1.9).83 
A recent study reveals that trivalent FeIII binds to Aβ via the phenolic oxygen of Tyr10 of 
the sequence (9GYEVHHQK16–NH2), in pH 7.4 and 1:1 molar ratio. In addition, 
carboxylate groups of Glu and Asp side chains are also bound to FeIII. On the contrary, 
for ZnII or CuII induced aggregation of the octapeptide with His residues acted as the 
primary metal binding sites.90 
 
Substantial advances in the field demonstrate that the combination of  well-defined self-
assembling Aβ with metal ions or complexes, through covalent or non-covalent 
interactions, is a flexible and versatile strategy for the rational construction of stable 
materials, finding a wide range of applications in material science and biotechnology; 
with representative examples associated with tissue engineering and regeneration, DNA 
binding capability, hydrogels, materials for medical or analytical flow devices, 
biologically inspired catalytic scaffolds, nanoscale wires, lithium-ion batteries, MRI 
agents.91    
 
Lanthanides, known for their luminescent properties and their applications as imaging 
materials have been studied for their interaction with biological systems.92 LnIII ions can 
induce aggregation of the Aβ and other amyloid fibrils containing Phe or Tyr residues.82,93 
Also, studies show that LuIII, TbIII and DyIII not only bind to the Tyr of C-terminal domain 
of α-synuclein, but they also interact with residues containing carboxyl groups, like Glu 
and Asp, in the N-terminal. Meanwhile, the latter binding sites were not found for the 
divalent ions FeII, CuII, CoII, NiII, ZnII, MnII, CdII, MgII.94 
 
1.2.3.3.2 An Overview of Amyloid Functionalization with 3d and 4f Complexes ‒ 
Chemical interactions and Properties of the Hybrid Materials in Brief 
Amyloid functionalization with complexes or PMCs can result materials with 
applications in various fields. For example, disruption of the aberrant metal-peptide 




considerable promise as a therapeutic strategy to combat Alzheimer’s disease.95  A 
variety of noble metal complexes that modulate or detect aggregation and inhibit toxicity, 
such as Pt, Ru, Ir, Rh have been used, 96 however reports about cost-economical 3d or 4f 
metal complexes including Cu,97–101 Gd,102,103 Co,101,104,105 Zn,101,106 Ni,97,101,107 and Fe106–
109 are less studied. Complexes with incorporated phenolic moieties have the potential to 
act as antioxidants,110 with the ability to prevent the generation of ROS,88 mainly through 
non-covalent interactions.  
     
 
Figure 1.2. (upper) Crystal structure of compound 1.2, CCDC ID 654013. (lower) Crystal 
structure of compound 1.3, CCDC ID 654015. Hydrogen atoms and solvent molecules 
are omitted for clarity. Colour code: Cu (blue), Ni (green), C (grey), N (light blue), O 
(red).97 
 
In 2007 Storr and co-workers developed two multifunctional square planar complexes 
[CuIIL2]·CH3OH·H2O (1.2) and [Ni
IIL2]·CH3OH (1.3), where H2L2 = N,N'-bis[(5-β-D-
glucopyranosyloxy-3-tert-butyl-2-hydroxy)benzyl]-N,N'-dimethyl- ethane-1,2-diamine, 
showed antioxidant capacity (Figure 1.2). Authors suggested that peptide aggregation was 




stable in a wide pH range, and no metal hydrolysis was observed. The hexoze moieties 
participated in hydrogen-bonding interactions between and along with the sheets.97    
 
   
 
Figure 1.3. (upper) crystal structure of compound 1.4, CCDC ID 1001049. (lower) 
Crystal structure of compound 1.5, CCDC ID 1001048. Hydrogen atoms and solvent 
molecules are omitted for clarity. Colour code: Cu (blue), C (grey), N (light blue), S 
(yellow).99 
 
The same year, Holland et al. synthesised mononuclear CuII bis(thiosemicarbazonato) 
complexes as platforms toward site-specific radiopharmaceuticals.111 In 2010 Lim and 
co-workers employed the same type of CuII complex, with an 
appended styrylpyridine functional group, known for its peptide intercalation properties 
through π-π stacking with Phe moieties, to bind to Aβ plaques.98 However, the relatively 
difficult radiolabeling of bis(thiosemicarbazonato) complexes with 64Cu and 
susceptibility towards hydrolysis from the thiocarbohydrazone linkage, could limit its 
application. To overcome the deficiency, Hickey et al. synthesised and characterized CuII 
species containing tetradentate hybrid thiosemicarbazone-pyridylhydrazine ligands 
containing p-dimethylaminostyryl-2-pyridylhydrazone functional groups (H2L3) with the 





(Figure 1.3), used as diagnostic imaging agents.99 The metal-based quasi-reversible 
CuII/CuI couples of the latter complexes can be used to predict intracellular reduction and 
stability in vivo.99  
 
In proteins, the rate of electron transfer by tunnelling decreases exponentially with 
distance. Fast electron transfer over distances greater than 14 Å can be accomplished 
using diffusible electron carriers, an array of closely spaced redox centres.112 Mimicking 
nature’s molecular wires consisting of chains of heme molecules, non-covalently bound 
to Cytochrome b562, for electron transfer purposes, Barker and co-workers demonstrated 
that high densities of FeII, FeIII, as well as ZnII metalloporphyrin molecules, can be 
displayed on the surface of an artificial gene, a 294-residue domain which forms fibrils, 
incorporating Cytochrome b562 moieties.
106 In another study, the use of metallo-
supramolecular [FeIIL43]·CH3CN·PF6·C6H6 (1.6), where L4 = (E)-4-((E)-4-((E)-pyridin-
2-ylmethyleneamino)benzyl)-N-(pyridin-2-ylmethylene)benzenamine, targets the Aβ-
discordant stretch and reduces Aβ cytotoxicity (Figure 1.4).107  Compound 1.6 binds non-
covalently to the Aβ13-26 central region. The aromatic amino acid, such as Phe19 and 
Phe20, can bind to the surface of the complex phenylene rings through hydrophobic 
interaction and π-π stacking.  
 
Figure 1.4.  Crystal structure of compound 1.6, CCDC ID 622770. Hydrogen atoms and 
solvent molecules are omitted for clarity. Colour code: Fe (brown), C (grey), N (light 
blue).107 
 
The first report of chiral Aβ inhibitors was recorded by Scott and co-workers when they 
employed two triple-helical dinuclear iron complexes with amino acid Schiff base 
ligands. The FeII complexes intercalated through hydrophobic and π–π stacking 




aggregation, the complexes can enantioselectively inhibit Aβ fibrillation and exhibit 
superoxide dismutase activity.108 Finally, Austen102 and Holler103 synthesised similar 
complexes of Gd–DOTA–side chain, where the side chain was curcumin or acid, 
respectively. Both coordinated through ligand-amyloid non-covalent interactions to the 
Aβ.  
   
On the antipode of non-covalent complex binding, cobalt–Schiff base complexes inhibit 
metalloproteins by binding essential His residues through a dissociative ligand exchange 
at the axial positions.114 His–coordination was selective over other amino acids, such as 
Cys and lysine (Lys).115 A CoIII–salen complex with the formula 
[CoIIIL5(His)2]·SPh4·EtOH (1.7), where L5 = bis(acetylacetone)ethylenediamine, was 
designed to covalently bind to the Aβ core via His residue coordination, following the 
axial ligand dissociation, altering the Aβ structure and oligomerization pathways (Figure 
1.5). Reduced synaptic binding of the oligomers to hippocampal neurons are observed, 
demonstrating the promise of transition metal complexes in Alzheimer’s therapy.105 
 
 
Figure 1.5. Crystal structure of (left) compound 1.7, CCDC ID 938577,105 and (right) 
compound 1.8, CCDC ID 1473344.101 Hydrogen atoms and solvent molecules are omitted 
for clarity. Colour code: Co (blue), C (grey), N (light blue), O (red).  
 
Peptide-cleaving catalysts, selective for proteins lacking active sites, have been employed 
by using cobalt sources along with cyclen-type ligands of macrocyclic polyamine 
backbone.104,116  Lim’s group reported a novel approach to validate the metal-mediated 
hydrolytic cleavage by divalent complexes towards the two major isoforms of Aβ 
(Aβ40 and Aβ42) and tune their proteolytic activity. The choice of metal centres (Co, Ni, 




dependent tunability was facilitated by employing a tetra-N-methylated cyclam ligand 
(L6) that imparts geometric and stereochemical control. The [CoIIL6(NO3)]·NO3 (1.8) 
complex was identified to noticeably cleave Aβ peptides and control their aggregation, 
reporting the first CoII complex for such reactivities (Figure 1.5).101 Mechanistic 
investigations evidenced the critical importance of the coordination environment and 
acidity of the aqua-bound complexes in promoting amide hydrolysis. ESI–MS spectra of 
Aβ40 incubated with the complexes reveal the peaks consistent with Aβ40 bound to all 
four metal complexes (e.g., Aβ40 + [Co
IIL6]2+). In the case of CuII and ZnII complexes, the 
Electrospray Ionisation Mass Spectrometry (ESI-MS) data suggest that a small amount 
of Cu and Zn may dissociate from the ligand, possibly by chelating to the N-terminal 
(e.g., His6, His13, and His14) in Aβ. The biological applicability of CoII complex was 
also illustrated.101  
 
1.2.3.4 Benzotriazole-based Ligands in Copper Chemistry  
The use of heterocyclic organic moieties that contain heteroaromatic ring systems,117 such 
as 2,2'-bipyridine,118 have been extensively used as the traditional N,N′-bidentate ligand 
in numerous approaches dealing with coordination chemistry. Benzotriazole (btaH) 
derivatives provide enormous coordination versatility in combination with metal ions 
yielding coordination compounds of various dimensions with fascinating structures. 
Benzotriazole exists in two tautomeric forms, 1H- and 2H-benzotriazole (Scheme 1.10A), 
with the 1H-tautomer to be the dominant species in solution and the only stable isomer 
existing in the solid-state.40 The most common synthetic methods involve the addition of 
nitrous acid in o-phenylenediamine.119,120 In 1947 Procter and Gamble submitted a patent 
involving the use of btaH as a corrosion inhibitor for metallic copper, while subsequent 
studies by Cotton and co-workers revealed that the protective layer consisted of a 
polymeric CuI-bta complex.121 More recently, Kokalj reported btaH to outperform simple 
triazole in copper corrosion inhibition.122 Since Cotton’s report, btaH and its C-
substituted derivatives have been combined with copper sources to enrich the 


































Scheme 1.10. A) Common synthetic route to benzotriazole. B) (upper) The two 
tautomeric forms of btaH. (lower) Common synthetic route to N-substituted 
benzotriazoles. 
  
The N-donor atoms of the deprotonated benzotriazolate anion (bta–) can stabilize the 
oxidation states and the coordination environment of the metal centre, acting as 
monodentate, terminal or bridging ligand.123 The N1  protonated triazole moiety is the 
thermodynamically favourable specie for metal coordination (Scheme 1.10B). However, 
btaH can act as bridging ligand for up to three metal ions, with possible bridging 
coordination modes μ1,3 , μ2,3, μ1,2, μ-η
2:η1 for the case of two metal centres or μ1,2,3 for 
the case of three different metal centres.40  Yan and co-workers reported a mixed-valent 
CuI5Cu
II complex with bta– ligands exhibiting different coordination modes for CuII and 
CuI atoms (N2 of the bta‒ and μ1,3 bridging mode respectively).
123 The synthetic versatility 
of btaH permits the synthesis of numerous benzotriazole-based ligands, with various 
levels of flexibility.40 These ligands can participate in various interactions, such as π–π 
stacking and hydrogen bonding,  stabilize the resultant structures and provide a better 
understanding of the system. In most cases, the resulting species are characterised by the 
favourable formation of polynuclear complexes or compounds with extended 
dimensionality against 0D mononuclear compounds, even with the presence of bulky 
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Scheme 1.11. (upper) Benzotriazole-based ligands mainly employed for the synthesis of 
PMCs; R1 and R2 are -OCH3, -COOH, -CH3, -Cl, -Br, -bta. (lower) Benzotriazole-based 
ligands for the synthesis of mono-nuclear complexes. 
 
Among the N,N'-chelating ligands, constituted from two heteroaromatic units connected 
with C–C or C–N bond, forming five-membered rings with the metal, the latter offers an 
enhanced electron-rich nature and a degree of flexibility in the ligand system due to the 
lone electron pair of the C–N bond (Scheme 1.11). They are usually prepared by the 
reaction of btaH with the corresponding halogen derivatives/ (hetero)aryl halides in 
aprotic solvents, followed by treatment with a base and subsequent separation (Scheme 
1.10B).124  
 
Steel reported the chemistry of N1-substituted bta with heteroaromatic ring systems 
employed as N,N′-chelated ligands for Cu, Ru, Pd, Ag.125 These hybrid moieties were 
designed to form 5- or 6-membered rings with the metal centre, however, the availability 
of the additional N3-donor of the benzotriazole unit for coordination allows the 1-
heteroaryl substituted benzotriazoles to act as terminal or bridging ligands depending on 
the metal, the coordinating ions, the heterocyclic substituent, and the reaction conditions. 




benzotriazole framework, with the resulting 0D complexes finding some notable 
applications in the field of catalysis.126–128 Among them [CuI(L7)(PPh3)2I] (1.9), with L7 
= 1-(2-pyridyl)benzotriazole, catalysed the synthesis of 2-aryl-1H-benzo[d]imidazoles 
from benzyl alcohols and diamines by acceptorless dehydrogenation and borrowing 
hydrogen reactions.127 The benzotriazole moiety is coordinated through the N3 of the 
triazole unit and the ligands were observed to play a key role in catalysis through the 
















Scheme 1.12. Synthesis of 1-benzyl-2-aryl-1H-benzo[d] imidazole derivatives as 
catalysed by 1.9. (inset) Crystal structure of compound 1.9, CCDC ID 1490296. 
Hydrogen atoms and solvent molecules are omitted for clarity. Colour code: Cu (dark 
orange), P (light orange), C (grey), N (light blue), I (purple). 
 
1.2.4 Synthetic Strategies  
The “serendipitous assembly”, uses various reaction conditions, leading to the formation 
of many unique structures, which can lead to novel properties,129,130 enabling the study of 
how the systematic variation of reaction conditions (solvent, reactant ratio, temperature, 
time of reaction, crystallisation method) affects the nature of the final product. For the 
“designed assembly” route of complex formation, the use of various analytical techniques 
(ESI-MS), Cold Spray Ionisation Mass Spectrometry (CSI-MS) has enabled the 
identification of standard structural units and rational design of high nuclearity PMCs 





Compound modification can also occur without altering the core topology of the complex. 
Other ions can replace 3d and 4f ions within complexes with similar electronic properties 
or coordination geometries. 3d-3d or 4f-4f substitutions,74,133 as well as 3d-4f 
substitutions and has resulted in enhanced properties of the complexes.134 With these 
synthetic advantages and knowledge of previous core topologies, synthesis of novel 3d/4f 
PMCs can be targeted for specific applications.135 
 
1.3 Methodologies for Catalysis  
 
1.3.1 Artificial Hybrid Metal-Peptide Homogeneous Catalysts  
 
1.3.1.1 Synthetic Approaches  
Since the 1970s, researchers have been trying to mimic natural metalloenzymes by 
synthesising hybrid metal-peptide catalysts using proteins with incorporated natural or 
non-natural metal-binding sites.136 These artificial ME and metallopeptide (MP)  
developed to date show that protein cofactor induces interactions which can alter the 
reactivity and selectivity of metal catalysts to enable regio-, enantio-, substrate- and site-
selective reactions, some of which are not readily achieved using small molecule 
catalysts.85,136–138 The essential role of catalytic chemistry in the production and 
functionalization of an enormous range of chemicals, biomolecules, and materials,139 and 
given the limitations of small-molecule ligands to offer static and dynamic control over 
the orientations of distal substituents, the demand is continuous for metal catalysts with 
well-defined secondary coordination environments. These environments should be able 
to be readily and extensively fine-tuned for particular applications. There are three main 
approaches for metal incorporation into the peptide or protein (scaffold) in order to make 
enzyme-type of molecules with improved properties. These approaches can be broadly 
classified as: (A) Covalent coordination of a scaffold’s donor atom (such as Nim of His or 
COO– of Asp) to the metal (ion or complexed), the scaffold–M approach. (B) Covalent 
scaffold modification with the employment of a catalyst, the scaffold–cat approach. The 
latter requires a bond-forming reaction between a reactive residue of the scaffold (usually 
a nucleophile) and a reaction partner (typically an electrophile) located in the organic 
periphery of a metal catalyst. Salen and chelating pyridine 3d complexes embodying 
reactive groups in the ligand chain have been used for covalent scaffold modification.140 




symbolized as cat⸦scaffold.85 Combinations can also occur, and the cases of (B) and (C) 
can be followed by metal coordination. Despite the progress noted in the field using the 
scaffold–cat approach, a detailed literature reference deviates from the purpose of the 
present thesis. Although there are challenges in synthesis and characterisation of these 
hybrid scaffolds, advances in peptide/protein modification highlight the contribution of 
the secondary coordination sphere effects141 in the imparted selectivity and efficiency.142 
 
 
Figure 1.6. Four anchoring strategies allow one to firmLy localize an inorganic cofactor 
within a protein scaffold: a) covalent, scaffold–cat; b) supramolecular, cat⸦scaffold; c) 
dative, scaffold–M; d) metal substitution, scaffold–M. Colour code: protein and natural 
cofactor (green), supramolecular anchor (red), variable spacer and ligand (blue), and 
abiotic metal (black). Reproduced with permission from ref. 140. Copyright 2018 
American Chemical Society.140  
 
1.3.1.1.1 Covalent Binding of Metal Ions or Complexes on Metalloenzymes: the 
Scaffold–M Approach 
Natural or artificial ME and artificial MP are subclasses of homogeneous transition metal 
catalysts. For ease of reference, we will characterize as peptide an aminoacid sequence  
of less than 50 units, while the term protein will be characterizing sequences of more than 
50 aminoacids. With the natural ME to be the basis of conceptual catalyst design, 
researchers have been working on various ways to fine-tune the metal coordination and 
stereostructure of hybrid-peptide catalysts and create new artificial ME or MP with the 





i) Replacement of the naturally binding metal with another metal. In this case, the organic 
scaffold can be investigated as a ligand and should be able to be expressed as a metal-
independent stable moiety (apoprotein), otherwise, an efficient method such as dialysis 
against a metal chelator can be used to remove the naturally occurring metal centre. This 
method was initially used in the 70’s by Yamamura and Kaiser to transmetallate the 
natural ZnII-containing carboxypeptidase A (CPA) into a CuII CPA lacking the catalytic 
activity of the former, but able to function as an oxidase. The donor-atom set in this CuII 
ME is {N2O2,} but the geometry around the metal ion is significantly distorted from 
square planar (ZnII-CPA) to tetrahedral.136 In agreement with this study, the ZnII–(His)3 
active site, of human carbonic anhydrase 2 (CA2), a ME responsible for transforming 
CO2 to HCO3
–, was reconstituted with MnII and enantioselectively catalysed alkene 
epoxidation.143,144 Myoglobin (Mb) has been mainly studied for its peroxidase activity by 
alteration of the heme co-factor. Other studies showed that Fe in heme proteins, such as 
hemoglobins and Mbs had been substituted by Co and Mn catalysing reversible 
oxygenation,145 C–H amination of arylsulfonyl azides,146 and  carbene C–H insertion (for 
related transformations refer to section 1.3.1.1.2).147  
 
  
Figure 1.7. Crystal structure of compound 1.10, CCDC ID 1534847. Hydrogen atoms 
and solvent molecules are omitted for clarity. Colour code: Cu (blue), C (grey), N (light 
blue), O (red), Cl (green).148 
 
ii) Naturally metal-free proteins, containing Lewis basic sites can be an alternative 
method for artificial ME formation, yet with limited range of primary coordination 
environments. However, sparce metal ion coordination leads to limited catalytic 
activities.85 Serum albumins, which naturally bind and transport hydrophobic substrates 
in blood serum, can also bind catalytically active metal ions and complexes with 





Recently, Mahy et al. showed that the A2A adenosine receptor living human cells could 
turn into a catalyst by covalent binding to a CuII complex with the formula 
[CuII(L8)Cl2(MeOH)]·2(MeOH) (1.10) (Figure 1.7), with L8 sharing the same 2-furanyl-
7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine core structure of various 
antagonists (for ligands employed for the synthesis of complexes 1.10-1.16 refer to 
Scheme 1.18). The resulting cells enantioselectively catalysed the abiotic Diels-Alder 
cycloaddition reaction of cyclopentadiene and azachalcone and the endo-isomer was 
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Scheme 1.13. Diels−Alder cycloaddition leading to four isomeric products.148 
 
iii) Artificial proteins with engineered metal-binding sites for selective metalation and 
controlled stoichiometry.140 This method limits the presence of varying active sites with 
varying degrees of selectivity. Relevant to organic synthesis, the Reetz group engineered 
His2Asp (HHD) site, following the removal of the native Cys residue, for Cu binding on 
tHisF thermostable protein. The artificial Cu−tHisF–HHD, the covalent binding of which 
is confirmed by EPR, catalyses a Diels-Alder reaction of azachalcone and 
cyclopentadiene with moderate enantioselectivity (35%) (Scheme 1.13).150 Notably, the 
mutation and incorporation of four Ala residues (A4), that could also bind Cu, increased 
reaction selectivity (up to 46% ee).150 In analogy to the aforementioned work, Mahy et. 
al. synthesised [CuIIL9(CH3CN)2]
2+ (1.11), where L9 = (5‐(Piperazin‐1‐yl) ‐1,10‐
phenanthroline) testosterone‐17‐hemisuccinamide, which could be incorporated into a 




the same Diels-Alder displayed in Scheme 1.13 and favoured the formation of the exo-
products.151 CuII pyridine-based hybrid systems were developed by Filice and Roelfes  as 
enantioselective Diels-Alderases.152,153  
 
Figure 1.8. Lowest‐energy docking solution for 2‐azachalcone bound to compound 1.11 
in the neocarzinostatin. The protein is represented in transparent cyan ribbons; 2‐
azachalcone bound to 1.11 (pink). Hydrogen atoms and solvent molecules are omitted for 
clarity. Colour code: Cu (dark orange), C (pink), N (light blue), O (red). Reproduced with 
permission from ref. 151. Copyright 2016 Wiley-VCH.151 
 
1.3.1.1.2 Non-covalent Linkage of Complexes and Metalloenzymes: The 
cat⸦scaffold  Approach 
The non-covalent interactions of a metal complex with the scaffold in an artificial 
metalloenzyme design offers the advantage of step-economy in the metalloenzyme’s 
design since lengthy workup or purification procedures are usually not needed. Although 
reactive cofactors for covalent binding are not necessary, the approach requires specific 
scaffold-cofactor interactions that restrict the range of scaffold proteins that can be used.85 
Mbs have been extensively used as hosts for metal complexes containing aromatic groups 
like porphyrins and Schiff bases. In natural heme proteins, the heme cofactor is tightly 
bound via hydrophobic interactions with the porphyrin ring (iron‐protoporphyrin IX), 




atom by an axial ligand (e.g., His93 in Mb). All of the aforementioned can be exploited 
to incorporate synthetic cofactors.85   
 
Figure 1.9. Crystal structure of 1.12⸦apo-A71GMbs, PDB ID 1UFJ. Hydrogen atoms, 
solvent molecules and protein chain are omitted for clarity. Colour code: Compound 1.12 
(blue), His of A71GMbs (pale yellow).154  
 
In 2003 the H2O2-dependent reactivity of Cr
III-salophen complex into the active site of 
apo-myoglobin for thioanisole sulfoxidation was reported.155 The results revealed 
moderate ee, while stabilization of the CrIII coordination sphere with His residues of the 
Wild-Type Mb was suggested.155 This assumption was confirmed by the same group 
when they crystallised [FeIIIL10(OH)] (1.12),154 [MnIIIL10(OH)] (1.13) and [CrIIIL10(OH) 
(1.14)156 with apo-A71GMbs, where (H2L10) = 2-((E)-(2-((E)-2-hydroxy-3-
methylbenzylideneamino) ethylimino) methyl) -6- methylphenol (Figure 1.9). The 
structures suggest that the position of the metal complex in apo-Mb is determined by non-
covalent interaction between the ligand and surrounding peptides. Non-covalent 
interaction is also suggested for the proximal His93 with the metal ion. In the case of FeIII, 
proximal His93 stabilized the coordination environment around the metal centre, by 
ligating to the iron with an Fe–N distance of 2.30 Å.154  
 
Assemblies similar to 1.12⸦apo-A71GMbs have since been reported, in some cases 
specifically investigating the impact of cofactor substituents on the metalloenzyme’s 
stability and activity.157,158 Up to 33% ee for thioanisole sulfoxidation was achieved using 
the aforementioned systems (Scheme 1.14).157  In all these and other similar systems 
crystal structure analyses have shown metal-His interaction and that little perturbation of 
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Scheme 1.14. Selective thioanisole sulfoxidation reactions catalysed by 1.12⸦apo-































Figure 1.10. (left) The ligands of compounds 1.15 and 1.16. (right) Lowest‐energy 
solutions for A) 1.15⸦Xylanase10A and B) 1.16⸦Xylanase 10A, catalysing 
enantioselective styrene epoxidation. Reproduced with permission from ref. 160. 
Copyright 2012 Wiley-VCH.160   
 
On the basis of the X-ray structure of Fe-protoporphyrin dimethyl ester,161 the Reetz 
group modelled water-soluble phthalocyanine complex conjugates of Serum Albumin 
(SA) as an enantioselective catalyst for Diels-Alder reactions, affording up to 98% ee.162 
Authors suggest that the cycloaddition occurs in the cavity opposite to the planar CuII 
complex.  Mahy and co-workers synthesised artificial FeIII hemoproteins also exhibited 
peroxidase activity and enantioselectively catalysed thioanisole sulfoxidation.163 
Subsequently, the reported planar [MnIIIL11]3+ (1.15) with N ,N′ ‐ethylene bis(2‐
hydroxybenzylimine)‐5,5′‐dicarboxylic acid ligand (H2L11) and [Mn
IIIL12]+ (1.16) with, 




Xylanase 10A. 1.16⸦Xylanase 10A catalysed the enantioslective styrene epoxidation. 









































Scheme 1.15. A) P450-Catalysed Intramolecular sp3 C–H Amination with Arylsulfonyl 
Azide Substrates.164   B) Proposed mechanism for Mb‐catalysed styrene cyclopropanation 
(carbene transfer) with diazo esters.165 
 
Transition metal-catalysed transfers of carbenes and nitrenes are powerful methods for 
functionalizing C=C and C–H bonds. The intermediates of the type heme-Fe–C=R and 
heme-Fe=NR enable P450-catalysed cyclopropanation using diazo compounds (Scheme 
1.15A).166 Fasan and co-workers opened new perspectives for engineered Mb derivatives 
in carbene and nitrene reactions. The engineered iron protein appeared to have some 




1.3.1.1.3 Binding Metal ions or Complexes on Metallopeptides 
Roefles et al. created an artificial CuII MP by grafting a new active site onto bovine 
pancreatic polypeptide (bpp), a 36 amino acid sequence with α-helical content.167 Metal-
binding amino acids, were incorporated into the peptide 7 positions, including His and 
the non-proteinogenic pyridylalanine (PyrAla). In situ binding with copper, catalysed the 
Diels-Alder reaction of azachalcones and cyclopentadiene (up to 83% ee, quantitative 
conversion) and the Michael addition of dimethylmalonate to azachalcones (up to 86% 
ee, 85% conversion) (Scheme 1.16). However, relatively high catalyst loading and 



















ee up to 83% ee up to 86%
 
Scheme 1.16. Diels-Alder of azachalcones and cyclopentadiene and Michael addition of 
dimethylmalonate to azachalcones catalysed by CuII MP.167 
 
Building on impressive progress in the field of de novo MP design, Degrado and 
Lombardi have reported a series of studies on the development of a family of 48-residue 
peptides that fold into helix-loop-helix motifs. These structures were designed to project 
two Glu residues and a His residue toward a putative C2 symmetric dimetal binding site 
along with the peptide dimer interface. Addition of various metal ions, including FeII, 
CoII, and ZnII, led to the predicted dimeric dimetallopeptides (Figure 1.11A).85,168 The di-
FeII structure was found to react with O2 to form an oxo bridged di-Fe
III species, in 
analogy to many natural oxidases.85 The design of a substrate-binding pocket into the di-
FeII structure,168 which improved the previous design,169 catalysed the oxidation of 4-
aminophenol to the corresponding benzoquinone mono-imine, with TON~50 (Figure 
1.11A).   
 
Pecoraro described the design of a hydrolytic three-helix bundle MP consisting of 
sequences with distinct metal binding sites for ZnII and HgII built from His3 and Cys3 sites 
respectively.170 The Zn-Hg MP catalysed the hydrolysis of p-nitrophenyl acetate (p-NPA) 
with  kcat = 0.002 s




CO2 to H2CO3 was also catalysed by the same bimetallic MP with high kcat value, 
approximate to 1.8×103 s−1, pH 9.5 and 25 °C. Crystal structure analysis of functionally 
similar peptides confirmed the expected metal binding design and indicated the presence 















Figure 1.11. A) Crystal structure of a designed dimeric carboxylate-bridged di-FeII helix-
loop-helix MP catalyst for the oxidation of 4-aminophenol; (inset) an expanded view of 
the catalytic [FeIIHisGlu2]2 centre, PDB ID 2KIK.
168 B) Crystal structure of a three-helix 
MP catalyst, containing HgIICys3 and Zn
IIHis3 sites, for the hydrolysis of p-NPA; (inset) 
an expanded view of the catalytic ZnIIHis3 site with water bound, PDB ID 3PBJ. Colour 
code: Fe/ Zn/ Hg (dark grey), C (green), N (blue), O (red). Reproduced with permission 
from ref. 85. Copyright permission 2013 American Chemical Society.85  
 
Amyloids not only catalyse their own formation, but they are able to catalyse other 
chemical reactions too. Rufo and co-workers designed a series of seven-residue peptides 
that act as ZnII-dependent esterases.171 ZnII helps stabilize the fibril formation, while also 
acting as a cofactor to catalyse (p-NPA) hydrolysis. Serpell and co-workers catalysed the 




authors suggested His residue coordination to ZnII ions and a CA2 model reactivity, 
examining the impact of sequence in the enzymatic activity (kcat = 0.008 s
−1).75 The same 
year Lee et al. determined the structure of ZnII-coordinated Ac–IHIHIQI–CONH2 
(capped ZnII–IHIHIQI) metalloamyloid esterase catalyst by solid-state NMR.172 The MP 
catalyses p-NPA hydrolysis with an initial rate that fits kcat = 0.034 s
−1. Other studies have 
demonstrated ATPase activity,173 and copper-mediated oxygen activation.174 The 
catalytic functions are metal- and fibril-dependent. The corresponding non-fibrillated 































































































1.3.2 Copper Homogeneous Catalysts in Imine Alkylation  
 
1.3.2.1 Copper Complexes and Catalysis. Mechanistic Insights 
Copper components can catalyse reactions that incorporate one and/or two-electron 
(radical and bond-forming) based mechanisms.175,176 Copper complex-mediated 
transformations with Schiff base, benzotriazole-based, chelate pyridine-based, chelate 




179 reduction processes are 
dominating today’s chemistry of copper well-characterized complexes; however, 
examples of C–H oxidation,180 C–C coupling reactions such as Henry,181,182 Michael,183 
Mannich-type condensations and other imine-based multicomponent reactions (MCRs) 
have also been reported in the literature (Scheme 1.19).18,175,184  
 
Mukherjee and co-workers showcased the redox properties of [CuIIN4] units by extensive 
studies in CuII–pyridine-based complexes with different geometries. Stereochemical 
changes around the CuII centre were caused by systematic ligand modification (ligand 
flexibility/rigidity), with impact in the stability of the CuI species formed in solution.185 



























Scheme 1.19. Copper-catalysed imine based MCRs involving alkynes, organoboron 





Besides, the chemistry of copper complexes with redox-active ligands has attracted 
attention, mainly because these ligands are known to play important roles in biological 
catalytic cycles.186 In nature, the phenoxide residue of aminoacid Tyr is redox-active and 
many phenoxide-based complexes with redox non-innocent ligands have been 
synthesised and used as catalysts in oxidation or C–C coupling reactions.187,188 The 
phenoxyl radical has been characterized as a stable species since 1990’s, when Knowles 
and co-workers reported the structural characterisation of Galactose oxidase (GO) (Figure 
1.12),189 which catalyses the oxidation of the primary alcohol by O2 to give the 
corresponding aldehyde and H2O2. In general, mononuclear Cu
II enzymes act as one-
electron oxidants by redox between CuII and CuI states. Studies on GO revealed that 
hydrogen abstraction from the alcohol to the phenolic Tyr495 moiety is involved in the 
rate-determining step (CuII-Tyr272•), which leads to the formation of aldehyde by one-
electron oxidation (CuII to CuI), and generation of the CuI-phenol species. Despite the 
progress on the field, information about the geometric characteristics of the CuI species 
is still unclear.176   
 
A copper complex with a redox-active ligand exists either as a high valent metalloligand 
[Cun+1(L–)] or a copper-ligand radical [Cun(L•)] complex. Examples of Cu-diphenolate 
ligands, such as salen, are known to exist in either form, and the factors that control the 
oxidation locus in these complexes are being actively pursued.176 In the case of CuII 
complexes, properties of the dinitrogen backbone of the salen-type ligands have an effect 
on the oxidation locus of the one-electron oxidized complexes.190  
 
 
Figure 1.12. Crystal structure of the active site of GO, PDB ID 1GOG; (inset) {N2O2} 




solvent molecules and protein molecules are omitted for clarity. Colour code: Cu (dark 
orange), C (green), N (blue), O (red), S (yellow).189 
 
1.3.2.2 Copper-mediated Propargylamine Synthesis    
Propargylamines are of significant importance for the production of various 
pharmaceuticals and natural products,191 and they are also present as intermediates in the 
synthesis of new heterocycles.192 Since the first report of CuCl catalysed coupling of the 
aldehyde, alkyne and amine, known as A3 coupling,193 various methodologies have been 
developed to facilitate the A3 and other imine-based MCRs. The A3 reaction mechanism 
is comparable to a Mannich condensation, but with the formation of an organometallic 
intermediate as a primary step, via coordination of the alkyne to CuI. The process involves 
a CuI-alkyne π bond, which increases the acidity of the sp C–H bond permitting 
deprotonation and Cu-acetylide σ-complex formation (Scheme 1.20).184 Knochel’s 
pioneering work determines the activation of the acetylide on the coordination sphere of 
the CuI centre and subsequently coupling with the corresponding imine.194 Methodologies 
that involve CuII sources have been reported,17,195–199 however, with limited mechanistic 
information. Besides, copper reduction may occur in the presence of alkynes, a 























































Scheme 1.21. Ligands employed for the synthesis of complexes 1.17-1.24.  
 
In homogeneous A3 catalysis with Cu sources simple salts, in situ protocols with Cu and 
chiral organic additives,201 mechanochemical protocols,202 microwave,203–209 as well as 
solvent free210 methodologies have been reported. Reactivity limitations are observed in 
the use of primary amines, since iminium ions are more electrophilic comparing to their 
imine counterparts.184 By fine-tuning the organic periphery of the pre-catalyst and by 
careful selection of the metal salts, solvents, additives and reaction conditions, the desired 
product can be obtained in one-pot procedures. In the present subchapter, the activity of 
crystallographically characterized complexes for propargylamine derivative formation 
will be discussed in detail (for their ligands, refer to Scheme 1.21). Selected examples 
highlighting the versatility of the different methodologies (microwave, enantioselective, 

















Scheme 1.22. Chiral Pybox- and Pybim-type ligands employed for enantioselective 




After Johnson and Evans’ finding regarding the catalytic activity of chiral CuII–BOX 
complexes in enantioselective cycloaddition, Aldol, Michael, and carbonylene 
reactions,183  Wei and Li reported the first enantioselective A3 strategy,213 with chiral 
bidentate and tridentate BOX-based ligands and CuOTf.211 Optimum ee values were 
obtained with tridentate bis(oxazolinyl)pyridine (Pybox) ligands ( Scheme 1.22). A few 
years later, bis(imidazoline) pyridine (Pybim) ligand optimized the CuOTf-catalysed 
protocol (Scheme 1.22).212 The up-to-date examples illustrate the improved performance 
of  chiral tridentate N-ligands of the pybox-type in enantioselectivity induction of 
secondary propargylamines. On the other hand, the enantioselective production of tertiary 
propargylamines usually requires a different type of organic co-catalysts.184 P,N Quinap 
ligands were used in 2002 by Knochel et al., who were the first to report a metal-catalysed 
route to chiral secondary propargylamines. They used CuBr and 1-(2-
(diphenylphosphino)naphthalen-1-yl)isoquinoline (L13) in situ, in 5 mol% loading at 
room temperature without the presence of additives (up to 98% yield and 90% ee).194 
Isolation of the [CuI(L13)Br]2 (1.17) complex and crystallographic characterisation shows 
a typical planar four-membered Cu2(μ-Br)2 ring and distorted tetrahedral geometry for 
CuI centres (Figure 1.13). The reaction scope was later extended to other enantioselective 
A3 products with Quinap-type,214  as well as phosphino-imidazoline ligands.215 chiral 1,2-
diaminocyclohexane acid thiourea with CuI were successful chiral A3 candidates.191  
 
 
Figure 1.13. Crystal structure of 1.17, CCDC ID 182716. Hydrogen atoms and solvent 
molecules are omitted for clarity. Colour code: Cu (blue), C (grey), N (light blue), O (red), 














A. yield 69% , ee 78% 







A. yield 91% , ee 79% 







Scheme 1.23. Propargylic amination of propargylic esters with amines catalysed by 1.19 
and 1.18. (left inset) Crystal structure of 1.19, CCDC ID 817911; (right inset) crystal 
structure of 1.18, CCDC ID 817910. Hydrogen atoms and solvent molecules are omitted 
for clarity. Colour code: Cu (blue), C (grey), O (red), P ( orange), Cl (green).216  
 
An important report by Hattori, Nishibayashi and co-workers involves propargylic 
amination of various propargylic esters with amines (Scheme 1.23). The best activity was 
obtained with optically active diphosphine complexes [CuI(μ-Cl)(L14)]2 (1.18), L14 = (R)-
2-(diphenylphosphino)-1-(2-(diphenylphosphino) naphthalen-1-yl) naphthalene and 
[CuI(L15)]2 (1.19), L15 = 1-chloro -3- (5-chloro-2-(diphenylphosphino) -6- 
methoxycyclohexa -1,3-dienyl) -4-(diphenylphosphino) -2-methoxybenzene (10mol%). 
Instead of copper-allenylidene complexes, authors attempted to isolate copper-acetylide 
complexes since the former are expected to be produced via copper-acetylide complexes 
from propargylic acetates. [CuI(μ-C≡Ctol)(L15)]2 (1.20), where C≡Ctol derives from 
lithium acetylide, was also isolated (Figure 1.14). Secondary amines exhibited better 
reactivity than primary, while the enantioselectivity was conversely dependent on the size 
of cyclic dialkylamine. Authors suggest that the attack of amines to the electrophilic γ-
carbon atom in the allenylidene complex is an important step for the stereo selection, 
while the copper-allenylidene intermediates are involved in the rate-determining step.216 
Excellent yields and ee values were obtained with secondary amines, while moderate ee 




of in situ catalysed propargylic amination with CuI and pybox ligand, where only aniline 
derivatives were suitable for good ee values (up to 88% ee).217  
 
 
Figure 1.14. Crystal structure of 1.20. CCDC ID 817912. Hydrogen atoms and solvent 
molecules are omitted for clarity. Colour code: Cu (blue), C (grey), O (red), P ( orange), 
Cl (green).216  
 
Figure 1.15. (Upper left) Crystal structure of 1.21. CCDC ID 986314. (upper right) 
Crystal structure of 1.22. CCDC ID 986315. (lower) Crystal structure of 1.23. CCDC ID 
986320. Hydrogen atoms and solvent molecules are omitted for clarity. Colour code: Cu 





In 2014, Grirrane and co-workers synthesised various CuI and AuI complexes,218 and 
applied them as catalysts for the propargylamine synthesis under inert atmosphere, with 
CuI complex activity surpassing the activity of AuI. The ligand L16 = 2-di-
tertbutylphosphanylbiphenyl was employed for the synthesis of the complexes (Figure 
1.15). X-ray crystallography and reactivity studies suggest that complexes 
[CuIL16(NCCH3)]·PF6 (1.21) and [Cu
IL16(NH2C6H5)]·PF6 (1.22) achieve quantitative 
conversion in 12 min, while complex [CuI(μ-Cl)L16]2 (1.23) yield the product in trace 
amount for the same reaction time. It is noticeable that Cu coordination via the P- and N-
donor atoms of the ligands is essential for catalysis, while  chloride coordination to the 
metal leads to the deactivation of CuI and AuI species.218  
 
Garcia et al. reported two CuI phosphine-based complexes for the A3 coupling. The first 
report involves the tetramer [CuI(μ-Cl)(L17)2]4 (1.24) where L17 = diallyl-tert-
butylphosphane, which adopts a distorted “cubane-like” structure  and shows catalytic A3 
reactivity under Ar atmosphere in 0.5 mol% and  solvent-free conditions (Figure 1.16).219  
 
 
Figure 1.16. Crystal structure of 1.24, CCDC ID 1453471. Hydrogen atoms and solvent 
molecules are omitted for clarity. Colour code: Cu (blue), C (grey), P (orange), Cl 
(green).219 
 
Subsequently, catalyst development leads to the synthesis of a mononuclear [CuI(L18)2Cl] 
(1.25) air-stable complex with L18 = 2-phenyl-1,3-di(thiophen-2-yl)-4,5,6,7-tetrahydro-
2H-isophosphindole.220 Lower loading (0.1 mol%) and improved reactivity is observed 



















Scheme 1.24. A3 coupling of aldehyde/secondary amine/1,7-octadiyne  catalysed by 
1.25.221 (inset) Crystal structure of 1.25, CCDC ID 1477669. Hydrogen atoms and solvent 
molecules are omitted for clarity. Colour code: Cu (blue), C (grey), S (yellow), P (orange), 
Cl (green).220 
  
Agrahari and co-workers crystallised complex [CuII(L19)]·0.5H2O (1.26), which was 
prepared by 6,6’-[(1E,1’E)-(cyclohexane-1,2-diylbis (azanylylidene)) 
bis(methanylylidene)bis(3- (diethylamino)phenol)] salen-type Schiff base ligand (H2L19) 
with Cu(OAc)2.H2O (Figure 1.17). The complex catalysed the A
3 coupling of 
aldehyde/secondary amine/phenylacetylene in 0.9 mol% loading in toluene, 7 h, 80°C.199  
The paramagnetic nature of the complex was confirmed by EPR studies, having giso= 
2.076 which indicated a distorted square planar geometry of the complex. Authors suggest 




of CuII complex was also demonstrated in the synthesis of 5-substituted 1H-tetrazoles in 
0.7 mol%.  
 
Figure 1.17. Crystal structure of 1.26, CCDC ID 1576528. Hydrogen atoms and solvent 











Scheme 1.25. CuII-pyridine catalysed ynimine formation. (inset) Crystal structure of (Z)-
2-cyclohexyl-N-((2,3-dimethylphenyl)(phenyl)methylene)ethynamine, CCDC ID 
844584. Colour code: C (grey), N (light blue), H (pink).222   
 
Laouiti, Evano and co-workers in 2012 further showcased the method versatility and 




reaction mixture, under O2 atmosphere. Alkynylation of diaryl imines with terminal 
















































Scheme 1.26. MW assisted strategies for the generation of: (A) (upper) 6,7-dihydro-5H-
dibenzo[c,e]azepines and 5,6,7,8-tetrahydrodibenzo[c,e]azocines, (lower) structurally 
similar alkaloids; 204 (B) symmetric 1,4-diamino-2-butynes. 206 
 
Microwave protocols with Cu salts and in situ complexes have resulted in interesting N-
heterocycles. The Van Der Eycken group has reported the MW synthesis of  6,7-dihydro-
5H-dibenzo[c,e]azepines, 5,6,7,8-tetrahydrodibenzo[c,e]azocines204 (Scheme 1.26A) and 
symmetric 1,4-diamino-2-butynes (Scheme 1.26B), achieving short reaction times.206 
Although Cu salts (20 mol%) were known to catalyse the production of secondary 
propargylamines under MW in moderate yields,205 in 2015, optimum results were 
recorded when CuCl with CuCl2 were combined in one pot under MW irradiation in 
water.207 Recently Balakrishna reported a MW methodology of minimum record reaction 

















































Scheme 1.27. (upper) Copper‐catalysed A3 coupling reactions using calcium carbide as 
the acetylene source by (A) solution‐based synthesis,223 and (B) mechanochemical 
synthesis.202 (lower) Mechanochemical synthesis of unsymmetric 1,4‐diamino‐2‐
butynes.202 
 
On the other hand, based on Zhang’s findings,223 Hernandez featured the potential of 
mechanochemistry as an efficient route for the production of unsymmetric 1,4-diamino-
2-butynes (Scheme 1.27), via CuI-catalysed aldehyde/ amine/ alkyne couplings using 
calcium carbide as the acetylene source to provide the selective formation of 1,4-diamino-
2-butynes over classical approaches which provide propargylamine-type of products. 
Among other salts, CuI and CuBr (10 mol%) were proven to be the best catalysts, while 
Cu(BF4)2 favoured propargylamine product.
202 Moreover, the use of 






1.3.3 The Role of Trifluoromethanesulfonate Anion as a Nucleophile  
The trifluoremethanesulfonate (triflate, OTf –) is an excellent leaving group with good 
metal-coordinating capability. The nucleophilicity of triflate partly arises from its ability 
to stabilize the negative charge. The acidity of OTf – in water has been estimated around 
–12 ± 5 pKa units,224 surpassing the acidity of bis(pentafluoroethyl)- sulfonamide, HBr, 
and HI (pKa: <−2, −9, and −9.5). However, this value decreases to –2 units in organic 
solvents and the gas phase, even though triflic acid is still a very strong acid.224 A 
computational study affords a ranking of reactivity: Cl−> Br− ≫ AcO− > MeSO3− > TfO− 
> MeOH.225 Selected examples of triflate reactivity in organic reactions involve the 
preparation of 1,4-ditrifloxybutan by the reaction of tetrahydrofuran with triflic 
anhydride, the reaction of phenylfluoroiodonium triflate with 1-hexyne and the synthesis 
of vinyl triflates,  derived from the addition of TfO− to aryl alkynyl ketones.226  
 
1.3.4 Multicomponent Reactions  
 
1.3.4.1 The Importance of Multicomponent Reactions in Synthetic Accessibility 
Small molecular mass compounds can affect the chemical and biological properties of 
macromolecules occurring in nature, such as living systems. Medicinal chemistry 
research has been focused around a limited set of molecular targets (around 900 distinct 
targets) for approved and commercially available drugs.227 During chemical synthesis, 
systematic variation of the molecular structure permits the control of the chemical and 
physical properties of these small entities (different building blocks, stereochemistries, 
functional groups and molecular frameworks).  
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Figure 1.18. (left) Multistep syntheses can be divergent (sequential) or convergent. 
(right) In analogy MCR reactions are convergent, and one- or two-component reactions 




Diversity-oriented synthesis (DOS) is a strategy aiming to generate unique compound 
collections of structurally diverse small molecules efficiently, not only in terms of 
collection/ library size but more importantly in terms of diversity, thus function. DOS 
involves ‘forward synthetic analysis’, where the products of each step become the 
branching substrates for subsequent steps. Target-oriented synthesis (TOS) of small 
molecules, refers to the divergent (sequential) synthesis of small molecules employing 
one or two starting materials (Figure 1.18).229 Both of the strategies mentioned above are 
employed to face the demand for efficient broad-region screening of chemical space in 
diversity construction;229,230 however the challenging goal regarding the synthesis of 
complex products from simple starting materials by using one-step processes, is directly 
achieved by DOS for most of the cases. These economic processes avoid costly protecting 
groups, time-consuming purification procedures after each step, as well as waste 
generation. In the last two decades, an impressive number of these powerful reactions 
have been developed employing simple starting materials, permitting high yields, 
diversity and stereocontrol, promoted by either metal catalysts or organocatalysts.231  
 
Multicomponent reactions are distinguished as classified transformations used from 
chemists as a tool for one-pot DOS. Typically, 1-3 synthetic steps are required for the 
synthesis of biologically-active scaffolds. The convergent nature of MCRs can offer the 
advantage of the efficient one-pot formation of the desired scaffolds by three or more 
starting materials.228 MCRs combine the advantages of atom economy, step economy and 
high compatibility with various unprotected orthogonal functional groups. As such, MCR 
can be considered to fall under the banner of “green chemistry”. Due to the shape,  variety 
and the high-substituent density of MCR scaffolds, the MCR scaffold libraries are more 
widely dispersed in the property space than others.228   
 
1.3.4.2 Selected Applications 
The Mannich-type condensation that involves amines, α-keto-acids and boronic acids, 
towards the synthesis of β,γ-unsaturated α-amino acids, developed by Petasis,232 known 
as the Petasis borono-Mannich reaction has received considerable attention because it 
produces skeletons that can easily be converted to amino acids, heterocycles and 
alkylaminophenols.233 Corticotropin releasing factor (CRF), a peptide hormone involved 
in stress response, exerts its activity through binding to the GPCR receptor, CRF1-r. 




are under investigations. N-Phenylphenylglycine amides, synthesised in a two-step 
process, by Petasis borono-Mannich MCR and a subsequent amidation, were found to 
work as CRF receptor antagonists.233 FTY720 is a clinically investigated 
immunosuppressive, and it also shows very promising clinical results in multiple sclerosis 
treatment. A short two-step synthesis using the Petasis reaction of dihydroxyacetone, 













































Scheme 1.28. (upper) CRF Receptor Antagonist (R) – (middle) Optimisation by 
Petasis.233 (lower) Immunosuppressive and Anti-MS Drug FTY720 synthesised by 
Petasis reaction.234  
 
Propargylamines are key intermediates for the formation of varieties of important 




biologically active molecules such as β-lactams, conformationally restricted peptides, 
isosteres, fungicides, herbicides and therapeutic drug molecules; pargyline 
(neurodegenerative disease),235 rasagiline (Parkinson's disease),236 selegiline,237 and other 
(hetero)arylalkenylpropargylamines as monoamine oxidase inhibitor (MAOI) 
(Parkinson’s disease) (Scheme 1.29).238,239 The A3 proves to be a powerful methodology 
as a coupling step of the Build/ Couple/ Pair approach in DOS because it can lead to the 
formation of polyfunctionalized intermediates suitable for the creation of different 
molecular entities.209  Cytotoxicities with IC50 values up to 1.1 μM against a human 
hepatocellular carcinoma cell line (HepG2) were exhibited by these artemisinin 
derivatives.240 The synthesis of nitrogen-containing small molecules with an alkynyl 
appendage is present in small bioactive molecules and approved drugs of peptidomimetic 













































Scheme 1.29. (top) The A3 coupling reaction of aldehyde, amine and alkyne. (A) 
Biologically important molecules containing an alkenyl appendage. (B) Propargylamine-
containing drugs.    
 
Recently, Innocenti et al. used cyclic α-amino aldehyde (prolinal) moieties for the 
microwave-assisted A3 coupling reaction with 20mol% of CuI as optimal pre-catalyst in 




exploited in intramolecular pairing reactions to obtain a pool of different alkynyl-
substituted peptidomimetic compounds.209 Intramolecular cyclization of the 1,2-diamine 
coupling product enabled the synthesis of a range of representative bi- and tricyclic 
pyrrolidines with an alkynyl chemical handle, with good coverage of the chemical space, 
as shown by PMI chemoinformatic tool.243 Specifically, A3 adducts differed in the 
chemical space positioning with respect to bi- and tricyclic compounds obtained under 
the pairing stage, suggesting the importance of including all the compounds in a 

































Scheme 1.30. (left) (A) The Pauson–Khand reaction of alkene, alkyne, and CO to 
generate cyclopentenones.244 (B) Synthesis of trans-4,5-diaminocyclopentanones by 
furfural and primary/ secondary amines. (C) Agelastatin A245 and (D) small molecule 
inhibitors of GSK-3β from GlaxoSmithKline.246  
 
A litany of higher-order and multicomponent cycloaddition reactions, many of which 
were unimaginable before the advent of transition-metal catalysis, have been, and 
continue to be developed.247 Classic examples include the [2+2+1] carbocyclization of an 
alkene, alkyne, and CO to generate cyclopentenones (the Pauson–Khand reaction, 
(Scheme 1.30 A).248 Various compounds within the cyclopentenone prostaglandin family 
possess potent anti‐inflammatory, anti‐neoplastic, and anti‐viral activity.249 In an effort 
for step-economical pathways towards the synthesis of the trans marine sponge 
bromopyrrole alkaloid Agelastatin A, Batey revealed a synthetic protocol towards the 
synthesis of trans-4,5-diaminocyclopentanones through a Lewis acid catalysed protocol 
(Scheme 1.30 B).245 Studies for Agelastatin A (Scheme 1.30) have shown that it stood out 




leukaemia, melanoma, breast cancer and bladder carcinoma cells.250,251 Moreover, 
researchers at GlaxoSmithKline discovered two small molecule inhibitors, with structures 
embedded in the same cyclopentanone motif selective for GSK-3β versus other kinases, 
which have been shown effective modulating glycogen metabolism in human liver 
cells,252 and inhibiting neuronal death mediated by reduced PI 3-kinase-pathway activity 
(Scheme 1.30).246   
 
1.4 Aim of This Thesis  
Section 1.1 of this chapter introduces the reader to the basic concepts of homogeneous 
catalysis with coordination compounds. Section 1.2 explores in detail the synthetic 
intricacies and refers to the catalytic properties of 0D 3d/4f Schiff base and Cu 
benzotriazole-based coordination complexes, demonstrating their potential and their 
popularity during the last few decades. A rationale is presented with regard to the metal 
and ligand applicability. Moreover, an overview of the recent advances in amyloid core 
functionalization via 3d/4f complex binding has been presented. The antagonistic binding 
behaviour of the different metals towards the peptide chain and the morphological impact 
on their tertiary fibril structure is highlighted. Section 1.3 describes innovative 
methodologies for homogeneous catalysis related to the work undertaken for the purposes 
of the present thesis. In this section, it is also demonstrated the underutilisation of 4f 
elements and well-characterized complexes interacting with peptide-based scaffolds for 
catalytic purposes.  
 
One of the most studied core structures in 3d-4f PMC chemistry is the defect dicubane 
topology (2,3M4-1). In this topology, the four metal ions are bridged by two μ3-O and 




2O6 core. The two 3d ions and two 4f ions can be co-planar, 
and the oxygen atoms are located above and below the plane with a centrosymmetric 
feature. The last few years, well characterised 3d-4f PMCs, many of which exhibit the 
same stable defect dicubane core topology in solution, have been used as catalysts in a 
variety of organic reactions; such species have shown enhanced catalytic activity 
comparing to their metal and/or organic precursors, without the addition of base.71 







73,74  PMCs with defect dicubane topology in C–C and C–N bond forming 




exchangeable solvent molecules (DMF/H2O), while the vacant positions of the 4f element 
are capped by solvent or counterions (DMF/NO3
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Scheme 1.31. (upper) The defect dicubane motif; (inset) ligand employed for the 
synthesis of compounds 2.1 and 3.1 adopting this motif. (A) A representation of the 





2+. (B) Hypothesised coordination environment of MII and DyIII of 
the isoskeletal analogue in solution. Colour code: MII (grey), DyIII (turquoise), O/ligand 
coordination (red), solvent/counterion/guest molecule (blue). 
 
These studies were the starting point for the research presented in this thesis. A main 
objective of this research is the systematic catalyst development and the study of 
reactivity of the 3d-4f PMC family towards a 4π electrocyclisation type of reaction. In 
Chapter 2, a novel compound was synthesised to catalyse the formation of trans-4,5-2-
bromo-4,5-diaminocyclopent-2-enones from 5-bromo-2-furaldehyde and amines. Based 
on the reported Ni2Ln2 PMCs found to catalyse the synthesis of trans-4,5-
diaminocyclopent-2-enones,73,74 and with the aim to broaden the reaction scope, using 
substituted furfural, as well as gain solid mechanistic evidence combining the knowledge 
of the research group from past and current findings related to this transformation, we 







2Cl2 series would serve as an ideal promoter for the water-
sensitive synthesis of the bromo-substituted trans-4,5-diaminocyclopent-2-enones.73,74 




secondary and primary amines) with an environmentally benign (use of minimum amount 
of solvents), time- and cost-effective character (inexpensive catalyst with very low 
catalyst loading loading as an alternative to expensive metal salts – for an overview of 
the catalysts employed to promote the same reaction please refer to scheme 2.1). (E)-2-
(((2-hydroxyphenyl) imino)methyl)-6-methoxyphenol (H2L20, Scheme 1.32) was 




20)4(DMF)6]·2(CF3SO3)·2(DMF) (2.1), described as Ni2Dy2. The 
exchangeable DMF molecules of 2.1 may permit DyIII interaction with substrate 






































Scheme 1.32. New ligands employed for the synthesis of compounds 3.1‒HYFNIF, 4.1 
and 5.1.  
 
Bearing in mind the partially saturated coordination environment of the metal centres and 




20)4(NO3)2(DMF)2] (3.1), described as Zn2Dy2,
69,72 to decorate the Ac–His–
Tyr–Phe–Asn–Ile–Phe–CONH2 (HYFNIF), amyloid peptide.
80 The resulting compound 
was described as 3.1–HYFNIF. Taking into account the structural integrity and solubility 
of the building units of the resulting hybrid material in protic solvents we aimed at 




peptide hybrid in a nanoscale level. Moreover, the 3d-3d/4f-4f substitution ability of these 
heterometallic PMCs enables detailed structural, as well as mechanistic studies and opens 
up new prospects for peptide functionalization.  
 
Various CuI (Section 1.3.2.1) and noble metal-based methodologies that facilitate the 
formation of metal-acetylide for the A3 coupling reaction have been developed, while the 
use of CuII in few existing reports is characterized by very limited mechanistic context. 
With the main notion being the exploration of the catalytic activity of CuII well 
characterised complexes in a traditionally CuI catalysed reaction, requiring inert 
conditions, emphasis was also placed on factors such as cost of reagents, general ease of 
chemistry following open air protocols, product library expansion by synthesis and 
characterisation of novel propargylamines and ligand electron-donating ability and 
tunability. Based on the recent advances in Cu catalysis (Sections 1.2.2 and 1.3.2.1) it 
was determined that such attributes would be best provided by a “chameleon” complex, 
bearing a redox non-innocent ligand that would facilitate the alteration of the Cu oxidation 
state promoting the acetylide formation in non-inert conditions. [CuIIL21-S] (4.1S) was 
synthesised bearing the 2-((E)- ((1S,2S) -2-((E)- 3,5-di-tert-butyl-2- 
hydroxybenzylideneamino) cyclohexylimino) methyl)-4,6-di-tert-butylphenol (H2L21-S, 
Scheme 1.32). The positive results indicated an impact of the copper coordination 
environment in catalysis. Subsequently, in an effort to further investigate this impact in 
A3 coupling, extend the catalyst’s applicability into primary amines, considered as 
challenging A3 substrates, and having in mind the success of N-heteroaromatic ligands in 
copper redox catalysis, albeit the scarcity of reports for such compounds in C–C bond-
forming reactions, [CuII(L7)2(CH3CN)2]·2(CF3SO3) (5.1) was synthesised and its 
catalytic reactivity was evaluated. 
 
In order to provide a clear comparison and fully determine the role and effect of the 
coordination sphere of the salen, as well as the benzotriazole moiety, additional 
compounds with analogous donor-atoms, including 2-(((1S, 2S)-2-(3,5-di-tert-butyl-2-
hydroxybenzylamino)cyclohexylamino)-methyl)-4,6-di-tert-butylphenol and bpy were 






2 Chapter 2: Solvent-free synthesis and key intermediate isolation in 
Ni2Dy2 catalyst development in the domino ring-opening 
electrocyclization reaction of furfural and amines  
 
Abstract: A solvent-free methodology that yields trans-4,5-diaminocyclopent-2-enones, 
main domains of natural products and variety of N-heterocycles, such as prostaglandins 




20)4(DMF)6]·2(CF3SO3)·2(DMF) (2.1) promotes the domino reaction of 
furfural and amines, with loadings as low as 0.01%, under stirring or microwave assisted 
conditions to afford the corresponding frameworks in very good to excellent yields (50%-
100% isolated yields). Crystallographic and theoretical studies shed light on the exclusive 
formation of the trans-diastereoisomers via a 4π-conrotatory electrocyclization process 
elucidating the key step in the catalytic process. 
 
External Contributions: Alaa Abdul-Sada was responsible for the collection of all ESI-
MS data. G. J. Tizzard and S. J. Coles collected some of the single-crystal XRD data. A. 
Vargas performed computational studies. A. McGown and J. Spencer provided part of 
the equipment and feedback on the catalytic study and the manuscript. A. McGown was 
also responsible for the purification of two catalytic products.  
 
2.1  Introduction  
New synthetic methodologies that reduce our dependence on fossil fuels and rare 
elements are highly profilic in current synthetic chemistry.253–258 Furfural, or 2-
furaldehyde, is a biomass derivative produced in million-ton quantities annually.259 The 
availability and ready affordability of this framework are compelling factors for its use to 
access high-value core building blocks,260–263 although the development of various 
methodologies to convert this oxygen-rich skeleton into building blocks for use in 
pharmaceuticals is required. On the other hand, bimetallic catalysts have been recognized 
as a powerful tool for molecular transformations enabling energy-efficient one-pot 
reactions as an alternative to multi-step protocols or achieving high 
enantioselectities.31,264–268 Kostakis’ group initiated a project toward the development of 
well-characterized 3d/4f bimetallic coordination entities that remain intact in solution and 




entities, the partially saturated coordination geometry of each metal center and in 
particular the distance separating the metals have been suggested to be key parameters 
for efficient catalysis.31,264 The presence of two different metals with significantly 
different binding selectivity (3d vs 4f), promotes the selective substrate binding; this is a 
significant advantage compared to homometallic catalysts. Additionally, the 4f centers 
retain their catalytic activity in the presence of Lewis basic N-groups allowing their use 
with unprotected amines,28 whereas the 3d centres can be redox active29,30 or promote 
other transformations.269 
 
In 2007, Batey reported a methodology that yielded trans-4,5-diamino-2-
cyclopentenones (Scheme 2.1) and involved furfural, secondary amines and Dy(OTf)3 as 
the promoter.270 This organic transformation proceeds via a domino ring-opening/4π-
electrocyclization pathway with only one equivalent of water generated as a side 
product.271–274 This organic framework can be found in several natural products and 
thereafter several efficient methodologies that promote the synthesis of racemic, trans-
4,5-diamino-2-cyclopentenones have been developed and recently reviewed.275–279 The 
methodology reported by Nardi proceeds in water and is microwave assisted,278 whilst 
immobilized alternates have been reported.280 However, in both occasions the protocols 
have moderate performance when primary amines are used therefore, the development of 








Reference                    Promoter             Loading       Solvent          Temperature       Time
2007 [270]                       Dy(OTf)3                  10%           CH3CN                 r.t.                16 h
2013 [277]                     ErCl3 6H2O               0.1%       Ethyl lactate              r.t.               30 min
2013 [279]                         AlCl3                       10%          CH3CN                  r.t.                5 h
2015-16 [73, 74]      Ni2Ln2L4Cl2                       1%           CH3CN                  r.t.                2 h 
2017 [280]              ErCl3 6H2O on silica         10%        n-butanol                  r.t.              30 min
2017 [278]                    no catalyst                     -              H2O                  MW 60
oC         40 min
2018 [276]                     Cu(OTf)2                     1%            H2O                        r.t.              10 min
This work,            {Ni2Dy2L4}
2+ 2(OTf)         0.01%       solvent-free                 r.t.              40 min
This work,            {Ni2Dy2L4}
2+ 2(OTf)         0.01%       solvent-free           MW 60oC        10 min
 









remarkable catalytic activity in the reaction of furfural and secondary or primary amines 
to yield trans-4,5-diaminocyclopent-2-enones or the corresponding and very well-known 
Stenhouse salts,281,282 respectively. We identified that treatment of Stenhouse salts under 
acidic conditions (silica gel or diluted HCl solution) yields the corresponding ring-closed 
product. Moreover, we identified a negligible contribution of the NiII moiety in the 
transformation confirming that the domino reaction is driven solely by the 4f ion, whilst 
functionalization of the organic skeleton (second coordination sphere effects) is feasible 
without lowering the catalytic efficacy. Our methodology is industrially appealing as it 
allows the reaction to proceed under air and provides the expected framework with 
secondary and primary amines and therefore being the only actual competent to the 
expensive Sc(OTf)3.
270 However, considering the aza-Piancatelli transformation as an 
excellent paradigm for sequential bimetallic catalysts to provide a wide range of nitrogen-
based heterocycles,283 it was of high importance to optimize our synthetic methodology 
before proceeding to more complex reactions. Therefore, capitalizing on our preliminary 
findings and considering the recent advances of this reaction,275 we report herein the 
development of our synthetic protocols and identify their applicability.  
 
2.2 Results and Discussion  
 
2.2.1 Synthetic Aspects  
Considering the efficiency of triflate anions in organic transformations,226 the recently 
reported reusable implementation of Cu(OTf)2
276 in yielding trans-4,5-
diaminocyclopent-2-enones, as well the enhanced stability in solution of the tetranuclear 
defect dicubane Ni2Ln2 framework, we envisaged that the corresponding triflate analogue 
of the previously reported NiII2Ln
III




20)4(DMF)6]·2(CF3SO3)·2(DMF) (2.1) (also abbreviated as 
Ni2Dy2) can be synthesised in two high yielding steps (97% total yield) under ambient 
conditions and commercial starting materials. The first step involves the near quantitative 
synthesis of the ligand (E)-2-(((2-hydroxyphenyl)imino)methyl)-6-methoxyphenol 
(H2L
20) from the condensation reaction between o-vanillin and 2-aminophenol.73 Ligand 
H2L




73,74 The ligand is then involved in a room temperature reaction in ethanol with 




precipitate (2.1) was then collected and crystallised in DMF and Et2O as a yellow-green 
crystalline material (Chapter 7, section 7.3). Compound 2.1 was characterised by SXRD 
(section 2.2.2.1.1), FT-IR, UV-Vis, thermogravimetric analysis (TGA), ESI-MS 












Scheme 2.2. Synthesis of compound 2.1.  
 
In our quest to shed light on the chemical transformation, we attempted to isolate an 
intermediate Stenhouse salt of the reaction between furfural and aniline (C2P3a HCl). 
Short-lived light red needle-shaped crystals are formed when dilute HCl is added directly 
to the NMR tube of the crude product, and thereafter the crystals are named C2P3a HCl 
(Figure 2.2). The SXRD study confirms the isolation of the intermediate with two 
crystallographically independent entities (section 2.2.2.1.2).  
 
2.2.2 Characterisation of Compounds 2.1 and C2P3a HCl. 
 
2.2.2.1 Crystal Structure Description of Compounds 2.1 and C2P3a HCl  
 
2.2.2.1.1 Crystal Structure Description of Compound 2.1  
Single-crystal X-Ray Diffraction (SXRD) crystallographic studies identified the structure 
of 2.1 as shown in Figure 2.1. The four organic ligands partially saturate the coordination 
environment of all metal centers (five out of six and six out of eight for Ni and Dy, 
respectively), whilst the remaining positions are occupied by exchangeable solvent DMF 











Figure 2.1. Crystal structure of compound 2.1, CCDC ID 1891851. Hydrogen atoms and 
lattice molecules are omitted for clarity. Colour code: Ni (green), Dy (turquoise), C 
(grey), N (light blue), O (red), F (light green), S (yellow).  
 
 
Scheme 2.3. Coordination modes of H2L20 in compound 2.1. 
 
2.1 crystallises in the monoclinic P21/c space group. The asymmetric unit of 2.1 contains 
one NiII ion, one DyIII ion, two doubly deprotonated organic ligands (L20), three 
coordinated DMF molecules, one to NiII and the other two to the DyIII ion and one lattice 
OTf counterion (Figure 2.1). The distance between the NiII and DyIII centre of the 




(2,3M4-1). Each NiII ion has an octahedral geometry and each DyIII centre has a square-
antiprismatic geometry. The H2L
20 ligand exhibits two different coordination modes 
(Scheme 2.2, modes I and II). In the first mode (Scheme 2.3, mode I), the two phenoxide 
oxygen atoms and the imine nitrogen atom are chelated to the NiII centre and the 
phenoxide atom (from the 2-aminophenol unit) is further bonded to the DyIII ion (Dy1). 
The methoxide oxygen atom is bound to the second Dy centre (symmetry-related 
counterpart of Dy1). In the second mode (Scheme 2.3, mode II), the two phenoxide 
oxygen atoms and the imine nitrogen atom are chelated to the DyIII centre, while the 
phenoxide oxygen atom (from the 2-aminophenol unit), is further bound to the two NiII 
centres, resulting in occupacy of five and six coordination sites of the NiII and the DyIII 
centres, respectively. The remaining sites are occupied by one and two DMF molecules 
on the NiII and DyIII centre respectively. The two lattice OTf ‒ anions balance the charge. 
No aromatic interactions, such as π-π stacking between the aromatic rings of the phenolic 
ligand, can be identified. 
 
2.2.2.1.2 Crystal Structure Description of Compound C2P3a HCl 
 
Table 2-1. Selected Bond Distances (Å) for N–C, C–C and C–O bonds in compound 
C2P3a HCl.a 
Entries First entity Second entity 
1 N1 C7 1.333(5) N51 C57 1.331(5) 
2 N1 C1 1.406(5) N51 C51 1.411(5) 
3 N2 C11 1.332(5) N52 C61 1.335(5) 
4 N2 C12 1.402(5) N52 C62 1.409(5) 
5 C8 C7 1.376(5) C58 C59 1.387(5) 
6 C8 C9 1.389(6) C58 C57 1.385(6) 
7 C10 C9 1.385(5) C61 C60 1.373(6) 
8 C10 C11 1.385(6) C59 C60 1.386(6) 
9 C1 C6 1.388(6) C62 C67 1.386(6) 
10 C1 C2 1.394(6) C62 C63 1.388(6) 
11 C12 C13 1.380(6) C51 C52 1.384(6) 
12 C12 C17 1.386(6) C51 C56 1.387(6) 




14 C8 O1A 1.402(6) C60 O51B 1.412(8) 
a Two crystallographically identical entities can be found in the crystal 
structure of C2P3a HCl, however only first entity is drawn in Figure 2.2.  
 
C2P3a HCl crystallises in the orthorhombic Pbca space group. The five carbon atoms 
(C7-C11 result of the ring opening of the furfural) are in a linear configuration. Bond 
distances (Table 2-1) and the freely refined H-atoms provide the following four valuable 
insights regarding the intermediate. 
 
Figure 2.2. (upper) Crystal structure and (lower) schematic representation of compound 
C2P3a HCl, CCDC ID 1891852. Solvent molecules are omitted for clarity. Colour code: 
C (grey), N (light blue), O (red), Cl (light green).  
 
A) The two carbon-nitrogen bonds (Table 2-1, entries 1 and 3,) are significantly shorter 
than the corresponding Caromatic–N bonds (Table 2-1, entries 2 and 4). Single (C–N) or 
double (C=N) bonds of reported aniline-based compounds are in the range of 1.434-1.472 
Å 284,285 and 1.260-1.278Å,286,287 indicating the hybrid intermediate (single/double) 
character of the (N1-C7, N2-C11) bonds. B) The four C–C (Table 2-1, entries 5-8) bonds 




aromatic ring (Table 2-1, entries 9-12). C) The C–O bond (Table 2-1, entries 13 and 14) 
is at 1.375(7) Å or 1.402(6) Å (56/44 ratio) which is indicative of a single bond, whilst 
the O atom is protonated. D) The freely refined H-atoms in the four C and two N atoms 
exclude a sp3 configuration. All these notes indicate the best described confirmation is 
the delocalized image shown in Figure 2.2. A survey in the Cambridge Crystallographic 
Database (CSD)288 for derivatives based on furfural and amines yielded in no results, 
therefore we may propose that C2P3a HCl is the first crystallographically isolated 
Stenhouse salt example. 
 
2.2.2.2 Solution Studies 
ESI-MS data (for the instrumentation refer to section 7.1), obtained from a solution of the 














2+ core remains intact in a series of protic 
and polar organic solvents such as MeOH, EtOH, DMF, CH3CN and H2O. ESI-MS 
spectra, along with detailed analysis of the fragments are presented in the Appendix 
(Figures S2-4, S2-5). The UV-Vis spectra of 2.1 (10–3 M) and H2L
20 (10–3 M) were 
measured in MeOH and further support ligand binding to the metal centres. Transitions 
in the region 340-500 nm correspond to metal-to-ligand charge transfer (MLCT) 
(Appendix, Figure S2-2). 
 
2.2.3 Catalytic studies  
 
2.2.3.1 Benchmarking and Optimisation  
 
With the catalyst in hand and aiming to further develop our protocols, we selected EtOAc, 
considered as a solvent with an enhanced “green” character,289 in the reaction between 2-
furaldehyde and morpholine. Following the reported protocols (Table 2-2, entries 1 and 
2), the catalytic reaction with 1% loading of 2.1 yielded the corresponding framework in 
a quantitative amount in 40 minutes (Table 2-2, entry 3), whilst reactions conducted with 
one and two orders of magnitude lower catalyst loadings (0.1% and 0.01%) were equally 





When compared with the prototype catalyst, Dy(OTf)3 (Table 2-2, entry 1),
270 our 
protocol proceeds with three orders of magnitude less catalyst loading, whereas a reaction 
under similar conditions with Ni2Dy2Cl2 yielded the corresponding framework in 40% 
conversion. This result identifies the important role of the OTf anion in the transformation 
(Table 2-2, entry 6), possibly via the generation of triflic acid in co-catalytic amounts.295 
However, aiming to develop a greener protocol and having in mind that the 
transformation is promoted by acidic ionic liquids under solvent-free conditions,290 we 
attempted a solvent-free reaction with a catalyst loading of 0.01% (Table 2-2, entry 7).  
 
To our delight, the reaction proceeded in excellent conversions within 40 minutes, whilst 
a further decrease in catalyst loading to 0.005% can afford the ring closed product in 70% 
conversion (Table 2-2, entry 8). Finally, considering the recent developments (Scheme 
2.1) in the atom-efficient domino condensation/ring-opening/electrocyclization 
reaction278 and that the use of microwaves291 is a very effective technique that facilitates 
the synthesis by significantly reducing the time, we attempted a solvent-free reaction 
under microwave conditions. To our delight, the solvent-free reaction proceeds in 
excellent yields in only 10 minutes and catalyst loadings of 0.01% (Table 2-2, entry 9).  
 
When simple heating is applied (Table 2-2, entry 10) a lower reaction conversion is 
observed, comparing to the conversion obtained by MW irradiation. It is important to 
state that according to the literature simple nickel metal salts do not efficiently promote 
this transformation, on the contrary to the choice of the 4f element, which has found to 
be critical. Moreover, the use of molecular sieves (MS) removes the water from the 
catalytic cycle and shifts the reaction equilibrium faster towards the Schiff base (reaction 
intermediate) formation, preventing hydrolysis.73,74 The methods involving stirring or 
microwave conditions are named thereafter as “C2A” and “C2B”, respectively. The 
resulting mixtures from methods C2A and C2B are subjected to CH2CL2 (20 mL) addition 
and filtration through celite to withdraw the catalyst, prior to crude NMR measurements 
and product purification by column chromatography (section 7.4.1).    
 












oC 10 24 hours 100270 
2 Ni2Dy2Cl2 25
oC 1 2 hours 10074 
3 2.1b 25oC 1 60 min 100 
4 2.1b 25oC 0.1 60 min 100 
5 2.1b 25oC 0.01 60 min 100 
6 Ni2Dy2Cl2
b 25oC 0.01 40 min 40 
7 2.1c 25oC 0.01 40 min 93 
8 2.1c 25oC 0.005 40 min 70 
9 2.1d 60oC (MW) 0.01 10 min 95 
10 2.1e 60oC 0.01 10 min 80 
a Relative conversion calculated by 1H-NMR based on the remaining reactant 2-
furaldehyde and the corresponding intermediate Schiff base of 2-furaldehyde and 
morpholine.  
b Reaction conditions: morpholine, 1.1 mmol; 2-furaldehyde, 0.5 mmol; 4Å MS 100 
mg; anhydrous EtOAc 2 mL; room temperature; catalyst loading (calculated per 
equivalent of Dy). 
c Reaction conditions: Stirring 40min, solvent – free, amine, 2.2 mmol; 2-furaldehyde, 
1 mmol; 4Å MS 100 mg; catalyst loading (calculated per equivalent of Dy). 
d Reaction conditions: Microwave 10 min, solvent–free, amine, 2.2 mmol; 2-
furaldehyde, 1 mmol; 4Å MS 100 mg; catalyst loading 0.01% (calculated per 
equivalent of Dy). 
e Reaction conditions: Heating 10 min, solvent–free, amine, 2.2 mmol; 2-furaldehyde, 





2.2.3.2 Scope of the reaction  
 
Table 2-3. The scope of the reaction of secondary amines and primary amines with 








































O 2.1, 0.01%, solvent free
molecular sieves
A. stirring, r.t., 40 min
B. MW, 60oC, 10 min
product [a]
C2P3b
C2A.  83% 
C2B.  92%
C2P2c










C2B.  97% (up to 
100%)[b]
C2P3c
C2A.  89% 
C2B.  92%
C2P3d






[a]Conditions: Method C2A. Stirring 40 min, Solvent – free, amine, 2.2 mmol; 2-
furaldehyde, 1 mmol; 4Å MS; 2.1 loading 0.01% (calculated per equivalent of Dy). 
Conditions: Method C2B. Microwave 10 min, Solvent-free, amine, 2.2 mmol; 2-
furaldehyde, 1 mmol; 4Å MS; 2.1 loading 0.01% (calculated per equivalent of Dy). 
[b]C2P3a was obtained in up to 100% isolated yield when it was purified three times by 
column chromatography. 
 
Table 2-4. The scope of the reaction with 3-bromo-2-furaldehyde, promoted by 2.1 under 




















O 2.1, 0.01%, 
























[a]Conditions: Microwave 10 min, 60°C, solvent CH3CN (100 µL to solubilise the 
aldehyde which is solid at room temperature), amine, 2.2 mmol; aldehyde, 1 mmol; 4Å 
MS; 2.1 loading 0.01% (calculated per equivalent of Dy). 
 
We then explored the scope of the reaction by employing a variety of secondary amines 
as substrates (Table 2-3, compounds C2P2a-C2P2d) and isolating the corresponding 




better performance. The use of 2.1, as a catalyst, in the reaction of furfural and primary 
amines yields the corresponding deprotonated Stenhouse salts (Table 2-3, compounds 
C2P3a-C2P3d).73,74 This result is in line with our previous findings and in contrast to the 
use of Cu(OTf)2
276 and Dy(OTf)3
270 as catalysts, in which no reactivity or the synthesis 
of  the corresponding Schiff base is observed, respectively. This difference supports the 
applicability of our catalyst and methodology and justifies our choice in further 
investigating its catalytic efficacy. The ring closing of the zwitterion to the corresponding 
cyclopentanones proceeds under acidic conditions, as we have shown before,73,74 and is 
independent of the Dy moiety but dependent on the electron withdrawing substitution in 
aromatic primary amines; i.e. treatment of C2P3d under acidic conditions does not afford 
the corresponding ring-closed product. Overall, the products were obtained in very good 
to excellent yields (66%-100% isolated yields). The electron withdrawing –CF3 
substitution of the aniline ring is possibly the reason behind the lower yield obtained for 
product C2P3d (66% for method C2A). For the case of product C2P3a, when three 
column chromatography purification procedures by took place, the product was obtained 
100%. 
 
To further identify the versatility of our protocol for this transformation, we incorporated 
3-brom-2-furaldehyde instead of 2-furaldehyde (Table 2-4). This has been suggested as 
an ideal pathway to afford 2-bromo trans-4,5-diaminocyclopent-2-enones, which can 
then be transformed into natural product-like scaffolds.292 The reaction proceeds in the 
presence of the minimum amount of CH3CN or EtOAc as a solvent to solubilize the 
substituted furfural moiety and achieves very good to excellent yields (48%-96% isolated 
yields) with almost three orders of magnitude less catalyst loading when compared to the 
previously reported catalysts for the same domino reaction.292 The reaction of morpholine 
or aniline with 3-bromofurfural, in absence of molecular sieves, yielded the 
corresponding morpholinium bromide293 and anilinium bromide,294 as it was confirmed 
by single X-Ray studies. This outcome indicates that the reaction is highly sensitive and 
limited from the presence of water; therefore, other developed microwave assisted 





2.2.3.3 Mechanistic insights 
 
Mechanistic studies employing DFT computational protocols  
Previous theoretical studies by Kostakis et al.,74 identified that the pathway from the 
Stenhouse salt to the final product (Scheme 2.4) is highly favourable, indicating that the 
catalysis takes place prior to this step, and the total electronic energy of intermediate C 
(Scheme 2.4) concerns a pyramidal-to-planar evolution of the beta-nitrogen, a key feature 
that is likely involved in the catalytic process. The intermediate Stenhouse salt of the 
reaction between furfural and aniline upon addition of HCl, C2P3a HCl, was isolated and 
characterized crystallographically as described in section 2.2.2.1.2.  
 
 
Figure 2.3. Calculated structure and frontier orbitals of C2P3a. The two MOs in the top 
are the lowest unoccupied, whilst the two MOs in the bottom are the highest occupied. A 
bond stick model is given for clarity.  
 
We sought to put into context the “position” of the observed planar intermediate within 
the transformation frame by considering the electronic structure, geometry and both 
quantitative and qualitative metrics based on partial charges, molecular electrostatic 
potentials and molecular orbitals (MO). Hence, calculations were carried out based on 




indicates selected bond distances for different zwitterionic forms of the intermediate 
(C2P3a HCl, C2P3a+ and C2P3a) and one transition state C2P3a TS in which the aryl 
next to nitrogen is perpendicular to the molecular plane. Table S2–2 shows Hirshfeld 
charge at some selected atom centers. Figure S2-8 shows the frontier orbitals of C2P3a 
and the other forms. As with the X-ray structure, the calculations present a highly planar 
geometry for C2P3a. 
 
Figure 2.4.  Energy profile of the planar 3a going to the perpendicular aryl bearing 3a TS 
and finally towards the Stenhouse salt. 
 
This stems from the highly conjugated C–C framework between the two N atoms as can 
be seen in Figure 2.3 and this is observed for all forms, that is, the overall (planar) 
structure is not affected whether the molecule is neutral, protonated, or in the presence of 
counter-ion; importantly, this feature is also present in the transition state. Some 
differences start to appear when considering the partial charges, though this just mainly 
reflect the fact that in both C2P3a and C2P3a TS the oxygen is anionic. A further 
similarity between the latter two is shown by the Coulombic molecular electrostatic 
potential as mapped on the surface density as shown in Figure S2-9. However, where the 
important distinction lies is in the overall electronic energy; Figure 2.4 shows the 




the twisting of the aryl next to N2 is the first step towards cyclisation, this step already 
puts the system to 40% of the energy required to attain the non-linear structure. We 
conclude that the planar intermediate is a key step in the catalysis and the conjugation it 
bears plays a major role, that is, it is highly stable but an induced slight variation in its 
geometry pushes it easily towards to the observed reaction products.  
 
 
Scheme 2.4. A proposed mechanism incorporating the key intermediate characterized in 
this study and possible roles of catalyst according to the literature.295 
 
Taking into account : a) the reaction takes place in solvent free conditions, b) the partially 
saturated coordination environment of the Dy centers, c) the rigidity of the tetrametallic 
unit as well its possibility to exchange solvent molecules, d) kinetic studies in which the 
Dy(OTf)3 catalysed aza-Piancatelli rearrangement is controlled by a key off-cycle binding 




either bond to hydroxyl group HO– (byproduct trap), substrate (activation) or both, we 
propose a mechanism of the 4π-conrotatory electrocyclization process (Scheme 2.4) that 
involves the bimetallic entity. Such an observation, we believe, provides valuable insight 
into the full detailed mechanism of the reaction, attempts to understand the detailed role 
of the bimetallic catalyst as well may explain the reactivity of the bimetallic system at 
very low loadings.  
 
2.3 Conclusion  
We report herein an efficient synthetic methodology that yields trans-4,5-
diaminocyclopent-2-enones in a diastereoselective manner. Developing our previous 
methodology, the triflate analogue of the tetranuclear Ni2Ln2 moiety (2.1), enhances the 
catalytic efficacy of the bimetallic catalyst by two orders of magnitude and when 
compared with state-of-the-art catalysts of this reaction this attains two276 or three270 
orders of magnitude in terms of improvements. Moreover, our effort to identify 
environmentally friendly protocols showcased that the reaction can take place in EtOAc 
as a solvent, however, excellent yields are obtained when solvent-free, stirring or 
microwave assisted, conditions are followed. The developed methodology is applicable 
to a series of secondary and primary amines as well the substituted 3-
bromofurfulaldehyde, yielding the corresponding frameworks. The first crystallographic 
characterisation of the Stenhouse salt intermediate supports the exclusive formation of 
the trans-diastereoisomers via a 4π-conrotatory electrocyclization. Theoretical studies 
shed light on the formation of the planar intermediate and suggest the latter to be a key 
step in the catalytic process. The optimized present catalytic protocol paves the way to 
use 2.1 or its derivatives as dual/tandem catalysts in other organic transformations, such 







3 Chapter 3: Zinc-Dysprosium Functionalized Amyloid Fibrils  
 
Abstract: The heterometallic Zn2Dy2 entity bearing partially saturated metal centres 
covalently decorated a highly ordered amyloid fibril core and the functionalized assembly 
exhibits catalytic Lewis acid behaviour. 
 
External contributions: Y. K. Al-Hilaly was responsible for providing advice regarding 
the preparation and characterisation of the amyloid fibrils. L. C. Serpell was responsible 
for the collection and analysis of the XRFD data, as well as providing part of the 
equipment and feedback on the analysis of the results. S. I. Sampani, L. C. Serpell and G. 
E. Kostakis were collectively responsible for the initial conception of the research and the 
writing of the paper. 
 
3.1 Introduction  
Amyloid fibrils represent a class of self-assembled peptides that share a very well ordered, 
cross-β core structure and are suitable for further decoration.296 Although amyloid is well 
known for a pathological role in diseases such as Alzheimer’s disease and Diabetes type 
2, short self-assembling peptides have been developed and characterised as templates for 
functionalisation (for selected examples on amyloid functionalisation refer to section 
1.2.3.3.2).75,297,298 Hexapeptides have been particularly useful in forming highly ordered 
amyloid cores and several of these have been characterised to provide structural 
information. X-ray fibre diffraction, transmission electron microscopy have been 
combined to provide a cross-β structural model for the self-assembling capped peptide 
sequence Ac–His–Tyr–Phe–Asn–Ile–Phe–CONH2 (HYFNIF).
80 HYFNIF along with 
several other hexapeptides was first identified as a highly amyloidogenic peptide 
sequence using the amyloid propensity algorithm Waltz.81 This amyloid-forming peptide 
contains several side chains that are ideal for further functionalisation, such as the 
imidazole-N of His and the -OH group of Tyr. Peptides containing histidine residues are 
the most widely studied in coordination chemistry, due to their presence in many 
important metalloproteins.12  
 
Functionalisation of these entities with metals depends on several parameters, i.e. lability 
of metal centres, use of protic solvents, and the presence of other amino acids with 




the successful self-assembly of biomolecules and metal centres has yielded various 
supramolecular architectures301 i.e. macrocycles, cages, metal-organic frameworks,302–306 
spherical shells or fibrils,307,308 of which some exhibit biomimetic functions such as 
selective recognition309 and allosteric cooperativity.310  
 
Kostaki’s group has previously established the structural integrity and the transformative 
character, of the bimetallic entity [ZnII2Dy
III
2L4(NO3)2(DMF)2]  (3.1) (Figure 3.1, 
left).69,72 3.1 entity is centrosymmetric and can be considered as an ideal moiety to bind 
with His-containing biomolecules because is a) built solely by the organic ligands which 
partially saturate the coordination environment of all metal centres (the remaining sites 
are occupied by exchangeable solvent and anion molecules) and b) the metal centres in 
the 3.1 unit are in a close proximity (3.3Å); Dy is oxophilic and Zn can coordinate to N-
atoms, thus permitting either the Zn (A), or Dy (B) or both (A&B) centres to bind to one 
or two positions in the biomolecule (Figure 3.1, left). We utilised HYFNIF (Figure 3.1, 
right) as model peptide to investigate its binding to 3.1, as it contains various binding 
sites, starting with the His in position-1 as well as one Tyr residue in position-2 with the 
–OH group of the phenolic ring. Here we have fully characterised the complexation and 
architecture of the functionalised amyloid structure, described as 3.1–HYFNIF.  
 
Figure 3.1. (left) The structure of the 3.1 entity used for binding; A and B point potential 
binding sites. (right) A ChemDraw representation of the capped HYFNIF hexapeptide 
used in this study. 
 





3.2.1 Synthetic aspects 
Compound 3.1 was synthesised according to the previously reported procedure.69,72 
Capped HYFNIF self-assembles to form amyloid-like fibrils, which are characterised by 
their regular cross-β architecture.80 This molecule forms mature fibrils in H2O (2 mg/mL) 
after 7 days incubation. CD spectra for HYFNIF in water have been found to provide 
essential structural information for the hexapeptide.80 To investigate the effect of 
compound 3.1 on the HYFNIF fibrils, 1.26x10-3 M HYFNIF fibrils in aqueous methanol 
were treated with metal sources 3.1 (3.1‒HYFNIF), Zn(NO3)2·6H2O (Zn‒HYFNIF), 
Dy(NO3)3·5H2O (Dy‒HYFNIF) or Zn(NO3)2·6H2O/Dy(NO3)3·5H2O (Zn‒Dy‒HYFNIF) 
and incubated for 24 h at room temperature. Circular Dichroism (CD), UV-Vis, 
Transmission electron microscopy (TEM), X-ray Fibre Diffraction (XRFD), Field 
Emission Scanning Electron Microscope with Energy Dispersion X-ray analysis 
(FESEM/EDX) (Appendix, Table S3‒2), Tyr-Fluorescence (Appendix, Figure S3-3) 
measurements were performed.  
 
3.2.2 Characterisation of Compounds 3.1 and 3.1‒HYFNIF 
 
3.2.2.1 Crystal Structure Description of Compound 3.1  
SXRD data show that the four organic ligands partially saturate the coordination 
environment of all metal centers (five out of six and six out of eight for Zn and Dy, 
respectively), whilst the remaining positions are occupied by solvent DMF molecules and 
NO3




3.1 crystallises in the monoclinic P21/c space group. The asymmetric unit of 3.1 contains 
one ZnII ion, one DyIII ion, two doubly deprotonated organic ligands (L20), one 
coordinated DMF molecule to ZnII and one nitrate anion to the DyIII ion (Figure 3.2). The 
main core of 3.1 can be described as a defect dicubane (2,3M4-1). Each ZnII ion has an 
octahedral geometry and each DyIII centre has a square-antiprismatic geometry. The 
H2L
20 ligand exhibits two different coordination modes, similar to those described in 
section 2.2.2.1 for the 3d and the Dy element. The remaining sites are occupied by one 
and two DMF molecules on the NiII and DyIII centre respectively. The two lattice OTf 






Figure 3.2. Crystal structure of compound 3.1, CCDC ID 1452417. Hydrogen atoms and 
solvent molecules are omitted for clarity. Colour code: Zn (dark grey), Dy (turquoise), C 
(grey), N (light blue), O (red).  
 





Figure 3.3. X-ray Fibre diffraction (XRFD) confirms that the decoration of the fibrils by 
3.1 does not affect the structure of the amyloid fibril core. 
 
XRFD data confirm that the binding of 3.1 to HYFNIF fibrils does not affect the 




HYFNIF (Figure 3.3) showing the characteristic 4.7Å reflection on the meridian, arising 
from the hydrogen-bonded β-strands that run perpendicular to the fibre axis and 12 Å 
signal on the equator, arising from the spacing between the β-sheets. The fibres of 
HYFNIF and 3.1‒HYFNIF showed the lower angle reflections on the equator at 16 Å 
and 18 Å respectively, possibly suggesting that packing is affected by the introduction of 
the compound (Figure 3.3).  
 
Transmission Electron Microscopy  
 
 
Figure 3.4. TEM images of HYFNIF amyloid-like fibres in H2O-MeOH without 
(left) and with 3.1 (right). 
 
TEM studies were performed to compare the morphology of HYFNIF in aqueous 
methanol and 3.1‒HYFNIF in aqueous methanol (Figure 3.4). These show the 
appearance of very thin fibrils in dense networks after one-week incubation, in all cases. 
HYFNIF in aqueous methanol forms ordered fibrils with dimensions of 8.85±0.73 nm 
STDEV short width, 12.69±1.62 nm STDEV long width, and 59.78±8.35 nm STDEV 
periodicity compared to 3.1‒HYFNIF in aqueous methanol with dimensions of 
9.38±0.57 nm STDEV short width, 11.99±1.24 nm STDEV long width, and 65.39±12.15 
nm STDEV periodicity (Figure 3.4). Therefore, we can conclude that no significant 
morphological difference was observed after treating the preformed HYFNIF fibre with 







To further identify the elemental composition of the functionalised 3.1‒HYFNIF entity 
FESEM/EDX was recorded despite their qualitative rather than quantitative character. 
3.1‒HYFNIF, suspended in Milli-Q H2O˗MeOH, was prepared by pipetting a drop onto 
a polished Si chip and dried overnight at room temperature to afford a light yellow film. 
The measurements are summarized in Appendix, Table S3‒2 and demonstrate the 
presence of Zn, Dy, O, C and N elements and that a 1:1 Zn:Dy ratio is reasonable. 
 
3.2.2.3 Solution Studies  
 
Circular Dichroism 
HYFNIF self-assembles to form amyloid-like fibrils, which are characterised by their 
regular cross-β architecture.80 Capped HYFNIF (2mg/mL) forms mature fibrils in H2O 
after 7 days incubation (Appendix, Figure S3-1). CD spectra for HYFNIF in water 
revealed a strong, positive signal at 200 nm which indicates a linear dichroism (LD) 
contribution arising from the alignment of the fibrils and this has been previously reported 
for HYFNIF fibrils.80 CD spectra recorded at 0o and 90o confirmed LD arising from lateral 
alignment of the fibrils. CD showed a small signal at 275 nm (Appendix, inset, Figure 
S3-1) attributed to the Tyr residue. HYFNIF amyloid-like fibrils were incubated with 3.1 
for 24 h in aqueous methanol at room temperature and any conformational changes were 
monitored using CD and compared to the CD spectrum of HYFNIF in aqueous methanol 
alone (Figure 3.5). The CD spectra of HYFNIF in water and water-methanol are similar 
(Appendix, Figure S3-1 and Figure 3.5). However, the CD spectrum of 3.1-treated 
HYFNIF fibrils in aqueous methanol shows the appearance of new signals at 190, 202, 
230, and 238 nm with significantly enhanced contribution from the Tyr residue at 275 nm 
as well as an increased intensity at 202 nm. This enhanced signal indicates changes in the 
vicinity of the Tyr residue which may suggest the binding of the Tyr residue with 3.1. 
The signal at 202 nm belongs to LD contribution as shown by the CD spectra that were 
collected at 0 and 90 deg (inset, Figure 3.5). The CD spectra with Zn, Dy or Zn/Dy did 
not appear to show contribution of LD and gave a signal at 218nm consistent with β-sheet 
content and differed significantly from the spectrum arising from 3.1‒HYFNIF 








Figure 3.5. CD spectra of HYFNIF untreated (black) and treated with 3.1 (red), in H2O-
MeOH and incubated for 24 h at room temperature. (inset) CD spectrum of 3.1‒HYFNIF 
was collected at 0° and 90°. 
 
UV-Vis  
UV-Vis data were recorded in the region of 190-800 nm. ZnII is diamagnetic (3d10), whilst 
Dy has a 4f9 electronic configuration, thus all transitions are very weak and the observed 
peaks are anticipated to correspond to metal-to-ligand charge transfer (MLCT) bands. 
Indeed, the UV-Vis spectrum of 3.1 shows a peak in the 400-460 nm region which may 
be attributed to a MLCT band (Figure 3.6), however this peak is shifted by 100 nm, at 
350 nm, in the 3.1‒HYFNIF spectrum (inset, Figure 3.6). In the UV region, in agreement 
with the CD data, the 3.1‒HYFNIF exhibits a maximum (at 275 nm) with significant 
signal enhancement comparing to the maximum exhibited by the HYFNIF. Notably, the 
3.1 entity does not show any peak at this area. This peak can be attributed to the presence 
of aromatic Tyr residues in the fibril (Figure 3.6, red and black lines).80 These findings 
support the successful binding of the 3.1 entity to HYFNIF. Within the region 300-500 
nm, the presence of two minima at 308 and 401 nm and one maximum at 347 nm in the 
3.1‒HYFNIF spectrum, comparing to the three maxima at 308, 378, 417 nm and a 




of the coordination cluster (inset, Figure 3.6). Strong absorption appeared near 200-240 
nm for the HYFNIF, while in the same region, Dy and mixture of Zn/Dy salts slightly 
induced hypochromicity in the peptide solutions (Figure 3.6).  
 
 
Figure 3.6. UV-Vis spectra of the Zn2Dy2 entity and HYFNIF fibrils treated and untreated 
with Zn/Dy sources in H2O-MeOH, incubated for 24 h at room temperature. (inset) The 
absorption minima at at 308 and 401 nm, the enhanced maximum at 275 and the 
maximum at 347 nm in the 3.1‒HYFNIF spectrum support binding of the coordination 
cluster to the peptide.  
 
Previous studies have indicated the spatial structure together with the chirality of the 
chromophores (C=O,–COOH) and auxochromes (–OH, –NH2) of peptides change upon 
zinc binding,311,312 inducing changes in the absorption intensity. According to the 
literature, lanthanides have been found to accelerate fibrillation,94 while zinc can inhibit 
fibril formation313 and promote intermolecular interactions314 or indirectly inhibit/change 
the binding mode of other metals.315 The latter may also occur here, where zinc salt and 
dysprosium salt co-exist with HYFNIF (Zn‒Dy‒HYFNIF).  
 
Dityrosine Fluorescence 
Moreover, bearing in mind that Tyr-10 fluorescence is a better tracker for interactions 




incubation for HYFNIF and treated HYFNIF, in the area 300-320 nm, where the 
characteristic Tyr fluorescent emission is observed, we identify that HYFNIF exhibits a 
maximum with intensity 345, Zn‒Dy‒HYFNIF exhibits a maximum with intensity 305, 
whilst the 3.1‒HYFNIF exhibits a maximum with intensity 132. The suppression of the 
tyrosine signal of 3.1‒HYFNIF may indicate that 3.1 binds to the Tyr. When salts of both 
metals were incubated with HYFNIF, a significant difference in interaction is observed; 
this may signifies the antagonistic behaviour of both metal centres for binding or changes 
in the fibril structure.  
 
 
Figure 3.7. Proposed model of the 3.1‒HYFNIF fibrils. 
 
 
3.2.3 Catalytic Studies  
 
3.2.3.1 Benchmarking and optimisation  
Furfural and amines yield, via a Lewis acid promoted domino reaction, trans-4,5-
diaminocyclopent-2-enones (Table 3-1); this synthon is a versatile building block in the 
synthesis of natural products and therefore several methodologies that promote this 
reaction have been developed, as described in Chapter 2. To identify the catalytic efficacy 
of the functionalised 3.1‒HYFNIF, several screening experiments were performed 
(Table 3-1, Entries 1-8).  
 
The catalytic conversion was performed in nanoscale (10-3 M) and we used 
environmentally friendly solvents. From these data, it is evident that the reaction is 




tested HYFNIF (Table 3-1, entry 5), as well as combinations of HYFNIF with metal salts 
(Table 3-1, entries 6-8).  
 
Table 3-1. The catalysed formation of trans-4,5-diaminocyclopen-2-enonea. 
 
Entry Catalyst Solventb Amine Conversion%c 
1 - MeOH Morpholine 2 
2 - MeCN Morpholine 8 
3 - MeCN/MeOH Morpholine 8 
4 Zn(NO3)2·6(H2O) + 
Dy(NO3)3·5(H2O) 
MeCN/MeOH Morpholine 53 
5 HYFNIF MeCN/MeOH Morpholine 2 (3d) 
6 Zn‒HYFNIF  MeCN/MeOH Morpholine 56 
7 Dy‒HYFNIF MeCN/MeOH Morpholine 57 
8 Zn‒Dy‒HYFNIF MeCN/MeOH Morpholine 58 
9 3.1 MeCN/MeOH Morpholine 95 
10 3.1‒HYFNIF MeCN/MeOH Morpholine 67(100d) 
11 3.1‒HYFNIF MeCN/MeOH Aniline 84(100d) 
a Room temperature, concentration 3mM, 1% catalyst loading, using the working peptide 
solutions of 1.26x10-3 mol/L in HYFNIF, total volume 0.25 mL, time 24 h, ambient 
conditions. b Solvent: A = MeOH, B = MeCN, C = MeCN/MeOH (4/1). c Relative 
conversion calculated by 1H-NMR based on the remaining reactant 2-furaldehyde and 





The HYFNIF fibril is not catalytically active, but the small conversion may be attributed 
to the solvent, as this has been noted by others278 and our initial experiments (Table 3-1, 
entry 1). The moderate catalytic performance of the in situ generated HYFNIF-metal salts 
derivatives (Table 3-1, entries 6-8) and the almost identical yields when compared with 
that of the metal salts (Table 3-1, Entry 4) indicates that the metal salts are responsible 
for the conversion. Then, we tested the tetranuclear 3.1 unit under similar conditions 
(Table 3-1, entry 9), which exhibited very good catalytic behaviour. The functionalised 
3.1‒HYFNIF moiety promotes the transformation slightly better (conversion 67% for 
morpholine and 84% for aniline), when compared with metal salts (Table 3-1, Entry 4) 
and in situ mixtures (Table 3-1, Entries 6-8) and with full completion after four days 
(Table 3-1, entry 10).  
 
3.2.3.2 Scope of the Reaction  
To further validate the potential catalytic efficacy of 3.1‒HYFNIF we employed a 
primary amine, aniline, (Table 3-1, entry 11), and the entity was found to be catalytically 
active with a very good yield of product. Notably, simple metal salts such as Cu(OTf)2 or 
Dy(OTf)3 fail to promote this transformation.
270,276 The present data identify the 
applicability of the present catalytic protocol, i.e mixture of non-protic/protic solvents, 
concentration (10-3 M) and that 3.1‒HYFNIF is a promising Lewis acid candidate that 
may be used in future studies at a nanoscale level.  
 
3.3 Conclusion  
In addition to the mechanistic information provided in Chapter 2 regarding the 
tetranuclear MII2Ln
III
2 motif in the formation of trans-4,5-diaminocyclopen-2-enones, it 
is important to add that protic solvents are strong coordinating ligands, which may occupy 
the coordination sites of the metal centres or favour metal hydrolysis. Such a behaviour 
would lead to unsuccessful binding or quenching of the desired property. Moreover, 
terminally acetylated peptides containing His tend to form imidazole coordinated 
complexes with transition metals in slightly acidic or neutral solutions. However, for ZnII, 
hydrolysis can mainly be observed in basic solutions.318 Ln centres are oxophilic and 
therefore can bind to O atoms, such as the -OH group of the Tyr moiety of HYFNIF. 
Bearing all these in mind, we propose a binding model of HYFNIF through the N atom 
of His (Zn) and possibly through the neighbouring –OH group of Tyr (Dy), shown in 




4 Chapter 4: Shedding light on the use of CuII-salen complexes in the 
A3 coupling reaction 
 
Abstract: A CuII complex has been synthesised, in two high yielding steps under ambient 
conditions, and characterised by SXRD, IR, UV-Vis, CD, Elemental analysis, TGA and 
ESI-MS. This air-stable compound enables the generation, at room temperature and open-
air, of twenty propargylamines, nine new, from secondary amines, aliphatic aldehydes 
and alkynes with a broad scope with yields up to 99%. Catalyst loadings can be as low as 
1 mol%, while the recovered material retains its structural integrity and can be used up to 
5 times without loss of its activity. Control experiments, SXRD, CV and theoretical 
studies shed light on the mechanism revealing that the key to success is the use of 
phenoxido salen-based ligands. These ligands orchestrate topological control permitting 
alkyne binding with concomitant activation of the C–H bond and simultaneously acting 
as template temporarily accommodating the abstracted acetylenic proton, and continuous 
generating, via in situ formed radicals and Single Electron Transfer (SET) mechanism, of 
a transient CuI active site to facilitate this transformation. The scope and limitations of 
this protocol are discussed and presented. 
 
External contributions: M. Danopoulou was in part responsible for the catalytic 
screening experiments. M. C. Leech and K. Lam recorded the CV data. A. Abdul-Sada 
was responsible for the collection of all ESI-MS data. G. J. Tizzard and S. J. Coles 
collected the SXRD data. A. Tsipis performed computational studies. V. Zdorichenko and 
B. Cox provided part of the equipment. V. Zdorichenko also provided feedback on the 
catalytic product characterisation.  
 
4.1 Introduction 
The discovery of atom/energy-efficient and low-cost catalytic processes has been a 
longstanding goal for synthetic chemists; thus, various sophisticated approaches, 
including multicomponent reactions, have been developed.319 These methodologies 
dominate synthetic chemistry because they yield products from simple starting materials, 
in fewer steps, and in a shorter time. However, the significant challenges of these 
protocols are to identify a) the appropriate catalyst to promote a specific transformation, 




versatility. The MCR of aldehydes, amines and alkynes, known as the A3 coupling, is a 
vital route to propargyl amines.17,191,201,215 These organic scaffolds are essential 
intermediates in the synthesis of biologically active nitrogen-containing compounds, such 
as acrylamidines, oxazoles, pyrroles, pyrrolidines and natural products.17,191,320 
Remarkably, few enantioselective A3 methodologies are known,321,322 and even fewer are 
known in which the role of the catalyst is well understood.323 From these studies, it is 
established that the aldehyde and amine combine to form an iminium ion, which in turn 
reacts with the alkyne to yield the product. In light of this, various metal-based 
methodologies, for example, AuI/AuIII,324–326 AgI,327–330 CuI,331–335 or RhIII,336 that 
facilitate the formation of the corresponding metal acetylide have been developed. 
However, other transition elements such as CuII195–197 and FeIII,337–339 have also been used, 
although with higher catalyst loadings and less mechanistic evidence.  
 
Copper is abundant, of low cost, has incredibly versatile chemistry and its oxidation state 
varies (I, II and III) while its components can catalyse reactions that incorporate one 
and/or two-electron (radical and bond-forming) based mechanisms. Most importantly, 
copper easily coordinates to heteroatoms and forms π-bonds to organometallic 
intermediates, which may be a key step of the observed transformation.18,340,341 The huge 
majority of the A3 protocols that incorporate CuI require inert conditions. Work by Li,213 
Benaglia,342 and Seidel,332 have addressed crucial catalyst, in situ formed, design 
parameters including operational stability and partially saturated coordination 
environment. In general, the designed ligands provide two or three heteroatoms for 
coordination. Kostakis group has recently initiated a project aimed at developing efficient 
methodologies to promote the A3 coupling using CuII coordination compounds.198 From 
these initial studies, the optimum pre-catalyst features a CuII center with octahedral 
{N4O2} geometry and the, retained in solution, planar {N4} environment of Cu
II is a 
crucial factor that favours the coordination of the alkyne with concomitant activation of 
the C–H bond and the formation of the corresponding CuI-acetylide.  
 
Salen51 ligands offer a {N2O2} planar coordination pocket. Stack demonstrated the 
peculiar redox potential of Cu-salen compounds in different oxidation states revealing the 
non-innocent character of the salen based ligands.343–345 Depending on various parameters 
(i.e. ligand substitution, temperature, solvent) oxidation or reduction can occur at the 




two monomeric units and thus yielding infinite components via radical pathways.348–352 
Moreover, in Cu-salen derivatives reversible methanolysis of an azomethine C=N bond 
can be observed.353 Bearing all these in mind, we envisaged that a well-characterised CuII-
salen derivative would be an efficient vehicle towards the A3 coupling; recent works 
support this hypothesis,354 although evidence of the mechanism is uncertain. Inspired by 
our recent work with salen based ligands,62 we identified that a CuII-salen compound 
made with 2-((E)-((1S,2S)-2-((E)-3,5-di-tert-butyl-2-hydroxybenzylideneamino) 
cyclohexylimino)methyl)-4,6-di-tert-butylphenol (H2L
21-S) shown in Scheme 4.1 is an 
ideal candidate to serve this purpose.355 The substitutions on the ligand have a twofold 
role; to promote the reduction of the metallic centre from CuII to CuI through radical 
pathways, even at room temperature and under non-inert atmospheric conditions,343–352 
and simultaneously prevent self-polymerisation via C‒C bond activation. To the best of 
our knowledge and our surprise, this is the first crystallographic report of the 
enantiomerically pure [CuIIL21-S], (4.1S) component shown in Scheme 4.1.356,357 
Moreover, control experiments, SXRD, CV and theoretical studies shed light on the 
mechanism of this reaction. The scope and limitations of this methodology are also 
discussed.  
 
4.2 Results and discussion 
 
4.2.1 Synthetic aspects  
The enantiomerically pure version of the ligand (H2L
21-S) can be synthesised in one high 
yielding step (yields over 95%) by refluxing the corresponding (1S,2S)-(−)-1,2-
diaminocyclohexane and 3,5-di-tert-butyl-2-hydroxybenzaldehyde in EtOH. Then, the 
combination in open air of H2L
21-S with Cu(OTf)2.2H2O, at room temperature and under 
ambient conditions, in the presence of Et3N in CH3CN, in a molar ratio 1 : 1 : 2, afforded 
the air-stable compound 4.1S in yields over 70%; Reactions of H2L
21-S with other CuII 
salts, CuCl2, Cu(NO3)2·3(H2O), CuBr2, Cu(ClO4)2·6(H2O) in the presence of a base, 
affords 4.1S, but in lower yields (<65%). The enantiomeric compound was obtained as 
brown crystals and characterised by SXRD (section 4.2.2.1.1 and Appendix, Tables S4-
1 – S4-4), CV, Elemental analysis (Chapter 7, section 7.3), FT-IR, ESI-MS, CD, TGA, 
UV-Vis (Appendix, Figures S4-2, S4-3, S4-5 ‒ S4-7 respectively). TGA of 4.1S under N2 
atmosphere, shows that the material is stable up to 288oC, and then decomposition starts; 





























Scheme 4.1. (upper) The chosen ligand H2L
21-S and the enantiomerically pure CuII-salen 
novel compound (4.1S) primarily explored for its catalytic activity in the present study. 
(lower) The racemic reduced version of the organic ligand (H2L
22) and the corresponding 
CuII-salan compound (4.2),358 synthesised to assist mechanistic investigations.  
 
To further shed light on the performance of 4.1S in the A3 coupling, we attempted SXRD 
characterisation of the recovered material 4.1RS (after one cycle). The crystal used for the 
structure determination of 4.1RS (section 4.2.2.1.2 and Appendix, Tables S4-1 – S4-4),  
was twinned and despite obtaining almost identical unit cell parameters (Table 4-1), slight 
differences in bond distances could be identified when compared to 4.1S (Table 4-1 and 
Appendix, Table S4-2). The behaviour of 4.1RS was also studied in solution, by UV-Vis 
and CV (Appendix, Figure S4-8 and Figure 4-11 respectively). TGA of the recovered 
compound after the fifth catalytic cycle showed that the compound remains unaltered 
after catalysis (Appendix, Figure S4-9). To further validate our findings, we synthesised 
the racemic reduced version of the organic ligand, 2-((2-(3,5-di-tert-butyl-2-
hydroxybenzylamino)cyclohexylamino)methyl)-4,6-di-tert-butylphenol (H2L
22) and the 




following an already known synthetic protocol.359 The reduced organic scaffold provides 
a similar coordination environment to the metal centre and may generate in situ radicals 
due to the presence of the phenoxide moieties.  
 
4.2.2 Characterisation of Compounds 4.1S and 4.1RS  
 
4.2.2.1 Crystal Structure Description of Compounds 4.1S and 4.1RS   
 
4.2.2.1.1 Crystal Structure Description of Compound 4.1S 
Compound 4.1S crystallises in the triclinic space group P1. The Cu centre is coordinated 
by the {N2O2} donor set of chiral deprotonated organic ligand H2L
21-S, resulting in a 
distorted square-planar geometry (Figure 4.1) and there are two independent moieties in 
the asymmetric unit. The distance between the two CuII adjacent centres is 5.094 Å, while 
weak C-H…aryl but no aromatic interactions can be identified. The Cu–O  and Cu–N bond 
distances are typical for a CuII compound and follow previous crystallographically 
characterised components (Table S4-1).343,348,356,359 The bond angle values of the N–Cu–
N and O–Cu–O atoms are 84.7° and 91.3° respectively. 
 
Figure 4.1. Crystal structure of compound 4.1S, CCDC ID 1954036. Hydrogen atoms and 











Figure 4.2. A single unit of the crystal structure of compound (upper) 4.1S and (lower) 
4.1RS, CCDC ID 1954037. Hydrogen atoms and solvent molecules are omitted for clarity. 





Compound 4.1RS exhibits almost identical unit cell parameters with compound 4.1S 
(Figure 4.2 and Table 4-1). The distance between the two CuII adjacent centres is 5.101 
Å. The bond distances for Cu–O and Cu–N are summarized and compared with the 
corresponding bond distances of 4.1S in Appendix (Table S4-2). The bond angle values 
of the N–Cu–N and O–Cu–O atoms are 84.9° and 91.8° degrees respectively. The 
significant structural difference in bond lengths between 4.1S and 4.1RS catalyst is 
depicted in Table 4-1.  
 
Table 4-1. A ChemDraw diagram listing the significant structural difference in bond 
lengths between initial and recovered catalyst 
 
Crystal Data 4.1S 4.1RS 
a(Å) 9.8740(4) 9.8853(2) 
b(Å) 13.5904(5) 13.5954(3) 
c(Å) 14.8719(6) 14.8780(2) 
(o) 62.868(4) 62.868(2) 
β(o) 73.368(3) 73.374(2) 
γ(o) 78.772(3) 78.798(2) 
V(Å3) 1696.94(13) 1700.32(7) 
T/K 100(2) 100(2) 
Bond distances with significant differences 
N=C 1.255(13) 1.284(10) 
Cu‒N  1.916(8) 1.940(6) 
Cu‒O  1.893(7) 1.910(5) 
 
 
The slight differences in bond distances that could be identified (Table 4-1) were mainly 




main differences prior and post catalysis, respectively, are a) an imine C=N bond 
1.255(13) Å and 1.284(10) Å, b) one Cu‒N bond 1.916(8) Å and 1.940(6) Å, c) one Cu‒
O bond 1.893(7) Å and 1.910(5)Å. Interestingly, significant changes in the C–C bonds in 
both aromatic rings can be observed (Appendix, Table S4-2). Moreover, Bond Valence 
Sum analysis360 (Appendix, Table S4-3) for 4.1S prior and post catalysis signifies a slight 
(~3 %) change in the oxidation state of the Cu centre. The crystallographic datasets for 
4.1S and 4.1RS were collected in different instruments (see section 7.1) but at the same 
temperature (100 K). To validate these differences, we collected a further three 
crystallographic datasets for each catalyst, 4.1S and 4.1RS at the same temperature (100 
K) and using the same diffractometer. The data (Appendix, Table S4-4) indicate that there 
are only minor variations in bond lengths and unit cell parameters between 4.1S and 4.1RS 
and therefore exclude the possibility of structural change/alteration of the oxidation state 
of the metal centre in the recovered catalyst. In these six different data sets, the Cu–O and 
Cu–N bonds vary from 1.879(7) Å to 1.910(5) Å and from 1.916(8) Å to 1.940(6) Å, 
respectively, whilst more considerable differences can be found in only one sample for 
the C=N bonds (1.250(13) Å, 1.288(14) Å and 1.291(13) Å, 1.325(13) Å), however, this 
crystal was twinned and of low quality. A crystallographic dataset was collected for the 
recovered catalyst after the 5th run, which confirmed that stability and integrity of the 
system. 
 
4.2.2.2 Solution Studies   
Compounds 4.1S and 4.1RS in MeOH show one peak in the ESI-MS (positive-ion mode) 
which perfectly corresponds to the fragment {[CuIIL21-S] + H}+, indicating that the 
structure remains intact in solution (for the ESI-MS instrumentation refer to section 7.1). 
ESI-MS spectra, along with detailed analysis of the fragments are presented in the 
Appendix (Figures S4-3). The UV-Vis spectra of 4.1S and 4.1RS in DCM are similar and 
typical of a CuII chromophore with {N2O2} environments, at various concentrations 
(Appendix, Figures S4-7, S4-8).361,362 CD studies in DCM in concentration 1 mM confirm 
the chiral nature of the complex (Appendix, Figures S4-4,  S4-5). 
 





4.2.3.1 Benchmarking and Optimisation 
With the catalyst in hand and aiming to develop a user-friendly protocol, we performed 
reactions in the open air and considered that 4.1S would be an ideal candidate for aliphatic 
aldehydes (less stable in nature, thus more reactive compared to aromatic aldehydes) and 
secondary amines. Cyclohexanecarboxaldehyde (C4R1a), pyrrolidine (C4R2a), and 
phenylacetylene (C4R3a) were chosen as model substrates to evaluate the title reaction 
in a molar ratio 1: 1.1: 1.2 (Table 4-2).  
 













Entry Solvent Conversion (%)a,b 
1 MeOH 16 
2 EtOH 22 
3 iPrOH 64 
4 CH3CN 74 
5 DCM 71 
6 Acetone No reaction 
7 CHCl3 traces 
8 Toluene traces 
9 Hexane 11 
10 Ethyl acetate No reaction 
11 DCM 74c 
12 - 95 
a Relative conversion calculated by 1H-NMR based on the remaining C4R1a and the 
corresponding Schiff base between C4R1a and C4R2a. b Reaction conditions, 4.1S (3 
mol%), 1.0 mmol aldehyde, 1.1 mmol amine, 1.2 mmol alkyne, 5mL solvent, 72 hours, 
room temperature, concentration 0.2 M based on aldehyde. c In the presence of 





Given that the starting component consists of CuII, prolonged reactions were performed 
to allow reaction completeness and different solvents were used. Reactions with polar and 
coordinating solvents such as MeOH and EtOH (Table 4-2, entries 1 and 2,) gave low 
yields; however, the reactions in iPrOH gave C4Paaa in a moderate yield; this outcome 
is in line with our previous findings.198 The reactions in CH3CN and DCM (Table 4-2, 
entries 4 and 5,), had a better performance, while reactions in other solvents (Table 4-2, 
entries 6-10) gave C4Paaa in traces. The use of molecular sieves (Entry 11, Table 4-2) 
in DCM slightly increases the yield of the final product. When benzaldehyde was used as 
a substrate, under the same conditions, with and without molecular sieves, the observed 
conversions were 85% and 75% respectively.  Reactions with coordinating solvents lower 
the catalytic efficacy; this behaviour may be explained by solvent coordination to the 
metal centre, which prohibits substrate binding. This finding is in line with other 
experiments with and without the presence of molecular sieves; the latter captures the 
released H2O byproduct which may coordinate to the Cu centre, thus giving the expected 
product in higher yield. Interestingly, a reaction in the absence of solvent (Entry 12, Table 
4-2),363 gave C4Paaa in 95%, however, to avoid unexpected solidification of the final 
products and to take all the above notes, we chose DCM as the solvent for the subsequent 
reactions and the use of molecular sieves to capture byproduct H2O molecules.  
 
A control experiment in the absence of any catalyst, under the above-identified 
conditions, failed to produce product C4Paaa. To further evaluate the catalytic efficacy 
of compound 4.1S, we extended the pilot experiments varying concentration, loading, 
reaction time and other parameters. Concentration experiments (Entries 1-3, Table 4-3) 
identify that the reaction is highly dependent on the concentration, and the optimum 
performance is obtained in a reaction with 0.4 M (1 mmol of aldehyde in 2.5 mL). 
Keeping the concentration of aldehyde to 0.4 M, the catalyst loading experiments (Table 
4-3, entries 4-6) identify that a 1 mol% loading is efficient, but 2 mol% is ideal, while 5 
mol% of 4.1S (Entry 6, Table 4-3) results in a slower reaction conversion, possibly 
attributed to poor solubility of the reactants in the mixture. Shorter reaction times (Table 
4-3, entries 7-8) gave C4Paaa in lower yields. A reaction at a higher temperature and 
shorter time (Entry 9, Table 4-3) gave C4Paaa in good yield. The optimised protocol (2 
mol% loading, room temperature, 72 hours, 0.4 M) named as Method C4A is appealing 
since it operates in the absence of base and additives and at room temperature, however, 




approaches to increase the reaction rates. Following the above protocol, the reaction was 
performed in a microwave at 80oC, catalyst loading (2 mol%), in the open air and was 
complete within 30 minutes (Table 4-3, entry 10, named as Method C4B). Simple heating 
at 80oC, 30 min, also yielded good conversion to C4Paaa (Table 4-3, entry 11), a result 
which showcases the broad protocol applicability.  Method C4B is far more efficient when 
compared with other reported Cu based microwave protocols that yield propargylamines. 
These methods require Ar atmosphere high catalyst loading (15 mol%) and temperatures 
above 100oC.203  
 










Entry Loading (mol %) Time (h) Conversion (%)a,b 
1 3 72 75c 
2 3 72 84d 
3 3 72 96e 
4 2 72 97e 
5 1 72 93e 
6 5 72 87e 
7 2 24 43e 
8 2 48 86e 
9 2 24 88e,g 
10 2 0.5 100h 
11 2 0.5 89i 
a Relative conversion calculated by 1H-NMR based on the remaining C4R1a and and 
the corresponding Schiff base between C4R1a and C4R2a. b Reaction conditions 
catalyst (x mol%), 1.0 mmol aldehyde, 1.1 mmol amine, 1.2 mmol alkyne, molecular 
sieves 4Å (50 mg), solvent DCM, room temperature. c Concentration 0.2 M based 
on aldehyde. d Concentration 0.3 M based on aldehyde. e Concentration 0.4 M based 






4.2.3.2 Scope of the reaction  
 




































































































a Isolated Yields. b Reaction conditions, 4.1S (2 mol%), 1.0 mmol aldehyde, 1.1 mmol 
amine, 1.2 mmol alkyne, molecular sieves 4Å (50 mg), solvent DCM, concentration 
0.4 M, Method C4A (72 h, r.t.), Method C4B (MW, 80oC, 30min).c MW, 80oC, 1 h.   
 
The next step was to identify the limitations of both methodologies, and therefore we 
extended the scope of the reaction (Table 4-4) by employing a variety of secondary 
amines, aliphatic aldehydes and alkynes and produce in total twenty propargylamines out 
of which nine scaffolds are new. In all cases, the reaction proceeded smoothly, and we 
were able to isolate the corresponding products in moderate to excellent yields (16-99%). 
For compound C4Pcaa, following already known chiral column HPLC protocols,332 we 
identified a (75/25) 50 % ee for the product resulting with method C4A. This low level of 
enantioselectivity has been observed in other systems,342 without significant 
improvement, whilst the elevated temperature in method C4B removes the 
enantioselective character of the system, therefore we decided to discard the 
enantioselective characterisation of the remaining products. For compound C4Pfda, the 
NMR data showed the presence of two diastereoisomers with a ratio of 57:43 and 55:45, 
for methods C4A and C4B, respectively.  
 
To further validate the suitability of 4.1S for the A3 coupling, we performed control 
experiments using aniline (primary instead of secondary amine), benzaldehyde and 
phenylacetylene. The reason for this selection is that this reaction produces an oxonium 
H3O
+ entity as a temporary byproduct (one H2O molecule from the Schiff base and the 
abstracted proton from the triple bond), instead of water. After 72 hours, the expected 
product is produced in low yield (35%), indicating that modification of the catalytic 
system is required for 4.1S to be suitable for primary amines.   
 
4.2.3.3 Mechanistic insights 
 
Expanding the catalytic screening reactions 
Aiming to investigate the role of 4.1S in the reaction and shed light on the reaction 
mechanism, we performed a series of experiments altering reaction parameters following 
method C4A. Notably, reactions under N2 (Entry 1, Table 4-5) or Ar (Entry 2, Table 4-5) 
atmosphere gave C4Paaa in 97% and 95%, respectively. These data disfavour the 




the dimeric intermediate Cu‒O2‒Cu with variable oxidation states; the latter has been 
identified as a critical factor in other C‒C activation reactions catalysed by CuII 
components.364–366 Moreover, the addition of 10 mol% TEMPO (Entry 3, Table 4-5)  
under these conditions had a significant impact leading to activity cessation. This result 
signifies the presence of a radical pathway, possibly involving the CuI-complex species 
and supports the plausible in situ formation of the CuI‒acetylide intermediate, that may 
be responsible for the catalytic cycle.  
 












Entry Pre-catalyst Atmosphere Additives Conversion 
(%)a,b 
1 4.1S N2 - 97 
2 4.1S Ar - 95 




21‒S/Cu(OTf)2.H2O open-air - 96
c 
5 Cu(OTf)2 open-air - 100 
6 4.1RS (after 1 cycle) open-air - 96 
7 4.1RS (after 2 cycles) open-air - 95 
8 4.1RS (after 3 cycles) open-air - 95 
9 4.1RS (after 5 cycles) open-air - 94 
a Relative conversion calculated by 1H-NMR based on the remaining C4R1a and and 
the corresponding Schiff base between C4R1a and C4R2a, b Reaction conditions, 
catalyst (2 mol%), 1.0 mmol aldehyde, 1.1 mmol amine, 1.2 mmol alkyne, molecular 
sieves 4Å (50 mg), solvent DCM 2.5 mL, concentration 0.4 M, room temperature, 72 
h. c In situ formation of the catalyst with H2L
21‒S/Cu(OTf)2.H2O.  
 
Then we performed an experiment with in situ preparation of the catalyst (Entry 4, Table 
4-5). The one-pot reaction containing H2L




yielded C4Paaa in 96%. This data is indeed an impressive result, in line with other 
reported similar studies,212 however, it is unclear if the formation of the neutral complex 
4.1S proceeds before catalysis or if the metal salt promotes the organic transformation. In 
terms of operation ability, we believe that this in situ protocol is weak because of the 
following three factors. i) Two protons are released from the parent organic ligand upon 
complexation; these may participate in the organic transformation by facilitating the 
formation of H2O byproduct molecules. ii) The triflate is an extremely stable anion, the 
conjugate base of a very strong acid; therefore it may abstract a proton, forming triflic 
acid which in turn may facilitate the redox CuII - CuI conversion. iii) A reaction using 
solely Cu(OTf)2 as the catalyst, under similar conditions (Entry 5, Table 4-5) provides 
C4Paaa quantitatively while reactions with other CuII salts do not promote the formation 
of C4Paaa. These results showcase that the hydroxide (OH‒) moiety, produced from the 
condensation of aldehyde and secondary amine, is not an efficient base to facilitate 
acetylenic proton abstraction and/or the redox CuII - CuI conversion, therefore the 
combinatorial, or not, role of the two different bases (OH‒ and OTf ‒) and the role of 
Cu(OTf)2 in this A
3 catalytic cycle are questioned. We decided to investigate this protocol 
in future experiments.  
 
To identify the potential of our catalytic system, we attempted to recover the catalyst. 
After reaction completion, the crude product was placed in the fridge or left unattended 
in the open air, and well-formed needle-like brownish coloured crystals grew within two 
hours or four days, respectively. The recovered material was tested and found to catalyse 
the reaction without loss of its activity (Entries 6-9, Table 4-5); the procedure was 
repeated five times, without observing a loss of the catalytic efficacy. Moreover, the UV-
Vis spectrum (in DCM) and TGA analysis of the recovered (5 cycles) catalyst showed 
similar behaviour to that of 4.1S (Appendix, Figures S4-8 and S4-9 respectively).  
 
To further validate this notion, we synthesised the racemic reduced version of the organic 
ligand and the corresponding CuII-salan compound [CuL22] (4.2) (Scheme 4.2, Figure S4-
12), following an already known synthetic protocol.343,348,356,359 The reduced organic 
scaffold provides a similar coordination environment to the metal centre and may 
generate in situ radicals due to the presence of the phenoxide moieties. Notably, in 
previous results, compound 4.2 was found to perform poorly in oxidation and oxidative 




reaction with 4.2 as the catalyst under similar reaction conditions (Scheme 4.2) affords 
C4Paaa in excellent yield, similar to that of 4.1S, supporting our reasoning for topological 
control which permits alkyne binding with concomitant activation of the C–H bond and 
simultaneous accommodation of the abstracted acetylenic proton, and continuous 
generation, via in situ generated radicals, of a transient CuI active site.  
 
 
Scheme 4.2. The pilot reaction that the racemic CuII-salan compound (4.2) was tested as 
a catalyst. 
 
Cyclic Voltammetry studies 
To further shed light on the mechanism of this reaction the electrochemical behaviour of 
the ligand, 4.1S, 4.1RS and titrations of 4.1S or 4.1RS with phenylacetylene (Ph‒C≡C‒H) 
were studied in CH2Cl2 by cyclic voltammetry under N2. The ligand exhibits two distinct 
quasi-reversible waves (Appendix, Figure S4-10) that correspond to two successive 
oxidations of a phenol into a phenoxyl radical.344,367 The cyclic voltammograms of 4.1S 
display two well-separated one-electron reversible redox waves at E1/2
1
 = 0.51 and E1/2
2
 = 
0.81 V vs Fc+/Fc for 4.1S and E1/2
1
 = 0.52V and E1/2
2
 = 0.81 V for 4.1RS which showcase 
a typical behaviour with the reported similar systems (Appendix, Figure S4-11).344,367,368 
In the reductive region (Figure 4.3), 4.1S and 4.1RS  both show a non-reversible reduction. 
Notably, when a fresh sample of 4.1S and a sample of 4.1RS were titrated with Ph‒C≡C‒
H (0, 0.5, 1, 2, and 50 equivalent for 4.1S and 0, 0.5, and 50 for 4.1RS, 50 equivalents 
correspond to 2% catalyst loading), no significant effects on the oxidative process were 
observed. However, both 4.1S and 4.1RS show slightly different cathodic behaviour in the 
presence of Ph‒C≡C‒H. The cathodic wave’s current slightly increases with the 




different behaviour may be attributed to the reduction of the [CuII/ Ph‒C≡C‒H] species 
to the [CuI/ Ph‒C≡C‒H] species as this notion has been well established in other 
protocols.200,369 To further establish this notion, UV-Vis titration studies at room 
temperature and in the open air of 4.1S and 4.1RS and Ph‒C≡C‒H in a catalytic ratio 
(2:100) were performed (Figures S4-7 and S4-8), with no noted differentiation. 
 
  
Figure 4.3. CV data in the reductive region of 4.1S (left) and 4.1RS (right) in the presence 
of phenylacetylene.  
 
It is worth-noting that in the crude NMR spectra of all the above-studied reactions, no 
parent organic ligand nor the formation of the hetero-coupling (bis-adduct) product of 
terminal alkynes were observed, whereas precipitation of metallic Cu was not observed. 
Bearing in mind that a) terminal alkynes can reduce CuII to CuI,200,369 b) proton abstraction 
from the catalyst has been noted in mononuclear systems,370 c) the reaction takes place in 
a non-coordinating solvent, in the absence of base and at room temperature and d) the 
reaction rates and efficacy increase with temperature or microwaves, we propose the 
following three-step mechanism. Initially, the planar {N2O2} geometry of Cu
II promotes 
alkyne binding with concomitant activation of the C–H bond. In step II, the acetylenic 
proton is abstracted from one nitrogen atom of the organic framework to form the 
corresponding Cu-acetylide, which may be stabilised by radical pathways. This notion 
has been recently proposed in a similar system.371 Then, the symmetrical {N2O2} plane 
accounts for adequate electron delocalisation to ensure the reduction of CuII to CuI which 
then orchestrates the breaking of the Cu‒O bond as well as positional rearrangement of 
the acetylide group. Finally, the addition of the CuII-acetylide to the in situ generated 
iminium ion yields the corresponding propargylamine derivative and water, and 
regeneration of the catalyst. Given the absence of an initiator and that the reduction of 
CuII to CuI can be prolonged,372 we may envisage that step II is the rate-determining step. 
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It is well known in synthetic chemistry,373,374 especially for radical-triggered cascade 
reactions,375 that the CuI-acetylide intermediate can be formed by a SET mechanism, 
therefore the proposed mechanism (Scheme 4.3) accounts all parameters (oxidation 
states, proton abstraction, byproduct formation, substrate-coordination, metal 
coordination geometry) and we believe that is highly likely for the mechanism to follow 
a SET pathway.  
 
Mechanistic studies employing DFT computational protocols  
To further understand the mechanism of the A3 coupling reactions catalysed by 4.1S, we 
performed density functional theory (DFT) calculations to model the geometric and 




Figure 4.4. Geometric and energetic (ΔH in kcal/mol) reaction profile for the A3 coupling 
reactions catalysed by 4.1S calculated at the PBE0/Def2-TZVP level of theory in a 
solution using methanol solvent.  
 
The geometric and energetic reaction profile calculated at the PBE0/Def2-TZVP level of 
theory in solution (CH3OH solvent) is depicted schematically in Figure 4.4, while the 
geometrical structures of all reactants, intermediates and products directly optimised in 




optimised geometry of the catalyst in methanol solution (Figure S4-14) matches better to 
the crystal structure of the recovered 4.1RS and not the initial 4.1S catalyst. 
 
 
Scheme 4.3. Scheme 4. Frontier Molecular Orbitals (FMOs) of the iminium ion and the 
CuI intermediate. 
 
The course of the reaction involves initially a loose association of Ph‒C≡C‒H to 
Cu(salen) complex in an orientation almost parallel to the coordination plane with the H 
atom directed towards an N donor atom of the salen ligand. The estimated interaction 
energy in the adduct formed is only 0.06 kcal/mol. This orientation of Ph‒C≡C‒H 
activates the C‒H bond of Ph‒C≡C‒H accompanied by the proton transfer to the N-donor 
atom of the coordinated salen ligand and coordination of the phenylacetylide ligand to 
CuII centre in a η1-mode. The proton detachment process demands 213.4 kcal/mol with 
the proton affinity of the N-donor atom of salen estimated to be 144.8 kcal/mol. The 
proton transfer also promotes the rupture of one of the Cu‒O bonds yielding a three-
coordinated CuII complex (Figure S4-14). The three-coordinated CuII intermediate 
concomitantly is reduced to a three-coordinated CuI  intermediate by intramolecular single 
electron transfer (SET) from the Single Occupied Molecular Orbital (SOMO) localized 
mainly on the coordinated phenoxo moiety of the protonated salen ligand towards the 
Highest Occupied Molecular Orbital (HOMO) exhibiting high 3d character (cf HOMO-
3, Scheme 4.4). The intramolecular CuII → CuI reduction stabilises the three-coordinated 
CuI intermediate by 23.43 kcal/mol concerning the CuII congener considering an adiabatic 
SET. Notice that the experimentally determined reduction potential for 4.1S is 1.02 V 
(23.52 kcal/mol). Next, the CuI-intermediate having an open coordination sphere dispose 
of open channels for the in situ generated electrophilic iminium ion to attack the 
nucleophilic C atom of the coordinated phenylacetylide, thus affording the corresponding 
propargylamine product and water and regenerating the catalyst. The condensation of the 
cyclohexanecarboxaldehyde with pyrrolidine affording the cyclohexyl(pyrrolidin-1-




iminium ion by the detachment of the hydroxyl group from the aldol demands  45.79 
kcal/mol. Notice that the electrophilic C atom of the iminium ion and the nucleophilic C 
atom of the coordinated phenylacetylide acquire natural atomic charges of 0.318 |e| and -
0.375 |e| respectively. An inspection of the Frontier Molecular Orbitals (FMOs) of the 
iminium ion and the CuI intermediate (Scheme 4.5) reveals that the formation of the 
propargylamine product is also supported by LUMO (iminium) – HOMO-2 (CuI 
intermediate) interactions. In summary, the full catalytic cycle, supported by DFT 
calculations, is shown in Scheme 4.5, which is consistent with the proposed plausible 
catalytic cycle supported by experimental measurements. 
 
 
Scheme 4.4. The proposed reaction mechanism for the A3 coupling reactions catalysed 






Scheme 4.5. A plausible mechanism for this reaction.  
 
4.3 Conclusion 
We present a  CuII based protocol that efficiently catalyses the A3 coupling reaction in the 
open air and at room temperature. Vital to the success of this is the use of the phenoxido 
salen-based ligand which orchestrates topological control permitting alkyne binding with 
concomitant activation of the C–H bond and simultaneously acting as template 
temporarily accommodating the abstracted acetylenic proton, and continuous generating, 
via in situ formed radicals and SET mechanism, of a transient CuI  active site to facilitate 
this transformation. The present study identifies first-principle structural features for this 
well-characterised CuII system in the open air and paved the way for the future 
development of this easy to make and handle system that may apply to several organic 






5 Chapter 5: Structural and electronic control of 1-(2-
pyridyl)benzotriazole bidentate ligand in copper chemistry with 
application to catalysis in the A3 coupling reaction  
 
Abstract: We introduce the hybrid bidentate 1-(2-pyridyl)benzotriazole (pyb) ligand in 
3d-transition metal catalysis. Specifically, [Cu(L7)2(OTf)2]·2(CH3CN) (5.1),  enables the 
synthesis of a wide range of propargylamines in high yields (60-99%), via the A3 coupling 
reaction, at room temperature, in open-air and absence of additives. The labile character 
of the bridging N atom of the hybrid ligand is the key parameter that imposes the sole 
form of the trans-isomer and simultaneous ligand rotation, thus orchestrating structural 
and electronic catalyst control and permitting alkyne binding with concomitant activation 
of the C–H bond. 
 
External Contributions: V. Zdorichenko provided part of the equipment and feedback 
on the catalytic product characterisation and purification. J. Devonport was responsible 
for the synthesis and characterisation of one starting material. M. C. Leech and K. Lam 
recorded the CV data. A. Abdul-Sada was responsible for the collection of all ESI-MS 
data. V. Zdorichenko and B. Cox provided part of the equipment G.E. Kostakis collected 
the SXRD data. A. Vargas and G. Rossini performed computational studies.  
 
5.1 Introduction   
Copper is a transition metal, with plural oxidation states that promotes a variety of organic 
transformations either as a metal salt, in situ formed or well-characterised complexes.15,16 
In its dominant oxidation state (CuII), the d9 electronic configuration profound elongated 
or shorten axial axes, known as Jahn and Teller effect,376 and depending on the 
coordinating ligands various geometries and stereoisomers, i.e. cis – trans for Cu(N-
N)2X2 where N-N is a bidentate ligand, can be obtained. 2,2'-bipyridine (bpy) has been 
extensively used in coordination chemistry as a bidentate ligand377 and catalysis.378 The 
catalytic protocols that involve in situ blending of bpy, copper salts and substrates achieve 
high yields and new products;379 however, the role of each component in the catalytic 
cycle is questioned. Well characterised CuII and bpy based complexes have been used as 
models for the aerobic oxidation of alcohols18 and other organic transformations.380 In 




of isostructural compounds built with similar N,N'-bidentate ligands. This differentiation 
in catalytic efficacy may be a result of electronic and/or steric effects; however, the 
formation of different stereoisomers cannot be ignored. 381 
 
The importance of developing the coordination chemistry of new bidentate ligands and 
identifying better catalysts is fundamental. Our groups initiated a combined, experimental 
and theoretical, project to provide an in-depth description and understanding of the 
properties that govern the chemistry of the 1-(2-pyridyl)benzotriazole (pyb, L7) ligands 
(Scheme 5.1) and the resulting coordination complexes. When compared with bpy, the 
hybrid L7 ligand, has the following differences: a) additional N atoms that may participate 
in H-bonding interactions, b) another phenyl group that enforces an electron-rich 
character of the framework but also permits participation in stacking interactions, and c) 
the two, pyridine and benzotriazole, units are linked via an N atom, in which its lone 
electron pair may impose flexibility yielding different coordination behaviour when 
compared with the rigid C‒C based bpy ligand. Steel, in his pioneer work, identified pyb-
based compounds to be more electron-rich when compared with that of bpy;125 however, 
the applicability of pyb-based complexes in catalysis remains almost an unexplored 
research field.127,382–384  
 
 
Scheme 5.1. The traditional bidentate ligand 2,2'-bipyridine (bpy) and the bidentate 
ligand L7 used in this work.  
 
5.2 Results and discussion  
 
5.2.1 Synthetic aspects  
Following a previously described protocol,125 the ligand L7 can be made in one, high 




the use of microwaves improves yield and rate (Chapter 7). The room temperature 
reaction of Cu(OTf)2 and L
7 in a molar ratio 1 : 2, in CH3CN under aerobic conditions, 
affords compound [Cu(L7)2(OTf)2]·2(CH3CN) (5.1) in 85% isolated yield. Compound 5.1 
is characterised by SXRD, ESI-MS (Figure S5-2), UV-Vis (Figure S5-5), IR (Figure S5-
6), TGA (Figure S5-7), elemental analysis and CV (Figure S5-8).  
 
5.2.2 Characterisation of Compound 5.1  
 
5.2.2.1 Crystal Structure Description of Compound 5.1 
Compound 5.1 crystallises in the triclinic space group P-1. The ligands of the copper 
complex adopt a trans geometry and the copper sits in the centre of an octahedron; the 
equatorial positions are occupied by two L7 ligands providing a {N4} donor set, while two 
OTf ‒ anions hold the axial positions. There is a significant difference between the Cu‒N 
[1.998(8) - 2.017(8)] and the Cu‒O [2.440(5) - 2.440(7) Å] bonds, which is characteristic 
of the Jahn-Teller distortion. Bond valence calculations are in line for a CuII oxidation 
state.  
 
Figure 5.1. Crystal structure of compound 5.1, CCDC ID 1891851. Hydrogen atoms and 
solvent molecules are omitted for clarity. Colour code: Cu (blue), C (grey), N (light blue), 





5.2.2.2 Solution Studies   
ESI-MS (for the instrumentation refer to section 7.1) in MeOH identify the stability of 
this compound exhibiting only two peaks at 604.0338 m/z and 407.9566 m/z which 
correspond to the [Cu(L7)2(OTf)]
+ and [Cu(L7)(OTf)]+ species, respectively (Figure S5-2 
‒ S5-4). The UV-Vis in a solution of DCM shows a very broad (550-850nm) peak with 
the maximum at 685nm, characteristic of a CuII with Jahn Teller distortion (Figure S5-5). 
Besides, the cyclic voltammogram of 5.1 shows a reversible one-electron curve (Figure 
S5-8).  
 
5.2.3 Catalytic Studies  
 
5.2.3.1 Benchmarking and Optimisation 
With the catalyst in hand, the next step was to identify a challenging reaction. The A3 
coupling is a very well known, atom efficient, reaction that yields propargylamines with 
one molecule of water as a side product. Methodologies that involve CuII sources have 
been reported,17,195–199 however, with limited mechanistic information. The emphasis, in 
these studies, is given in the final product and achieving excellent yields, irrespectively 
of the extreme reaction conditions, i.e. elevated temperatures, prolonged time, high 
catalyst loadings; therefore mechanistic details are built based on the experimental 
findings. On the other hand, Knochel’s pioneering work determines the activation of the 
acetylide on the coordination sphere of the CuI  centre and subsequently coupling with 
the corresponding imine.194 Besides, copper reduction may occur in the presence of 
alkynes, and this process depends on temperature and concentration.200 
 
Taking into account that copper salts are less efficient in the A3 coupling reaction with 
primary amines, we chose cyclohexanecarboxaldehyde, aniline and phenylacetylene as 
model substrates to evaluate the title reaction in a molar ratio 1 : 1.1 : 1.2. Given that 5.1 
consists of CuII, prolonged reactions were performed to allow reaction completeness and 
different solvents were used. To make the protocol more user-friendly, reactions were 
carried out in open air and room temperature. Reactions in various solvents (Table 5-1) 
afforded the anticipated product in good to moderate yields, and therefore DCM, a non-





Table 5-1. Solvent Screening 
 
 
Entry Solvent Conversion (%)a,b 
1 MeOH 16 
2 EtOH 22 
3 iPrOH 29 
4 CH3CN traces 
5 DCM 93 
6 Ethyl acetate 47 
a Relative conversion calculated by 1H-NMR based on the remaining C4R1 and the 
intermediate Schiff base derived from C4R1a and C5R2g; b Reaction conditions: 5.1 
(1.5 mol%), 1.0 mmol aldehyde, 1.1 mmol amine, 1.2 mmol alkyne, 2 mL solvent, 
25°C, 24 hours, concentration 0.5 M based on aldehyde, in the presence of molecular 
sieves 4Å (50 mg). 
 
Keeping the concentration of aldehyde to 0.5 M, the catalyst loading experiments (Table 
5-2, entries 1-5) determines the optimum result when 1.5% loading is applied, while 5 
mol% and 3 mol% of 5.1 (Table 5-2, entries 1 and 2) results in a decreased reaction 
conversion, possibly due to the decreased reaction kinetics arising from the high density 
of the reaction mixture. Shorter reaction times (Table 4-3, entries 7-8) gave C4Paaa in 
lower yields. Reactions in less time cause a significant drop in the yield of C5Paga. 
(Table 5-2, entries 6 and 7). The reaction with copper salts provided similar yields; 
however, this was only achieved with higher catalyst loadings (10%), almost one order 
of magnitude more loading, which is in line with previous results (Table 5-2, Entry 8).197 
Given that the activation of alkynes is highly dependent on concentration,372 the next step 
was to identify the limits of this catalytic system. Thus, we performed a reaction in higher 
concentration (1 M) which yielded C5Paga in moderate yields and identifying that the 




Table 5-2. Optimisation of Reaction Conditions  
 
 
Entry Loading (mol %) Time (h) Conversion (%)a,b 
1 5 24 53c 
2 3 24 74c 
3 2 24 95c 
4 1.5 24 93c 
5 1 24 53c 
6 1.5 12 52c 
7 1.5 6 30c 
8 10 24 99d 
9 1.5 24 81e 
a Relative conversion calculated by 1H-NMR based on the remaining C4R1a and the 
intermediate Schiff base derived from C4R1a and C5R2g, b Reaction conditions: 5.1 (x 
mol%), 1.0 mmol aldehyde, 1.1 mmol amine, 1.2 mmol alkyne, molecular sieves 4Å 
(50 mg), DCM and concentration 0.5 M based on aldehyde. c 25oC and concentration 
0.5 M. d Reaction with 10 mol% Cu(OTf)2, 25
oC and concentration 0.5 M.  
e 25oC and 
concentration 1 M.   
 
5.2.3.2 Scope of the reaction  
This methodology applies to a variety of primary and secondary amines, and its scope is 
extended affording twenty products in good to excellent yields (60-99%), out of which, 
three (C5Paha, C5Pcia and C5Pcja) are synthesised and characterised for the first time 
(Table 5-3 and Appendix Figure S5-10 – S5-23). As expected, aldehydes with electron 
withdrawing -F substitution in para-position (C4Peaa, yield 68% and C4Peca, yield 
60%) showed moderate reactivity comparing to benzaldehyde and 3-fluorobenzaldehyde. 




reactivity (C5Paha, yield 94%, C5Pcia, yield 88%) comparing to the 3,5-dimethylaniline 
with electron-donating methyl-groups (C5Pcja, yield 63%).  
 






























































































a Isolated yields for the synthesis of propargylamines with 1.0 mmol aldehyde, 1.1 




concentration 0.5 M based on aldehyde, promoted by 5.1 (1.5 mol%). Method C5A: 
stirring in open-air at 25°C for 24 hours. Isolated yields of the products have been 
reported for method C5A.  
b Method C5C (applied for selected products where indicated in the table): stirring under 
Ar at 25°C for 2 hours and relative conversions have been calculated by 1H-NMR based 
on the remaining C4R1 and the intermediate Schiff base of C4R1 and C5R2. 
 
5.2.3.3 Mechanistic insights 
 
Expanding the catalytic screening reactions 
Aiming to shed light on the mechanism of the reaction and the applicability of the 
catalyst, the next step in our study was to perform reactions at elevated temperatures or 
microwave conditions as this has been noted in previous CuII systems.17,196,198,199 
Indeed, under reflux (Table 5-4, entry 1) or microwave (Table 5-4, entry 2) conditions, 
the prototype reaction that affords C5Paga is completed within one hour, affording 
similar, excellent yields. We performed a series of reactions to gain mechanistic 
insights. A reaction for the synthesis of C4Pcaa, in the presence of a radical trap 
(TEMPO, 10 mol% based on aldehyde), afforded the expected product (Figure S5-24), 
thus excluding the formation of a radical species. The reactions at elevated temperature, 
under N2 or Ar atmosphere, yielded product C5Paga in a similar yield (Table 5-4, entry 
3), excluding the activation of the catalyst via bonding to dioxygen.366 Finally, we 
performed a reaction under N2 at room temperature for only two hours, and C5Paga 
was obtained in a moderate yield (Table 5-4, entry 4). The same reaction was repeated 
under Ar atmosphere (Table 5-4, entry 5), providing the anticipated product in a similar 
yield. This unprecedented result provides us with a time-efficient synthetic protocol for 
the synthesis of propargylamines and will explore its potential in the future.  
 
An attempt to rationalise how the A3 coupling reaction is promoted from compound 
5.1, we decided to examine the catalytic efficacy of compound [Cu(bpy)2(OTf)2] 
(5.2)381,385 (Figure S5-9). This compound has been structurally characterised and found 
to possess a cis-octahedral geometry (Scheme 5.2); thus, 5.1 and 5.2 have different 
stereochemistry. Notably, the catalytic reactions at room temperature under Ar 




the expected product. Besides, despite compound 5.2 shows a reversible CV signal,381 
a titration CV study with phenylacetylene identified a non-reversible signal (Figure S5-
8) and the absence of precipitate or bpy moiety in the solution, in the crude 1H-NMR. 
 
Table 5-4. Various experiments to obtain mechanistic evidence.  
 
 
Entry Time (h) Atmosphere Catalyst Conversion 
(%)a,b 
1 1 Open air 5.1 95c 
2 1 Open air 5.1 96d 
3 2 N2/Ar 5.1 98
e 
4 2 N2 5.1 65
f 
5 2 Ar 5.1 68f 
6 2 Ar 5.2 Tracesf 
7 2 Ar Cu(OTf)2 Traces
g 
a Relative Conversion calculated by 1H-NMR based on the remaining C4R1a and the 
intermediate Schiff base of C4R1a and C5R2g. b Reaction conditions: 5.1 (1.5 
mol%), 1.0 mmol cyclohexanecarboxaldehyde, 1.1 mmol aniline, 1.2 mmol 
phenylacetylene, molecular sieves 4Å (50 mg), solvent DCM 2 mL, concentration 0.5 
M. c 80oC. d Microwave conditions at 80°C. e 80°C, f room temperature. g room 
temperature.  
 
We may attribute this behaviour that complex 5.2 is stable, none of the bpy moieties 
diffuses to the solution during these titrations; thus a very stable {CuII(bpy)x(Ph‒C≡C‒
H)y} species is formed which prevents alkyne activation and the reaction to proceed. 
Given the short reaction time (1h), these results indicate that the stereochemistry of the 
pre-catalyst is vital for the formation of the active species, during the catalytic process, 
which is in line with literature evidence.386,387 Given that even 1 mol% of the catalyst 




perform poorly (Table 5-4, entry 7),197 a full ligand dissociation in 5.1 is not considered 
as a plausible scenario. Instead, the formation of a stable CuI-complex is possibly the 
active catalytic species. This suggestion can be further evidenced by the presence of 
pure ligand peaks in the crude NMR and LCMS data (Figures S5-24 and S5-25). Efforts 
to trap, monitor, isolate and characterise this CuI-complex were unsuccessful. Besides, 
the absence of bulky groups in the pyridine or benzotriazole moieties, that would 
contribute steric effects and possibly prevent two different ligands from coordinating 
in the CuI centre, prevented us from isolating and characterising this species in reactions 
with CuI salts; this possibility will be explored in future studies.  
 
 
Scheme 5.2. A chemical diagram of 5.1 and 5.2, showcasing the trans and cis 
geometries.  
 
Cyclic Voltammetry studies  
However, to shed light into this very exciting result, we performed cyclic voltammetry 
titrations, under N2 atmosphere, of 5.1 in the presence of phenylacetylene (Figure 5.2 
and S5-8). This study confirms a structural change into the catalytic system when one 
equivalent of phenylacetylene is added and could be explained based on ligand 
dissociation upon reduction of the copper centre and the formation of a {CuII/I(L7)x(Ph‒






Figure 5.2. The cyclic voltamogram of 5.1 and 5.2 in the presence of phenylacetylene.  
 
Mechanistic studies employing DFT computational protocols  
To obtain further insight into the parameters governing the observed catalytic activity 
of 1, calculations based on the Kohn-Sham Density Functional Theory (DFT) at the 
OLYP/TZP level of theory within the ZORA formalism were carried out, whereby 
meaningful, a comparison is made with 5.1. In the absence of constraints due to 
environment, e.g. crystal packing effects, the optimised structure in the gas-phase 
possesses a non-planar geometry of the pyb ligands (Figure 5.3), showcasing 
conformational lability through rotation around the central C‒N bond, a feature not 
offered by bpy in 5.2. Such flexibility should hence allow dispersion interactions with 
neighbouring atoms.  
 





Inspection of molecular orbitals (MO) of 5.1 indicates a low-lying unoccupied beta 
(spin down) MO (Figure 5.4). Upon removal of one OTf (5.1a), the degenerated levels 
split, but even in the lowered symmetry, the unoccupied level is conserved. Given the 
unhindered quasi-planar geometry (inset Figure 5.4) and the alignment of in-phase 
p(N)-d(Cu)-p(N) orbitals as the main components spanning this unoccupied MO, 
binding to electron-rich molecules is thus facilitated. Furthermore, the presence of 
doubly degenerate levels points to potential symmetry lowering with concomitant 
lowering in energy hence possibly providing driving force towards reactivity. The 
slightly non-symmetrical deviation from planarity of the ligands upon the abstraction 
of OTf also points to another valuable property of the ligands.  
 
 
Figure 5.4. Molecular orbital levels of 5.1. (left) spin-up (alpha) electrons, (right) Spin-
down (beta electrons) levels in bold denote occupied levels, thin levels denote 





These neutral ligands can act as efficient charge sinks given the extended pi system and 
the ability to modulate conjugation through the C‒N rotation thus accommodate charge 
density upon change of oxidation state or any reductive process. This can be depicted 
for instance by considering the molecular electrostatic potential on the calculated 
[CuI(L7)2OTf] and [Cu
II(L7)2OTf]
+ (Figure 5.5) whereas the metal centres are relatively 
“unchanged” the ligands get highly charged with high accumulation on the unbound 
nitrogen. This is in line with the frontier orbitals (see Figure 5.3) showing that the 
unoccupied MOs are highly centred on the ligands. This speaks of the Cu centre just 
playing the role of a transit node in the system charge dynamics. Such property should 
facilitate the CuI/CuII redox equilibrium in the proposed mechanism. One does see that 
the ligands allow simultaneous play and full synergic combination of electronic 
structure, geometrical dictum, vibronic contribution and charge flux dynamics.   
 
The viability of key structures in the catalytic cycle were assessed with the aid of gas-
phase calculations. Optimisation in the gas-phase reveals the flexibility of the ligands. 
Upon removal of one OTf ligand, rotation around C‒N allows adopting a see-saw 
structure, possibly lowering the system energy. The CuI analogue is highly energetic, 
probably exist as short-lived intermediate. In the intermediate geometries of 
[CuI(L7)2(OTf)(HC≡CPh)], and [Cu
II(L7)2(OTf)(HC≡CPh)]
+, in the former the upon 
interaction of the alkyne with the metal, the triflate is displaced, leaving tetrahedral 
[CuI(L7)2]
+, however, in the CuII counterpart, the triflate is not displaced and the 
remaining [CuII(L7)2OTf]
+ adopts a see-saw geometry, identical to the structure 
previously described. In the case of the CuI, the departure of the OTf associated with 
increases in charge is aided by an additional stabilisation brought about by the two 
flanking ligands through dispersive interaction, this observation thus highly an 
equilibrium between the two oxidation states but with the [CuI(L7)2(OTf)(HC≡CPh)] 
being favoured. Finally, alkyne capture and hydrogen abstraction proceed uniquely 










 Based on all these observations and bearing in mind that a) Cu should simultaneously 
bind both nucleophile (phenylacetylide) and electrophile (imine)194 and b) the protocol 
proceeds in the absence of additional base or additives, c) the benzotriazole entity can 
simultaneously act as an acid or a weak base40,388 and possibly form radicals,388 and 
that [CuI(L7)2(OTf)(HC≡CPh)] species is favoured over [Cu
II(L7)2(OTf)(HC≡CPh)]
+ 
and d) previous mechanisms based on CuI or CuII sources 192,196–199,201,320 we propose 
the catalytic mechanism shown in Scheme 5.3. This mechanism has two different paths. 
The external path (highlighted in dashed lines) involves the following steps: one OTf 
dissociation, alkyne binding, copper reduction through the equilibrium 
[CuII(L7)2(OTf)(HC≡CPh)]
 + - [CuI(L7)2(OTf)(HC≡CPh)] process, ligand dissociation, 
OTf– dissociation and acetylide activation, reaction with the imine and catalyst 
regeneration. The internal pathway (highlighted in blue) discards the reduction-
oxidation process of the Cu centre but incorporates the triflate ion for the regeneration 
of the catalyst and alkyne activation purposes. Taking into account that the reduction 
of CuII to CuI by alkynes is a prolonged procedure,372 we consider the formation of the 
CuI-intermediate as the rate-determining step under ambient conditions, while under 






Scheme 5.3. A proposed mechanism, highlighting the two different pathways, dashed 
and pink lines.  
 
5.3 Conclusion 
We report the first example of a CuII complex, (5.1) that efficiently promotes the 
synthesis of propargylamines at room temperature through the A3 coupling reaction. 
The bridging N atom of the L7 is the key parameter, imposes exclusive trans-
coordination at Cu and allows ligand rotation,  while the overall construct of the ligand, 
in particular, the presence of the pyridine-N atom modulates charge distribution and 
flux, thus orchestrating structural and electronic pre-catalyst control permitting alkyne 
binding with simultaneous activation of the C–H bond through an in situ catalytically 
active [CuI(L7)(OTf)] species. By fine-tuning the conditions, the time efficiency of this 
system was improved from 24h to 2h. Experimental and theoretical comparison with 
the cis-[CuII(bpy)2(OTf)2] (5.2), suggest that stereochemistry of the pre-catalyst and the 
nature of the N,N’-bidentate ligand are important parameters for when designing such 
catalysts. The results presented herein pave the way for future discoveries and 
explorations in coordination chemistry, for bidentate ligands, and catalysis, for 







6 Chapter 6: Summary and Conclusions 
 
6.1 Concluding Remarks  
The purpose of this Chapter is to summarize the results of the research undertaken 
(Chapters 2-5) and contextualize them in regard to the aim of this thesis. Synthetic 
challenges, methodology limitations, as well as perspectives and future directions will be 
pointed out.  
 
Summary 
The aim of the present Thesis was the development of time- and cost-efficient 
methodologies for catalysis, under non-inert conditions with the employment of a single 
well-characterised specie as a pre-catalyst. The catalytic protocol development falls under 
the banner of “green” chemistry since parameters involving step-economy, minimum 
amount of solvents, room-temperature conditions, low catalyst loadings without 
additives/co-catalysts were carefully inspected. N-and O-based ligands, including Schiff 
base, pyridine-benzotriazole and a hexapeptide, were employed with metal sources to 
yield 3d-4f or CuII mononuclear coordination compounds with zero dimensionality. The 
variety in the ligand characteristics affected the final structure and electronic properties 
of each coordination compound, thus the applicability and capabilities of each catalytic 
system. In total six main compounds were synthesized and characterized in detail across 
Chapters 2-5.  
 
Chapter 2 described the Ni2Dy2 catalyst development for the domino reaction of furfural 
and amines towards the production of trans-4,4-diaminocyclopentenones, via a ring-
opening electrocyclization pathway which involves a Stenhouse salt intermediate in the 
case of primary amine. The triflate analogue of the previously reported Ni2Dy2Cl2, 
compound 2.1, enhances the catalytic efficacy of the tetranuclear catalyst. Specifically, 
the reaction proceeds with a five-times higher order of magnitude TOF (14776 h‒1 VS 
49.5 h‒1). The methodology is solvent-free in both stirring or microwave conditions. In 
the latter case the methodology is superior to other microwave assisted methodologies, 
since it does not require the presence of water in this water sensitive reaction. The use of 
2.1, as a catalyst, in the reaction of furfural and primary amines yields the corresponding 
deprotonated Stenhouse salts. This result is in line with our previous findings and in 




The first crystallographic characterisation of the intermediate C2P3a HCl, as well as 
theoretical calculations shed light on the mechanistic pathway towards the production of 
the ring-closed product.  
 
Chapter 3 reported the first, to the best of our knowledge, heterometallic entity to decorate 
an amyloid core. The Zn2Dy2 coordination compound (3.1), bearing partially saturated 
coordination environment in solution, binds, probably covalently, to the amyloid fibrils 
of an hexapeptide, with Lewis basic donor-groups, which maintains the highly ordered 
amyloid core. The resulting functionalized assembly 3.1‒HYFNIF exhibits catalytic 
Lewis acid behaviour in a nanoscale level. 3.1‒HYFNIF moiety shows superior catalytic 
activity when compared with metal salts and in situ mixtures of metal salts and peptide, 
under the optimized reaction conditions reported in the chapter.  
 
Chapters 4 and 5 embarked on the development of mononuclear CuII catalysts 4.1S and 
5.1 as excellent homogeneous catalytic precursors for the multicomponent A3 coupling 
reaction for the synthesis of propargylamines. 4.1S is recoverable and can be used up to 
five times in the catalytic cycle, in open-air, without any loss of its catalytic activity. The 
recovered 4.1S specie, 4.1RS, was also characterized crystallographically and a 
comparison of the bond lengths was undertaken in order to extract mechanistic evidence. 
Control experiments, solution studies and theoretical calculations revealed a radical 
pathway containing the CuI-complex species and supports the plausible in situ formation 
of the CuI‒acetylide intermediate, that may be responsible for the catalytic cycle. The 
applicability of 4.1S is restricted to secondary amines. Compound 5.1 finds applicability 
in both secondary and primary amines, under mild conditions. Experiments with the 
CuII/2,2'-bipyridine analogue, compound 5.2, reveal that the key to success is the 
stereochemistry of the pre-catalyst that permits alkyne binding with concomitant 




The development of well-characterized and stable in solution pre-catalysts from simple 
starting materials without tedious multi-step synthetic protocols serves one of the main 
purposes of this Thesis. Effectually, all of the procedures were followed in open-air, using 




vapour and liquid diffusion. The compounds are easily reproducible and the bulk 
materials are afforded in good to excellent yields.  
 
The Schiff base ligand H2L
20 has been employed in the past by Kostakis and co-workers 
to construct libraries of tetranuclear MII2Ln
III
2 compounds with the same defect dicubane 
topology (2,3M4-1). The L : M : Ln ratio is 4 : 2 : 1 or 2 : 1 : 1, depending on the choice 
of the 3d metal. Some of these compounds have been successfully employed as catalysts 
in a variety of transformations. The commercially available hexapeptide HYFNIF adopts 
a well-ordered amyloid core, stable in protic solvents, and can provide donor atoms, 
capable of coordination, such as -OH of Tyr and Nim of His. Moreover, the aromatic 
moieties of the aminoacid peptide chain do not exclude the possibility for non-covalent 
interactions (hydrogen bonding or π-π stacking) of the amyloid with a guest molecule 
containing phenolic moieties. Such ligands contribute to the architecture and possibly the 
properties (enantioselectivity, solubility etc) of the coordination compound due to the 
secondary coordination sphere effects and their functional groups. Salen ligand H2L
21‒S 
has been widely reported in coordination chemistry, especially with 3d metals, same as 
its enantiomer and its racemic analogue. It includes an {N2O2} pocket which controls 
nuclearity, with most cases the favourable formation of mononuclear complexes. The 
{N2O2} set provides a (distorted) planar environment, while coordinating ions/ solvents/ 
substrate molecules may occupy the the axial positions of the metal coordination sphere. 
H2L
21‒S is a redox non-innocent ligand and the behaviour of the resulting complexes has 
attracted a lot of interest in electrochemistry and enantioselective catalysis. L7 is semi-
rigid, capable for terminal, via the N3 of the bta unit, or chelating N-N coordination mode. 
L7 is appropriate for the synthesis of 0D complexes, with the nuclearity depending on the 
existence of co-ligand, anions and reaction conditions. Despite the electron-rich nature of 
L7, there are not many related reports for catalysis.  
 
Additional {N2O2} and N-chelating ligands were also tested for comparison and 
diagnostic purposes. The salan H2L
22 and bpy were combined with CuII to afford 
mononuclear compounds, according to previously reported synthetic routes. These 
ligands provide the same donor sets with H2L
21‒S and L7 respectively, but allow the study 
of the influence of the secondary coordination sphere, geometry and steric effects in the 
catalytic mechanism and the influence on the substrate scope. Despite the popularity of 




exhibited moderate activity for tertiary and no activity for secondary propargylamine 
synthesis. In the literature, CV studies have compared the redox potential of the type 
CuIIL2 complexes, employing L
7 and bpy and found that the former exhibit greater redox 
potentials than the ones with bpy. In Chapter 5, the CV studies confirmed a structural 
change into the catalytic system when one equivalent of phenylacetylene is added in the 
solution of 5.1. This could be attributed in the dissociation of one L7 from 5.1, providing 
a reversible signal and enabling the formation of the active catalytic CuI specie. In in case 
of 5.2 the signal was non-reversible, which might implies the inability of the system to 
form the active specie.     
 
Characterisation 
A range of characterisation techniques were employed to fully determine the nature of 
the synthesized materials in solid state and in solution. In regards to the solid-state 
methods, large efforts were made to generate crystalline material for every coordination 
compound. Apart from establishing purity, SXRD was essential since the study and 
optimisation of the catalytic properties of the compounds was often dependant on specific 
coordination characteristics such as geometry and environment. As a result, the use of 
SXRD proved critical in the determination of these features. Other solid-state 
characterisation methods (elemental analysis and FT-IR) were also used to confirm the 
structure of the bulk material. The thermal stability of the compounds was identified 
through TGA measurements. Characterisation of 3.1‒HYFNIF was challenging and 
required different techniques than the other compounds of the current Thesis. Although 
the SXRD of HYFNIF is not known in the literature, XRFD measurements provided 
information about the well-known tertiary fibril architecture of HYFNIF; After 
functionalisation of HYFNIF with 3.1, XRFD of compound 3.1‒HYFNIF provided 
important information for the functionalised material. TEM and FESEM/EDX analyses 
provided information about the sample morphology and composition.  
 
Determining the behaviour of the compounds in the solution was a more complex task. 
The HRMS (ESI-MS) spectra of the compounds and their ligands displayed several peaks 
that corresponded to various metal-ligand-anion fragments. This indicated that the 
compounds may retain their identity in solution. CV and UV-Vis studies for CuII based 
complexes were performed along with reactants, in order to provide the required 




LCMS and NMR was used for the characterisation of the catalytic products, some of 
which are novel. Solution studies for 3.1‒HYFNIF (CD, UV-Vis and Dityrosine 
Fluorescence) provided information regarding the binding of 3.1 to HYFNIF.  
 
Impact and System Limitations  
Reaching the completion of this work, it is felt that the objectives of the current Thesis 
have been met, while the results have notably contributed to the scientific literature, both 
from an inorganic and organic perspective. The crystal engineering and structural studies 
of the novel compounds provided a good insight of the capabilities of the resulting 
systems, but undoubtedly the exploration of the potential properties of the systems in 
catalysis, under various conditions, had the biggest impact.  
 
Despite the previous reports of the isostructural NiII2Ln
III
2 compounds to 2.1, and their 
application in the synthesis of trans-4,5-diaminocyclopentenones, the latter possesses a 
novel structure with extremely enhanced activity comparing to any reported catalyst for 
the same reaction. The first isolation of a Stenhouse salt intermediate and the extension 
of the reaction scope are determining factors that importantly contribute to the 
methodology and product development. The results summarise the importance of 
lanthanide selection, conditions, such as MW irradiation, coordinating ions, specifically 
OTf ‒ ions, and their role in the catalytic cycle. This study was reported in the Journal of 
Organic Chemistry.  
 
The amyloid self-assembling peptides with well-defined secondary coordination 
environments can be readily and extensively fine-tuned for particular applications. While 
up-to-date applications upon metal complex functionalization are mainly reported in 
regards to the antioxidant properties, therapeutic ability or diagnosis, the reports for 
catalysis are scarce. Moreover, when amyloid co-exists with more than one different 
metals in solution, a loss of their structural integrity is observed. The reported well-
characterized compounds that bear metals centres with organic linkers and have been 
employed for functionalization are monometallic. Chapter 3 presents the first example of 
such complexes with two different metal centres (Zn, Dy). ZnII2Dy
III
2 (3.1) combines with 
HYFNIF in H2O-MeOH to result the hybrid material 3.1‒HYFNIF, which shows 
catalytic activity in protic media, in a nanoscale level. The challenges to characterise such 




constituted of, thus the required characterisation techniques. Also, the ZnII2Dy
III
2: 
HYFNIF low ratio (1 : 20), did not permit analysis by Mass Spectrometry. Although the 
domino reaction of trans-4,5-diaminocyclopentenones is generally water-sensitive, 
catalysis was successful. The study was reported in the journal Dalton Transactions.  
 
Chapters 4 and 5 demonstrate the successful use of the first 0D CuII coordination 
compounds as catalysts in the A3 coupling reaction. The catalytic system was developed 
and optimised through the “inorganic approach”, that involve an electron-rich ligand with 
controllable coordination modes, electronic and/or steric effects, towards mononuclear 
CuII complexes, in order to obtain important mechanistic information. It is felt that the 
results significantly contribute to the scientific input in the currently underutilised CuII 
sources for propargylamine synthesis, and the key to success appears to be the ligand 
selection and the stereochemistry of the final pre-catalyst.  In contrast to most 
propargylamine catalytic protocols, we employed CuII in “bench” conditions, instead of 
CuI in inert atmosphere, in 1.5-2 mol% loadings and high concentrations. Starting with 
the recoverable 4.1S with {N2O2} environment and application to secondary amines with 
good yields at 60 °C under MW irradiation, we improved the CuII methodology by the 
synthesis of 5.1. For the latter, {N2N2} environment by the semi-rigid ligand contributes 
to the applicability of the system to primary amines, providing excellent yields in room 
temperature. Gram scale synthesis was feasible in both cases. In all these cases, the 
catalytic behaviour of the complexes were superior to the behaviour of Cu metal salts 
under the same conditions. The study in Chapter 4 was also reported in the journal Dalton 
Transactions, while the study in Chapter 5 will be submitted for publication.  
 
While these results were certainly encouraging, the systems present some limitations. Dy 
and CuII are paramagnetic, thus characterisation compounds, as well as catalysis 
monitoring by NMR was not feasible. Further limitations may be identified in the 
catalytic system; while propargylamine synthesis yielded very positive results, the 
catalysts did not operate in aqueous media and in the case of 5.1, the scope of primary 
amines was mainly limited to anilines. Also, despite the chiral ligand employment, 
compound 4.1S yielded propargylamines with low enantiomeric excess. Despite the 
limitations, it is hoped that the contributions of this Thesis will inspire scientists for a 




complexes in catalysis for natural product synthesis. The intriguing systems bridge the 
fields of Inorganic Chemisty, Organic Chemistry and Catalysis.  
 
6.2 Future Work  
In terms of the 3d-4f catalyst development, the PMCs of the type MII2Ln
III
2 can be 
expanded into several directions in catalysis. Taking into account the Aza-Piancatelli 
rearrangement catalysed by Dy(OTF)3,
295 the sequential bimetallic catalysis of the same 
reaction by Ca(NTf2)2 and Cu(OTf)2,
283 as well as In(OTf)3 for the Aza-Piancatelli 
rearrangement/ Friedel-Crafts alkylation,389 it would be interesting to explore the 
potential of compound 2.1 in such reactions (scheme 6.1). Regarding the Domino 
transformation of 2-furylcarbinols and anilines with 2.1 (3 mol%), preliminary results in 
CH3CN under MW irradiation revealed a moderate conversion for the desired product. 
The system can be further optimised (catalyst loading, time and temperature) for higher 







2(OTf)x isostructural to 2.1 could be synthesized and 
studied for these transformations. The Y permits titration studies of the catalyst with the 
reactants by 89Y NMR, while the role of Cu could be additionally studied by UV-Vis.  
 
 
Scheme 6.1. A) Aza-Piancatelli rearrangement promoted by Dy(OTf)3 and B) Aza-





Related to Chapter 3, the ZnII2Y
III
2 analogues with various coordination ions could be 
applied for HYFNIF functionalisation and study of the resulting compound by 1H NMR 
and 89Y NMR. A range of Complex : HYFNIF ratios could also permit studies regarding 
the interactions of these two units. Finally, replacement of the 3d element by NiII or CuII 
would permit further UV-Vis studies, while replacement of the 4f element by TbIII could 
give rise to fluorescent properties. Other amyloidogenic peptides can be used accordingly.  
 
Enantioselectivity was a significant omission for the CuII protocols developed herein, thus 
future studies on the A3 coupling and possibly other imine-based multicomponent 
reactions should concentrate on this. The employment of enantiopure BINOL-salen 
unsymmetrical ligands, such as H2L
23-H2L










7  Chapter 7:  Experimental and Synthetic Details 
7.1 General Methods 
 
Materials 
All reagents were purchased from Sigma-Aldrich, Fluorochem, Tokyo Chemical 
Industry, Apollo Scientific, Fischer Scientific, Alfa Aesar or JPT Peptide Technologies 
and used without further purification. Unless otherwise stated, all experiments were 
performed under aerobic conditions.  
 
Instrumentation  
FT-IR. IR spectra were recorded over the range of 4000-650 cm‒1 on a Perkin Elmer 
Spectrum One FT-IR spectrometer fitted with a UATR polarization accessory.  
 
ESI-MS. HRMS (ESI-FTMS) data were obtained on a VG Autospec Fissions instrument 
(EI at 70 eV).  
 
LCMS. Reactions were monitored with the assistance of liquid chromatography-mass 
spectrometry. All products were analysed using the following conditions: Column - 
Waters XSelect CSH C18 5 μm 4.6 x 50 mm @ 50 °C. Flow Rate - 1.7 mL/min. Eluents 
A - Water, B – Acetonitrile, both with +0.1% TFA. Gradient - 0.0 min 5% B, 0.4-3 min 
5-98% B, 3-3.5 min 98%B, 3.5-3.6 min 98-5% B, 3.6-4 min 5% B. Method - ES positive. 
 
NMR. NMR spectra were measured on a Varian VNMRS solution-state spectrometer (at 
400, 500 or 600 MHz) using residual isotopic solvent (DMSO-d6, δH= 2.50 ppm or CDCl3, 
δH= 7.26 ppm) as internal reference. Chemical shifts are quoted in parts per million (ppm). 
Coupling constants (J) are recorded in Hertz (Hz).  
 
TGA. TGA analysis was performed on a TA Instruments Q-50 model (TA, Surrey, UK) 
under N2 and at a scan rate of 10 °C/min.  
 
UV-Vis. Chapters 2 and 3: UV−vis spectra for compounds were collected using 
NanoDrop Spectrophotometry. Chapters 4 and 5: UV-Vis measurements for compounds 




indicated with quartz cuvettes. The collected data were processed using the Vision Pro 
software. 
 
Electrochemistry. Chapters 4 and 5: Electrochemical measurements of the CuII 
complexes were carried out using an Autolab 302N potentiostat interfaced through Nova 
2.0 software driven by a personal computer. Electrochemical measurements were 
performed in a dinitrogen glovebox under oxygen levels of less than 5 ppm using solvent 
that had been purified by passing through an LC Technology Solutions SPBT-104 solvent 
purification system. All the measurements were carried out in either CH2Cl2 or MeCN 
(0.1 M TBA PF6 was used as the supporting electrolyte), with sample concentrations of 
0.1 mM. The systems were analysed at 25°C with a three-electrode assembly comprising 
of a diamond-polished glassy carbon working electrode (3mm diameter), platinum wire 
counter electrode, and a silver wire coated with anodically deposited silver chloride as a 
pseudo-reference electrode. Potentials are reported relative to the [FeCp2]
0/+ redox couple 
through the addition of ferrocene to the analyte solution.  
 
SXRD. Data for compounds 2.1 and 5.1 were collected (ω-scans) at the University of 
Sussex, using an Agilent Xcalibur Eos Gemini Ultra diffractometer with CCD plate 
detector under a flow of nitrogen gas at 173(2) K, using Cu Kα radiation (λ = 1.54184 Å). 
CRYSALIS CCD and RED software was used respectively for data collection and 
processing. Reflection intensities were corrected for absorption by the multi-scan method.  
Data for compounds 4.1S, 4.1RS and the Stenhouse salt intermediate C2P3a HCl were 
collected at the National Crystallography Service, University of Southampton.390 4.1S was 
mounted on a MITIGEN holder in perfluoro ether oil on a Rigaku FRE+ equipped with 
HF Varimax confocal mirrors and an AFC12 goniometer and HG Saturn 724+ detector.  
4.1RS and C2P3a HCl were mounted on a MITIGEN holder in perfluoroether oil on a 
Rigaku 007HF equipped with Varimax confocal mirrors and an AFC11 goniometer and 
HyPix 6000 detector. The crystals were kept at a steady T = 100(2) K during data 
collection. The data were processed with CrysAlisPro and solved by intrinsic phasing 
methods with SHELXT.391  
 
All structures were then refined on Fo2 by full-matrix least-squares refinements using 
SHELXL.391 Geometric/crystallographic calculations were performed using PLATON,392 




non-H atoms were refined with anisotropic thermal parameters, and H atoms were 
introduced at calculated positions and allowed to ride on their carrier atoms. The formula 
of compound 3.1 has already been reported,69,72 and its successful synthesis was 
confirmed by SXRD, ESI-MS and TGA. 
 
The crystallographic datasets for 4.1S and 4.1RS were collected in different instruments 
(National Crystallography Service, University of Southampton390)  but at the same 
temperature (100K). To validate these differences, a further three crystallographic 
datasets were collected for each catalyst, 4.1S and 4.1RS, at the same temperature (100K) 
and using the same diffractometer.  
 
TEM. The peptide working solutions (1.26 mM, 4 μL) were incubated for 1 min on a grid 
(400 mesh copper grid with Carbon/Formvar film from Agar Scientific), blotted and then 
washed with 4 μl of 0.22 μM filtered milli-Q water. Uranyl acetate (4 μL of 2% w/v) was 
placed on the grid once for one minute and then blotted and the grid was allowed to air-
dry. TEM projection images were collected using a JEOL JEM1400-Plus Transmission 
Electron Microscope operated at 120 kV equipped with a Gatan OneView camera 
(4kx4k). Images were recorded at 25 fps with drift correction using GMS3. 
 
CD. Peptide sample solutions and 4.1S were monitored at 25 °C, using a Jasco J-715 
spectropolarimeter with a Peltier temperature control system at 21 °C. Peptide samples 
(30 μl) were placed into 0.1 mm path length quartz cuvettes (Hellma), and scanned from 
180-320 nm.  4.1S and the corresponding ligand were placed into 1 mm path length quartz 
cuvettes (Hellma) and scanned from 180-800 nm. The parameters were set as the 
following: a pitch of 0.1 nm, a scan speed 50 nm min−1, response time 4 s, slit widths 1 
nm and with standard sensitivity. Each set of data was collected in triplicate. Spectra of 
the blank experiments, were subtracted from the readings. Spectra were converted to 
molar ellipticity per residue (MER).  
 
XRFD. X-Ray fibre diffraction was collected for HYFNIF and 3.1‒HYFNIF. Fibre were 
aligned by placing 10 μL between wax-tipped capillary tubes allowed to dry overnight. 
The partially aligned samples were mounted on a goniometer head and a diffraction 
pattern was collected using a Rigaku rotating anode with Saturn CCD detector, using an 




distance was 50 mm or 100 mm, respectively. Diffraction data were converted to TIFF 
format using Mosflm396 and inspected using CLEARER.397  
 
FESEM/EDX. The sample 3.1‒HYFNIF suspended in Milli-Q H2O˗MeOH, was 
prepared by pipetting a drop onto a polished Si chip and leaving it to dry overnight at 
room temperature to afford a light yellow film with some "folds". EDX measurements 
were performed with a Zeiss Leo 1530 SEM operating at 20kV. The EDX were acquired 
using the "Point & ID" option in INCA software using an Oxford X-MaxN 50 detector. 
The EDX system (LINK ISIS 300, Oxford Corp.) is equipped with a high-resolution Ge 
detector (112 eV @ 5.9 keV). As the sample was placed on a polished Si chip, Si is 
excluded from the EDX analysis.  
 
Dityrosine Fluorescence. Fluorescence measurements were carried out on a Varian Cary 
Eclipse fluorimeter (Varian Ltd., Oxford, UK) using a 1 cm path length quartz cuvette 
(Starna, Essex, UK), and dityrosine fluorescence was monitored using an excitation 
wavelength of 320 nm. Dityrosine emission was monitored between 340 and 500 nm, 
with maximum fluorescence intensity at around 400–420 nm at a controlled temperature 
of 21°C. Tyrosine fluorescence signal was monitored using an excitation wavelength of 
280 nm and emission wavelength of 305 nm. Excitation and emission slits were both set 
to 10 nm, and the scan rate was set to 300 nm/min with 2.5 nm data intervals and an 
averaging time of 0.5 s. The photomultiplier tube detector voltage was set at 500 V.  
 
Microwave Synthesis. The synthesis involving the use of microwave irradiation was 
performed in: 
Chapter 2: A CEM Discover SP microwave reactor unit with a CEM Explorer Microwave 
auto sampler and undertaken using a CEM 10 mL sealed microwave reactor vials with 
polytetrafluoroethylene (PTFE) caps. Chapters 4 and 5: A Biotage Initiator Robot Sixty 
in pressure-rated 5 mL Biotage glass vials. In both cases, an internal infrared probe was 
utilized to monitor and control the temperature of the reaction allowing for precise and 
reproducible reaction conditions.  
 
Purification of compounds. Chapter 2 and 3: Compounds were purified manually by 
normal-phase silica column chromatography in a solvent mixture of ethyl acetate/hexanes 




flash column chromatography, conducted in a Biotage Isolera with UV detection at 254 
nm and the solvent mixture of diethyl ether/petroleum ether (fraction 40-60) was used as 
the gradient eluent (0:100-30:70 v/v). 
 
Methods A, B, C 
In the present work, catalytic methods CXA, CXB and CXC, where X is the number of the 
Chapter, refer to catalysis under: open-air conditions (method CXA), MW irradiation 
(method CXB) and inert atmosphere (method CXC) with one of the catalysts synthesized 
for the aims of this Thesis. 
 
7.2 Ligand Synthesis 
 
Supporting Figures and Tables for 1H NMR, 13C NMR, FT-IR, HRMS (ESI-FTMS), 
LCMS, UV-Vis, CD, TEM, FESEM/EDX, Dityrosine Fluorescence may be found in the 
Appendix.   
 
Synthesis of (E)-2-(((2-hydroxyphenyl)imino)-methyl)-6-methoxyphenol (H2L20) 
O-vanillin (0.025mol, 3.35g) and 2-amino-phenol (0.025mol, 2.73g) were dissolved in MeOH (5 
mL). The suspension was refluxed for 1 h, during which time a bright orange solid precipitated. 
After cooling to room temperature, the solid was filtered off and washed with cold MeOH and 
Et2O. The solid was dried in vacuo. 
 
The ligand H2L20 was synthesized following previously reported procedure.69,72 The 
ligand H2L20 was synthesized by reflux using a round-bottomed flask equipped with a 
reflux air condenser and a magnetic stir bar. The round bottom flask was charged with o-
vanillin (1.33 g, 10 mmol), 90 mL of EtOH absolute and 2-amino-phenol (1.09 g, 10 
mmol).  Yield 2.33 g, 96%. 1H NMR (500 MHz, DMSO-d6) δ 9.75 – 9.71 (m, 1H), 8.95 
(s, 1H), 7.36 (dd, J = 8.0, 1.6 Hz, 1H), 7.21 – 6.99 (m, 3H), 6.96 (dd, J = 8.1, 1.4 Hz, 1H), 
6.91 – 6.81 (m, 2H), 3.80 (s, 3H). HRMS (ESI-FTMS) m/z: ([M + H]+) calcd for 








Synthesis of Acetyl-HYFNIF-NH2 
The lyophilized peptide capped HYFNIF (1 mg) was purchased from JPT Peptide 
Technologies, Germany, was incubated for one week in 0.5 mL Milli-Q H2O to produce 
fibrils at a 2.38 mM (stock solution I). Characterisation of the behaviour of Acetyl-
HYFNIF-NH2 in H2O and H2O-MeOH can be found in the Appendix (Figure S3-1). The 
results are in agreement to those in the literature.80 
 
Synthesis of 2-((E)-((1S,2S)-2-((E)-3,5-di-tert-butyl-2-hydroxybenzylideneamino) 
cyclohexylimino)methyl)-4,6-di-tert-butylphenol (H2L21-S)  
The ligand H2L21-S was synthesized by reflux using a round-bottomed flask equipped with 
a reflux condenser and a magnetic stir bar. The round bottom flask was charged with 3,5-
di-tert-butylsalicylaldehyde (4.70 g, 20 mmol) in 90 mL of EtOH absolute. A solution of 
(1S,2S)-(−)-1,2-Diaminocyclohexane (1.14 g, 10 mmol) in 10 mL of EtOH absolute was 
added. The flask was heated at reflux for 2 hours with the appearance of the Schiff base 
as a bright yellow precipitate. Yield 5.31 g, 97%, based on (1S,2S)-(−)-1,2-
diaminocyclohexane. 1H NMR (500 MHz, CDCl3) δ, ppm: 13.67 (s, 2H), 8.33 (s, 2H), 
7.31 (d, J = 2.1 Hz,  2H), 6.98 (d, J = 2.1 Hz,  2H), 3.36 (s, 2H), 2.0–1.4 (m, 8H), 1.43 (s, 
18H), 1.26 (s, 18H). HRMS (ESI-FTMS) m/z: ([M + H]+) calcd for C36H55N2O2, 
547.8341; found, 547.8347. The results are in agreement to those in the literature.398  
 
Synthesis of 2-((2-(3,5-di-tert-butyl-2-hydroxybenzylamino) cyclohexylamino) 
methyl)-4,6-di-tert-butylphenol (H2L22)  
The racemic form of H2L
21-S, ligand 2-((E)-(2-((E)-3,5-di-tert-butyl-2-hydroxybenzyl 
ideneamino) cyclohexylimino)methyl)-4,6-di-tert-butylphenol (2 g, 3.65 mmol), was 
dissolved in 30 mL of MeOH and the solution was cooled to 0°C. NaBH4 (0.28 g, 7.30 
mmol) and 2 mL of acetic acid were added. The mixture was stirred at room temperature 
for 5 h and subsequently was quenched with saturated aqueous NaHCO3 solution. The 
aqueous phase was extracted with 3 × 20 mL EtOAc. The organic phase was dried with 
anhydrous Na2SO4, which was subsequently removed by filtration, and concentrated in 
vacuo.358 Yield 1.99 g, 99%.  1H NMR (500 MHz, CDCl3) δ, ppm: 7.21 (d, J = 2.76 Hz, 
2 H), 6.86 (d, J = 2.28 Hz, 2 H), 4.04 (d, J =13.2 Hz, 2 H), 3.90 (d, J = 13.2 Hz, 2 H), 
2.47–2.46 (m, 2 H), 2.19–2.16 (m, 2 H), 1.71–1.70 (m, 2 H), 1.45–1.40 (m, 20 H), 1.28–
1.21 (m, 24 H) ppm. HRMS (ESI-FTMS) m/z: ([M + Na]+) calcd for C36H58N2O2Na, 





Synthesis of 1-(pyridin-2-yl)-1H-benzotriazole (L7) 
The ligand L7 was synthesized by two different methods (i) and (ii), appropriate for 
synthesis in large and small scale respectively:  
Method (i): Reflux under N2 using a round-bottomed flask equipped with a magnetic 
stirrer bar. The round bottom flask was charged with 2-bromopyridine (3.15 g, 20 mmol), 
K2CO3 (12 g, 86.20 mmol), KI (0.50 g, 3 mmol) and benzotriazole (4.76g, 40 mmol)  in 
20 mL of acetone. The flask was heated at reflux for 8 hours. The reaction mixture was 
dissolved in ethyl acetate (250mL), washed with cold 10% KOH (2 x 150 mL), dried with 
anhydrous MgSO4, filtered and evaporated to afford the pure product as a white solid 
which was recrystallized from H2O/EtOH. Yield 4.65 g, 79%, based on 2-bromopyridine.  
Method (ii): A 5 mL sealed vessel equipped with magnetic stir bar was charged with   2-
bromopyridine (0.32 g, 2 mmol) and benzotriazole (0.48 g, 4 mmol)  and was exposed to 
microwave irradiation at 160˚C for 3 hours, under solvent-free, non-inert conditions, 
according to previously reported protocol.399 After reaction completion, the cooled to 
ambient temperature mixture, was diluted in 1 mL DCM and purified by flash column 
chromatography. The product is isolated through silica gel flash column chromatography 
using a diethyl ether/petroleum ether (fraction 40-60) mixture as the gradient eluent 
(01:99-30:70 v/v). The 1-(2-pyridyl)benzotriazole was obtained as a white solid. Yield 
5.06 g, 86%, based on 2-bromopyridine. 1H NMR (600 MHz, CDCl3) δ 8.66 (dt, J = 8.4, 
1.0 Hz, 1H), 8.64 – 8.60 (m, 1H), 8.31 (dt, J = 8.4, 0.9 Hz, 1H), 8.12 (dt, J = 8.4, 0.9 Hz, 
1H), 7.94 (ddd, J = 8.4, 7.4, 1.8 Hz, 1H), 7.61 (ddd, J = 8.1, 6.9, 1.0 Hz, 1H), 7.46 (ddd, 
J = 8.0, 6.9, 1.0 Hz, 1H), 7.33 (ddd, J = 7.4, 4.8, 0.9 Hz, 1H), 1.54 (d, J = 0.6 Hz, 2H). 
MS (LCMS) m/z: ([M + H]+) calcd for C11H9N4, 197.2; found, 197.1, Rt = 2.64 min.  
 
7.3 Synthesis of Coordination Compounds 2.1, 3.1, 3.1‒HYFNIF, 4.1S, 4.2, 5.1 
and 5.2 
 
Synthesis of [NiII2DyIII2(L20)4(DMF)6]·2(CF3SO3)·2(DMF) (2.1) 
H2L
20 (48 mg, 0.20 mmol), Dy(OTF)3. (61 mg, 0.10 mmol) and Ni(OTF)2 (36 mg, 0.10 
mmol,) were added in EtOH (20 mL) and the resulting mixture was stirred for 1 hour. 
During this time, a yellow precipitate was formed from the yellow solution. The 
precipitant was filtered off, then washed with cold EtOH (20 mL) and Et2O (10 mL) and 




Et2O, forming yellow-greenish crystals. Yield 1.62 g, 95%, based on Dy. Selected IR 
peaks (cm‒1): 3409 (w), 1607 (m), 1460 (m), 1223 (m), 1026 (s), 965 (m), 820 (m), 733 
(s). Elemental analysis (%) for Ni2Dy2C74H86N10O18(CF3SO3)2(C3H7NO)2: C 42.96, H 
4.40, N 7.34; found C 42.62, H 4.51, N 7.13. HRMS (ESI-FTMS) m/z shows the presence 








+ 1629.0521 ; found, 1629.0894. 
 
Synthesis of [ZnII2DyIII2(L20)4(NO3)2(DMF)2] (3.1)  
Compound 3.1 was synthesized following previously reported procedure.69,72 H2L
20 (48 
mg, 0.20 mmol) and Et3N (61 μL, 0.40 mmol) were added to EtOH (20 mL) and the 
resultant solution was stirred for 5 min under reflux. Subsequently, Zn(NO3)2·6H2O (56 
mg, 0.20 mmol) and Dy(NO3)3·5H2O (39 mg, 0.10 mmol) were added and the solution 
and were refluxed for further 2 h. After cooling, the yellow precipitate was filtered, 
washed with Et2O and dissolved in DMF (10 mL). The resultant solution underwent 
vapour diffusion and after 1 week long yellow crystals with the formula 
[ZnII2Dy
III
2(C14H11NO3)4(NO3)2(DMF)2] had formed. Yield 1.49 g, 92%, based on Dy. 
Elemental analysis (%) for Zn2Dy2C74H86N10O18(NO3)2(H2O)4: C 41.58, H 3.24, N 




2+ 710.0143; found, 710.0163. 
 
Synthesis of 3.1‒HYFNIF  
The lyophilized peptide Acetyl-HYFNIF-NH2 (1 mg) was incubated for one week in 0.5 
mL Milli-Q H2O to produce fibrils at a 2.38 mM stock solution I. Working peptide 
solution AI with the coordination compound 3.1 was freshly prepared by mixing the stock 
solution I (100 μL) with 0.12 mM solution of 3.1 in methanol (90 μL) and incubated for 
24 hours, resulting a mixture of HYFNIF and 3.1, the 3.1‒HYFNIF solution. 
Accordingly, working peptide solutions BI-DI with metal sources (Zn(NO3)2·6H2O and/ 
or Dy(NO3)3.5H2O) were freshly prepared, resulting the Zn‒HYFNIF, Dy‒HYFNIF, Zn‒
Dy‒HYFNIF solutions. Accordingly, working peptide solutions EI was prepared by 
mixing peptide stock solution (100 μL) with methanol (90 μL) and incubated for 24 hours. 
FESEM/EDX analysis (%) for [ZnII2Dy
III
2(C14H11NO3)4(NO3)2(DMF)2]‒(C45H56N10O9) 
(3.1‒HYFNIF) showed the presence of C, N, O, Zn and Dy in the sample. A 1 : 1 ratio 


















AI 3.1 1.26 0.06 3.1‒HYFNIF 
BI Zn(NO3)2·6H2O 1.26 0.06 Zn‒HYFNIF 




1.26 0.06 Zn‒Dy‒HYFNIF 
EI none 1.26 0.00 HYFNIF 
     
[a] Molarity of HYFNIF (1.26 mM) in Milli-Q H2O-MeOH. [b] Molarity of the 
coordination compound 3.1 (0.06 mM) in Milli-Q H2O-MeOH.   
 
Synthesis of [CuIIL21-S] (4.1S) 
H2L21-S (55 mg, 0.10 mmol), Cu(OTF)2 (36 mg, 0.10 mmol) and Et3N (27 μL, 0.20 mmol) 
were added in methanol (20mL), using a round-bottomed flask equipped with a reflux 
condenser and a magnetic stir bar. The resulting mixture was refluxed for 1 hour. The 
solution mixture was filtered, and the filtrate was then collected and underwent slow 
evaporation, forming brown needle-shaped crystals after two days. Yield 0.44 g, 76%, 
based on CuII. Selected IR peaks (cm‒1): 2946 (m), 2854 (w), 1621 (s), 1525 (s), 1461 
(m), 1431 (m), 1381 (m), 1347 (m), 1321 (m), 1252 (m), 1165 (s), 878 (s), 832 (s), 787 
(s). Elemental analysis (%) for CuC36H52N2O2: C 71.13, H 8.63, N 4.61; found C 71.03, 
H 8.57, N 4.67. HRMS (ESI-FTMS) m/z: ([M + Na]+) calcd for C36H58N2O2Na, 







Synthesis of [CuL22] (4.2)  
4.2 was sunthesized following previously reported procedure.359 H2L
22 (55 mg, 0.10 
mmol), Cu(OTF)2.4CH3CN  (36 mg, 0.10 mmol) and Et3N (27 μL, 0.20 mmol) were 
added in methanol (20 mL), using a round-bottomed flask equipped with a reflux 
condenser and a magnetic stir bar. The resulting mixture was refluxed for 1 hour, and 
green oil was formed after the evaporation of the solvent. Yield 0.49 g, 80%, based on 
CuII. HRMS (ESI-FTMS) of (4.2) in methanol m/z: ([M+H]+) calcd for CuC36H57N2O2, 
612.3715; found, 612.3655 (Appendix, Figure S4-12). 
 
Synthesis of [CuIIL7(CH3CN)2]·2(CF3SO3) (5.1)  
5.1 was synthesized by the following procedure: L7 (39 mg, 0.20 mmol) and Cu(OTF)2 
(36 mg, 0.10 mmol) were added in acetonitrile (10mL), using a round-bottomed flask 
equipped with a magnetic stirrer bar. The resulting mixture was stirred for 1 hour. The 
solution mixture was filtered, and the green filtrate was then collected and underwent 
slow evaporation, forming green block-shaped crystals after four days. Yield 0.08 g, 85% 
based on CuII. Selected IR peaks (cm‒1): 2948 (m), 1620 (s), 1526 (m), 1432 (s), 1164 (s), 
879 (s), 832 (s). Elemental analysis (%) for CuC28H28F6N10O6S2: C 39.93, H 3.35, N 
16.63; found C 40.01, H 3.31, N 16.66. HRMS (ESI-FTMS) of (5.1) in methanol m/z: 
([M]+) calcd for [CuC23H16N8F3O3S]
+, 604.0314; found, 604.0338 (Appendix, Figure S5-
2). 
 
Synthesis of [CuII(bpy)2(CF3SO3)]+ (5.2)  
5.2 was synthesized according to the reported procedure.381 Bpy (47 mg, 0.30 mmol) and 
Cu(OTF)2 (54 mg, 0.15 mmol) were added in a round-bottomed flask equipped with 
acetonitrile (10mL) and a magnetic stirrer bar. The resulting mixture was stirred for 1 
hour. The solution mixture was filtered, and the light blue filtrate was then collected and 
underwent slow evaporation, forming light blue block-shaped crystals after three days. 
Yield  0.09 g, 83% based on CuII. The identity of compound 5.2 was confirmed by HRMS 
(ESI-FTMS) of the 5.2 in methanol m/z: ([M]+) calcd for [CuC21H16N4F3O3S]
+, 524.0191; 





7.4 Catalytic protocols  
 
7.4.1 General Catalytic Protocol for the Synthesis of trans-4,5-
diaminocyclopentenones/ Stenhouse salts 
 
Chapter 2  
 
General Catalytic Protocol for the Synthesis of C2P2a-C2P2d and C2P3a-C2P3d 
products. 
In a capped vial equipped with a magnetic stirbar, aldehyde (1 mmol), amine (2.2 mmol) 
3mg of catalyst (0.01% total of Dy) were added. The resultant mixture was stirred at room 
temperature for 40 minutes (method C2A) or placed under microwave irradiation at 60°C 
for 10 mins (method C2B). The (cooled to ambient temperature in the case of method C2B) 
reaction mixture was diluted with 20 mL CH2Cl2 (DCM) and filtered through celite to 
withdraw the catalyst. The resultant solution was concentrated under reduced pressure 
and the residue was purified by silica gel column chromatography (ethyl acetate in 
hexanes), according to the previously reported procedure.73  The products were obtained 
as red or yellow oils, which solidified on standing. Supporting Figures and spectra may 
be found in the Appendix. 
 
General Catalytic Protocol for the Synthesis of C2P4a-C2P4d and C2P5a-C2P5b 
products. 
In a capped vial equipped with a magnetic stirbar MeCN (100μL), aldehyde (1 mmol), 
amine (2.2 mmol) and 3 mg of catalyst (0.01% total of Dy) were added. The resultant 
mixture underwent microwave irradiation at 60°C for 10 mins (method C2B). The cooled 
to ambient temperature reaction mixture was diluted with 20 mL DCM and filtered 
through celite to withdraw the catalyst. The resultant solution was concentrated under 
reduced pressure and the residue was purified by silica gel column chromatography (ethyl 
acetate in hexanes). The products were obtained as red or yellow oils, which solidified on 








General Catalytic Protocol for the Synthesis of C2P2a and C2P3a products 
To determine the catalytic ability of 3.1‒HYFNIF (AI), the procedure described below 
was applied to the synthesis of trans-4,5-diaminocyclopent-2-enones from 2‑furaldehyde 
and primary or secondary amines. The solvent mixture (H2O-MeOH) was evaporated (at 
36°C) from each peptide solution AI-DI, and the remaining precipitates (3.1‒HYFNIF, 
Zn‒HYFNIF, Dy‒HYFNIF, Zn‒Dy‒HYFNIF) were tested as catalysts. Three stock 
solutions, one of each substrate in MeCN [2-furaldehyde (0.5 M), morpholine (1.2 M) 
and aniline (1.2 M)] were used to prepare fresh working solutions in MeCN-MeOH [2-
furaldehyde (4.8 mM), morpholine (10.6 mM) and aniline (10.6 mM)]. Specifically, 
MeCN (200 μL), MeOH (50 μL), furfural (1.2 μmol, 2.4 μL from the stock solution), 
amine (2.64 μmol, 2.4 μL from the stock solution) and the appropriate amount of catalyst 
(1 mol %), were added. 1H NMR spectra of the products were recorded in CDCl3 for the 
reactions between 2-furaldehyde ‒ morpholine (C2P2a) and 2-furaldehyde ‒ aniline 
(C2P3a), catalysed by 3.1‒HYFNIF. The latter, shows the co-existence of both trans-
4,5-bis(phenylamino)cyclopent-2-enone and (1E,2Z,4E)-5-(phenylamino)-1-
(phenyliminio)penta-2,4-dien-2-olate in the solution. Supporting Figures and spectra may 





7.4.2 Chapters 2 and 3: Characterisation of trans-4,5-diaminocyclopentenones/ 
Stenhouse salts 
trans-4,5-Dimorpholin-4-yl-cyclopent-2-enone (C2P2a) 73 
 
Chapter 2: The product by each method was obtained as yellow oil, which solidified on 
standing. Method C2A provided the sample whose purity is documented by NMR. 1H 
NMR (500 MHz, CDCl3) δ 7.59 (1H, dd, J = 6.0, 2.0 Hz), 6.22 (1H, dd, J = 6.0, 2.0 Hz), 
3.79 (1H, ddd, J = 3.0, 2.0, 2.0 Hz), 3.71 (4H, t, J = 4.5 Hz), 3.67 (4H, t, J = 4.5 Hz), 3.28 
(1H, d, J = 3.0 Hz), 2.84-2.79 (2H, m), 2.67-2.55 (6H, m). 13C NMR (151 MHz, CDCl3) 
δ 206.3, 160.8, 135.6, 68.3, 67.5, 67.3, 66.9, 66.9, 60.3, 50.3, 50.1. (Method C2A) 
conversion 93%, isolated yield = 232 mg, 92%; (method C2B) conversion 95%, isolated 
yield = 235 mg, 93%.  
 
Chapter 3: In air, MeCN (200 μL), MeOH (50 μL), furfural (1.2 μmol, 2.4 μL from the 
stock solution), morpholine (2.64 μmol, 2.4 μL from the stock solution) and the 
appropriate amount of catalyst (1 mol %), were added in a 2.5 mL capped vial equipped 
with a magnetic stir bar. The resultant mixture was stirred at room temperature for 24 h. 
After evaporation of the solvents (36°C), CDCl3 was added and the mixture was analysed 
by 1H NMR. 1H NMR (600 MHz, CDCl3) δ 7.61 (1H, dd, J = 6.0, 2.0 Hz), 6.24 (1H, dd, 
J = 6.0, 2.0 Hz), 3.81 (1H, ddd, J = 3.0, 2.0 Hz), 3.71 (4H, t, J = 4.5 Hz), 3.67 (4H, t, J = 
4.5 Hz), 3.29 (1H, d, J = 3.0 Hz), 2.86-2.82 (2H, m), 2.67-2.51 (6H, m).  HRMS (ESI-
FTMS) m/z: calcd for C13H21N2O3 253.1575; found, 253.1547. Conversion=67%.  
 





The product by each method was obtained as yellow oil, which solidified on standing. 
Method C2A provided the sample whose purity is documented by NMR.  1HNMR (500 
MHz, CDCl3) δ 7.46 (1H, dd, J = 6.0, 2.0 Hz), 6.16 (1H, dd, J = 6.0, 2.0 Hz),5.91-5.77 
(4H, m), 5.26-5.10 (8H, m), 4.11 (1H, ddd, J = 3.0, 2.0, 2.0 Hz), 3.59 (1H, d, J = 3.0 Hz), 
3.38-3.31 (2H, m), 3.23-3.10 (6H, m), 13C NMR (151 MHz, CDCl3) δ 207.9, 162.6, 136.7, 
136.3, 135.0, 117.6 (2 peaks), 65.2, 63.7, 54.6, 53.8. (Method C2A) conversion 83%, 
isolated yield = 215 mg, 79%; (method C2B) conversion 83%, isolated yield = 212 mg, 
78%. 
 
trans-4,5-bis-(2,3-Dihydroindol-1-yl)-cyclopent-2-enone (C2P2c) 73 
 
The product by each method was obtained as yellow oil, which solidified on standing. 
Method C2A provided the sample whose purity is documented by NMR. 1H NMR (500 
MHz, CDCl3) δ 7.68 (1H, dd, J = 6.0, 2.0 Hz), 7.08 (1H, d, J = 7.0 Hz), 7.05 (1H, d, J = 
7.5 Hz), 6.96 (1H, dd, J = 7.5, 7.5 Hz), 6.91 (1H, dd, J = 7.5, 7.5 Hz), 6.67 (1H, dd, J = 
7.5, 7.5 Hz), 6.63 (1H, dd, J = 7.5, 7.5 Hz), 6.49 (1H, dd, J = 6.0, 2.0 Hz), 6.35 (1H, d, J 
= 8.0 Hz), 6.07 (1H, d, J =8.0 Hz), 5.01-4.99 (1H, m), 4.40 (1H, d, J = 3.5 Hz), 3.52 (1H, 
ddd, J = 7.5, 7.5, 7.5 Hz), 3.50 (1H, ddd, J = 8.0, 8.0, 8.0 Hz), 3.41 (1H, ddd, J = 8.0, 8.0, 
8.0 Hz), 3.34 (1H, ddd, J = 8.0 Hz), 3.06-2.90 (4H, m), 13C NMR (151 MHz, DMSO-d6) 
δ 192.1, 159.3, 150.8, 150.6, 129.4, 128.9, 127.4, 124.6, 123.7, 117.8, 117.3, 107.5, 106.7, 
62.2, 58.2, 53.1, 49.5, 48.4, 40.5, 27.8, 27.7. (Method C2A) conversion 89%, isolated yield 
= 269 mg, 85%; (method C2B) conversion 95%, isolated yield = 294 mg, 93%.  
 





The product by each method was obtained as yellow oil, which solidified on standing. 
Method C2A provided the sample whose purity is documented by NMR.  1H NMR (500 
MHz, CDCl3) δ 7.70 (1H, dd, J = 2.0 Hz), 7.16-7.00 (8H, m), 6.32 (1H, dd, J=2.0 Hz), 
4.25-4.13 (2H, m), 3.95-3.90 (3H, m), 3.62 (1H, d, J = 3.0 Hz), 3.12-2.86 (8H,m), 13C 
NMR (151 MHz, CDCl3) δ 207.0, 161.4, 135.4, 135.1, 134.5, 134.4, 134.2, 128.9, 126.6, 
126.5, 126.4, 126.0, 125.8, 125.6, 67.9, 67.4, 53.0, 52.4, 47.5, 47.4, 30.3, 29.8. (Method 
C2A) conversion 80%, isolated yield = 258 mg, 75%; (method C2B) conversion 89%, 
isolated yield = 299 mg, 87%. 
 
(1E,2Z,4E)-5-(Phenylamino)-1-(phenyliminio)penta-2,4-dien-2-olate (C2P3a) 73 
 
The product by each method was obtained as red oil, which solidified on standing. 
Method C2A provided the sample whose purity is documented by NMR. 1H NMR (500 
MHz, DMSO-d6) δ 7.68 (dd, J = 6.1, 1.9 Hz, 1H), 7.11 – 7.01 (m, 4H), 6.63 – 6.44 (m, 
6H), 6.39 (dd, J = 6.1, 1.5 Hz, 1H), 6.20 (d, J = 8.6 Hz, 1H), 6.06 (d, J = 7.5 Hz, 1H), 
4.63 – 4.57 (m, 1H), 4.01 (dd, J = 7.6, 3.4 Hz, 1H), 1.22 (s, 1H). 13C NMR (126 MHz, 
DMSO-d6) δ 205.1, 161.9, 152.4, 151.6, , 132.6, 129.7, 129.5, 129.2, 126.5, 121.3, 117.3, 
116.7, 116.1, 114.36, 113.17, 112.9, 64.9. (Method C2A) conversion 99%, isolated yield 
= 256 mg, 97%; (method C2B) conversion 99%, isolated yield = 256 mg, 97%.  
 
Chapter 3: In air, MeCN (200 μL), MeOH (50 μL), furfural (1.2 μmol, 2.4 μL from the 
stock solution), morpholine (2.64 μmol, 2.4 μL from the stock solution) and the 
appropriate amount of catalyst (1 mol %), were added in a 2.5 mL capped vial equipped 
with a magnetic stirbar. The resultant mixture was stirred at room temperature for 24h. . 
After evaporation of the solvents (36°C, 72 h), CDCl3 was added in the reaction mixture, 
which was analysed by 1H NMR.  1H NMR (600 MHz, CDCl3) δ 8.25 (s, 1H), 7.58 (s, 
1H), 7.33 – 7.35 (m, 2H), 7.21 – 7.09 (m, 6H), 6.94 (d, J = 3.4 Hz, 1H), 6.76 – 6.64 (m, 
4H), 6.52 (s, 1H). The 1H NMR spectrum shows the (1E,2Z,4E)-5-(phenylamino)-1-
(phenyliminio)penta-2,4-dien-2-olate (C2P3a) as the main product, with the co-existence 




bis(phenylamino)cyclopent-2-enone in the solution. HRMS (ESI-FTMS); m/z: calcd for 
C17H15N2O 263.1173; found, 263.1179. Conversion 84%.  
 
 (1E,2Z,4E)-5-((2-Methoxyphenyl)amino)-1-((2-methoxyphenyl)iminio)penta-2,4- 
dien-2-olate (C2P3b) 73 
 
The product by each method was obtained as red oil, which solidified on standing. 
Method C2A provided the sample whose purity is documented by NMR. 1H NMR (500 
MHz, DMSO-d6) δ 8.35 (s, 1H), 7.61 (dt, J = 6.1, 1.7 Hz, 2H), 7.29 – 7.17 (m, 2H), 7.07 
(d, J = 7.8 Hz, 1H), 7.02 – 6.94 (m, 3H), 6.89 – 6.69 (m, 19H), 6.55 (dt, J = 3.5, 1.7 Hz, 
1H), 6.41 (dt, J = 6.1, 1.4 Hz, 1H), 3.96 – 3.69 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 
204.3, 160.9, 147.3, 147.2, 132.5, 126.9, 121.4, 121.2, 118.2, 118.1, 112.0, 111.9, 111.5, 
110.6, 110.1, 109.7, 66.1, 61.9, 55.5. (Method C2A) conversion 85%, isolated yield 269 
mg, 83%; (method C2B) conversion 95%, isolated yield = 298 mg, 92%. 
 
 (1E,2Z,4E)-5-((2-Fluorophenyl)amino)-1-((2-fluorophenyl)iminio)penta-2,4-dien-
2-olate (C2P3c) 73 
 
The product by each method was obtained as red oil, which solidified on standing. 
Method C2A provided the sample whose purity is documented by NMR. 1H NMR (500 
MHz, DMSO-d6) δ 8.35 (s, 1H), 7.61 (dt, J= 6.1, 1.7 Hz, 2H), 7.29 – 7.17 (m, 2H), 7.07 
(d, J = 7.8 Hz, 1H), 7.02 – 6.94 (m, 4H),6.89 – 6.69 (m, 22H), 6.55 (dt, J = 3.5, 1.7 Hz, 
1H), 6.41 (dt, J = 6.1, 1.4 Hz, 1H), 3.96 – 3.69 (m, 27H). 13C NMR (151 MHz, DMSO-
d6) δ 204.0, 150.5 (d, 
1JF,C= 238.8 Hz), 150.8 (d, 
1JF,C= 239.9 Hz), 134.9 (d, 
2JF,C= 11.74 
Hz), 134.4 (d, 2JF,C= 11.74 Hz), 123.5 (d, 
4JF,C= 3.39 Hz), 123.3 (d, 
4JF,C= 3.49 Hz), 116.4 
(d, 3JF,C= 6.87 Hz), 116.3 (d, 
3JF,C= 7.03 Hz), 116.2 (d, 
3JF,C= 6.75 Hz), 116.1 (d, 
3JF,C= 
7.03 Hz),  113.4 (d, 2JF,C= 18.83 Hz), 113.2 (d, 





Hz),  112.2 (d, 4JF,C= 2.47 Hz), 64.6, 59.4. (Method C2A) conversion 91%, isolated yield  
267 mg, 89% (method C2B) conversion 94%; isolated yield = 276 mg, 92%. 
 
(1E,2Z,4E)-5-((2-(Trifluoromethyl)phenyl)amino)-1-((2- (trifluoromethyl) phenyl) 
iminio)penta-2,4-dien-2-olate (C2P3d) 73 
 
The product by each method was obtained as red oil, which solidified on standing. 
Method C2A provided the sample whose purity is documented by NMR.  1H NMR (500 
MHz, DMSO-d6) δ 8.19 (s, 1H), 8.01 – 7.95 (m, 1H), 7.75 – 7.44 (m, 17H), 7.36 – 7.29 
(m, 5H), 7.25 (d, J = 5.1 Hz, 1H), 7.12 (s, 1H), 7.06 (d, J = 7.5 Hz, 1H), 6.94 – 6.84 (m, 
8H), 6.73 (d, J = 8.7 Hz, 1H), 6.64 – 6.57 (m, 5H). 13C NMR (151 MHz, DMSO-d6) δ δ. 
151.9, 150.6, 150.5, 147.6, 146.6 (q, 4JF,C = 1.7 Hz), 134.2, 133.4, 126.4 (q, 
3JF,C= 5.3 
Hz),126.2 (q, 3JF,C= 5.3 Hz), 125.9, 126.2 (q, 
1JF,C= 273.2 Hz), 124.4 (q, 
1JF,C= 273.6 Hz), 
122.4 (q, 2JF,C= 29.2 Hz), 120.3, 119.1, 117.2, 115.6, 113.1, 111.1 (q, 
2JF,C= 29.2 Hz). 
(method C2A) conversion 69%, isolated yield 174 mg, 66%; (method C2B) conversion 




The product was obtained as yellow oil. Method C2B provides the sample whose purity is 
documented. 1H NMR (600 MHz, CDCl3) δ 7.71 (d, J = 2.4 Hz, 1H), 3.76 – 3.63 (m, 9H), 
3.38 (d, J = 2.9 Hz, 1H), 2.85 (dt, J = 10.2, 4.6 Hz, 2H), 2.62 (tdd, J = 17.0, 11.6, 4.5 Hz, 
6H). 13C NMR (151 MHz, CDCl3) δ 198.3, 158.4, 126.8, 111.5, 110.8, 110, 67.4, 67.2, 
67.0, 66.3, 60.35, 50.1, 49.8. HRMS (ESI-FTMS) m/z: ([M + H]+) calcd for 





 trans-4,5-2-Bromo-4,5-bis(diallylamino)cyclopent-2-enone (C2P4b) 
 
The product was obtained as yellow oil. Method C2B provides the sample whose purity is 
documented. 1H NMR (600 MHz, CDCl3) δ 7.58 (d, J = 2.3 Hz, 1H), 5.81 (dtdd, J = 15.8, 
10.5, 5.6, 2.9 Hz, 3H), 5.22 (dt, J = 17.2, 1.7 Hz, 3H), 5.17 – 5.10 (m, 3H), 4.04 (t, J = 
2.8 Hz, 1H), 3.68 (d, J = 3.1 Hz, 1H), 3.32 (dd, J = 14.0, 7.7 Hz, 2H), 3.23 – 3.18 (m, 
2H), 3.20 – 3.09 (m, 3H), 1.30 – 1.24 (m, 1H), 1.24 (s, 2H), 0.90 – 0.79 (m, 1H). 13C 
NMR (151 MHz, CDCl3) δ 200.0, 160.5, 136.1, 135.9, 125.8, 118.0, 117.7, 64.6, 63.4, 
54.5, 53.7. HRMS (ESI-FTMS) m/z: ([M + H]+) calcd for C17H24Br1N2O1 351.1071, 
found 351.1067. Conversion>99%; isolated yield 333 mg, 95%. 
 
 trans-4,5-2-Bromo-4,5-di(indolin-1-yl)cyclopent-2-enone (C2P4c) 
 
The product was obtained as yellow oil. Method C2B provides the sample whose purity is 
documented. 1H NMR (600 MHz, CDCl3) δ 7.79 (d, J = 2.3 Hz, 1H), 7.08 (ddd, J = 19.4, 
7.3, 1.3 Hz, 2H), 6.99 (td, J = 7.7, 1.2 Hz, 1H), 6.93 (td, J = 7.8, 1.3 Hz, 1H), 6.68 (dtd, 
J = 27.4, 7.5, 0.9 Hz, 2H), 6.37 (d, J = 7.8 Hz, 1H), 6.07 (d, J = 7.8 Hz, 1H), 4.95 (dd, J 
= 3.6, 2.4 Hz, 1H), 4.49 (d, J = 3.6 Hz, 1H), 3.58 – 3.47 (m, 2H), 3.39 (ddt, J = 33.6, 9.7, 
8.3 Hz, 2H), 3.03 – 2.98 (m, 4H). 13C NMR (151 MHz, DMSO-d6) δ 195.9, 161.4, 150.8, 
150.6, 129.4, 128.9, 127.4, 124.6, 124.4, 117.8, 117.3, 107.5, 106.7, 62.2, 58.2, 53.1, 
49.5, 48.4, 40.5, 27.8, 27.7. HRMS (ESI-FTMS) m/z: ([M + Na]+) calcd for 









The product was obtained as yellow oil. Method C2B provides the sample whose purity is 
documented.  1H NMR (600 MHz, CDCl3) δ 7.82 (s, 1H), 7.17 – 7.07 (m, 6H), 7.03 – 
6.97 (m, 2H), 4.21 (d, J = 14.6 Hz, 1H), 4.08 (s, 1H), 3.94 – 3.85 (m, 3H), 3.71 (d, J = 
2.9 Hz, 1H), 3.07 (dt, J = 12.1, 5.6 Hz, 1H), 2.90 (dq, J = 17.1, 6.6, 5.5 Hz, 7H). 13C NMR 
(151 MHz, CDCl3) δ 199.2, 159.3, 134.6, 134.2, 134.0, 133.9, 128.8, 126.7, 126.6, 126.4, 
126.4, 126.1, 125.8, 125.6, 67.1, 66.7, 60.4, 52.7, 52.1, 47.3, 47.2, 29.9, 29.4. The product 
was obtained as yellow oil. HRMS (ESI-FTMS) m/z: ([M + H]+) calcd for C23H24Br1N2O1 





The product was obtained as yellow oil. Method C2B provides the sample whose purity is 
documented. 1H NMR (600 MHz, DMSO-d6) δ 7.95 (d, J = 2.1 Hz, 1H), 7.08 – 7.05 (m, 
2H), 7.04 – 7.01 (m, 2H), 6.66 – 6.63 (m, 2H), 6.59 – 6.52 (m, 4H), 6.22 (s, 2H), 4.61 (s, 
1H), 4.19 (d, J = 3.2 Hz, 1H). 13C NMR (151 MHz, DMSO-d6) δ 198.5, 160.2, 147.8, 
147.4, 124.1, 117.40, 117.0, 113.2, 112.9, 63.4, 59.0, 39.9. HRMS (ESI-FTMS) m/z: ([M 
‒ H]˗) calcd for C17H14Br1N2O 341.0289, found 341.0292. Conversion 98%, isolated yield  






2,4-dien-2-olate (C2P5b)  
 
The product was obtained as yellow oil. Method C2B provides the sample whose purity is 
documented. 1H NMR (600 MHz, DMSO-d6) δ 7.96 (d, J = 2.1 Hz, 1H), 7.05 – 6.81 (m, 
5H), 6.77 – 6.67 (m, 1H), 6.56 (dtdd, J = 21.6, 7.8, 4.8, 1.6 Hz, 2H), 6.11 (dd, J = 9.5, 2.2 
Hz, 1H), 6.04 (dd, J = 9.3, 2.4 Hz, 1H), 4.83 – 4.77 (m, 1H), 4.54 (dd, J = 9.2, 3.5 Hz, 
1H). 13C NMR (151 MHz, DMSO-d6) δ 197.6, 159.5, 151.0 (d, 
1JF,C= 237.6 Hz), 150.7 
(d, 1JF,C= 237.4 Hz), 135.6 (d, 
2JF,C= 11.2 Hz), 135.1 (d, 
2JF,C= 11.5 Hz),124.9 (d, 
4JF,C= 
3.7 Hz), 124.6 (d, 4JF,C= 3.3 Hz), 123.9, 116.8 (d, 
3JF,C= 7.2 Hz), 116.5 (d, 
3JF,C= 7.4 Hz), 
114.7 (d, 2JF,C= 18.2 Hz), 114.6 (d, 
2JF,C= 18.2 Hz), 112.6 (d, 
3JF,C= 3.4 Hz), 112.5 (d, 
3JF,C= 3.6 Hz), 62.9, 58.8. HRMS (ESI-FTMS) m/z: ([M ‒ H]
+) calcd for C17H12Br1F2N2O 










General Catalytic Protocol for the Synthesis of C4Paaa-5C4Pfda products 
A mixture of aldehyde (1 mmol), amine (1.1 mmol), alkyne (1.2 mmol), Cu catalyst (4.1S, 
2 mol%, based on aldehyde), and CH2Cl2 (dry, 2 mL) was placed in a sealed tube 
equipped with 4 Å molecular sieves (50 mg) and magnetic stir bar and was (Method C4A) 
stirred at room temperature for 72 hours or (Method C4B) exposed to microwave 
irradiation at 80˚C for 30 min. The reaction was monitored by thin-layer chromatography 
(TLC). After completion, the (cooled to ambient temperature, in the case of method C4B) 
slurry is filtered through filter paper, the filtrate is evaporated under vacuum and iPrOH 
is added to it. The reaction mixture stands for one hour at 5˚C towards precipitation of 
the catalyst and subsequently is filtrated through filter paper (to withhold the recovered 
catalyst). The resultant solution is concentrated under reduced pressure, and the residue 
is then loaded into a flash chromatography column. The product is isolated using a diethyl 
ether/petroleum ether (fraction 40-60) mixture as the gradient eluent (01:99-30:70 v/v). 
Propargylamines were obtained as red or yellow oils, which solidified on standing. 
Supporting Figures and spectra may be found in the Appendix. 
 
Reactions with TEMPO 
A mixture of cyclohexanecarboxaldehyde (1 mmol), pyrrolidine (1.1 mmol), 
phenylacetylene (1.2 mmol), Cu catalyst (4.1S, 2 mol%, based on aldehyde), 2,2,6,6-
Tetramethyl-1-piperidinyloxy, free radical (TEMPO, 10mol% based on aldehyde) and 
CH2Cl2 (dry, 2 mL) was placed in a sealed tube equipped with 4 Å molecular sieves (50 
mg) and magnetic stir bar and was (Method C4A) stirred at room temperature for 72 hours. 
The reaction was monitored by thin-layer chromatography (TLC). After completion, the 
slurry is filtered through filter paper, the filtrate is evaporated under vacuum and iPrOH 
is added to the remaining mixture. The reaction mixture stands for one hour at 5˚C 
towards precipitation of the catalyst and is filtrated through filter paper (to withhold the 
recovered catalyst). Subsequently, the excess of TEMPO is removed from the reaction 









General Catalytic Protocol for the Synthesis of C5Paga – C4Pafa products. 
A mixture of aldehyde (1 mmol), amine (1.1 mmol), alkyne (1.2 mmol), 5.1 (1.5 mol%, 
based on aldehyde), and CH2Cl2 (dry, 2 mL) was placed in a sealed tube equipped with 4 
Å molecular sieves (50 mg) and magnetic stir bar and was stirred at 25˚C (method C5A) 
for 24 hours or (method C5C) for 2 hours under Ar atmosphere. In each case the reaction 
was monitored by thin-layer chromatography (TLC). After completion, the slurry was 
filtered through filter paper and subsequently upon a short pad of silica (to withhold the 
catalyst). The resultant solution is concentrated under reduced pressure, and the residue 
is then loaded into a flash chromatography column. The product is isolated through silica 
gel using a diethyl ether/petroleum ether (fraction 40-60) mixture as the gradient eluent 
(01:99-30:70 v/v). Propargylamines were obtained as red or yellow oils, which solidified 
on standing. Supporting Figures and spectra may be found in the Appendix. 1H NMR, 13C 
NMR, HRMS (ESI-FTMS) and LCMS spectra are reported for the propargylamines, 
synthesized for the first time. Method C5A provided the samples whose purity is 
documented. 
 
Reaction with TEMPO 
A mixture of benzaldehyde (1 mmol), pyrrolidine (1.1 mmol), phenylacetylene (1.2 
mmol), 5.1 (1.5 mol%, based on aldehyde), 2,2,6,6-Tetramethyl-1-piperidinyloxy, free 
radical (TEMPO, 10mol% based on aldehyde) and CH2Cl2 (dry, 2 mL) was placed in a 
sealed tube equipped with 4Å molecular sieves (50 mg) and magnetic stirbar and was 
heated at 80˚C for one hour. The reaction was monitored by thin-layer chromatography 
(TLC). After completion, the slurry was filtered through filter paper and subsequently 
upon a short pad of silica (to withhold the TEMPO and the catalyst). The resultant 
solution is concentrated under reduced pressure. The 1H NMR of the crude reaction 
mixture in CDCl3 shows product formation by full conversion of the starting materials 





7.4.4 Chapters 4 and 5: Characterisation of propargylamines 
 
1-(1-Cyclohexyl-3-phenylprop-2-yn-1-yl)pyrrolidine (C4Paaa)  
 
Propargylamine C4Paaa was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.45 – 
7.41 (m, 2H), 7.29 (dd, J = 5.3, 2.0 Hz, 2H), 3.36 (d, J = 8.4 Hz, 1H), 2.79 – 2.62 (m, 
4H), 2.12 – 2.06 (m, 0H), 1.95 (d, J = 13.0 Hz, 0H), 1.78 (pd, J = 5.8 Hz, 5H), 1.68 (d, J 
= 12.1 Hz, 0H), 1.63 – 1.54 (m, 1H), 1.32 – 1.04 (m, 3H). 13C NMR (151 MHz, CDCl3) 
δ 131.9, 128.3, 127.9, 123.8, 61.4, 50.2, 41.5, 30.9, 30.4, 26.8, 26.4, 26.4, 23.7. MS 
(LCMS) m/z: ([M + H]+) calcd for C19H26N, 268.2; found, 268.2, Rt = 2.37 min.  





Propargylamine C4Paba was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.46 – 
7.39 (m, 2H), 7.33 – 7.22 (m, 3H), 3.11 (d, J = 9.8 Hz, 1H), 2.63 (s, 2H), 2.41 (s, 2H), 
2.13 – 2.06 (m, 1H), 2.03 (ddt, J = 13.6, 4.0, 2.0 Hz, 1H), 1.80 – 1.72 (m, 2H), 1.67 – 
1.52 (m, 6H), 1.43 (dd, J = 15.0, 8.9 Hz, 2H), 1.36 – 1.11 (m, 3H), 1.09 – 0.88 (m, 2H). 




31.5, 30.6, 26.9, 26.4, 26.3, 24.8, 22.7. MS (LCMS) m/z: ([M + H]+) calcd for C20H28N, 
282.1; found, 282.1, Rt = 2.50 min. (Method C4A) isolated yield = 275 mg, 97%, (method 
C4B) isolated yield = 280 mg, >99%. (Method C5A) isolated yield = 275 mg, 98%. 
 
1-(1-Cyclohexyl-3-phenylprop-2-yn-1-yl)azepane (C4Paca)  
 
Propargylamine C4Paca was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 
1H NMR (600 MHz, CDCl3) δ 7.45 – 7.39 (m, 2H), 7.33 – 7.23 (m, 3H), 3.16 (d, J = 10.1 
Hz, 1H), 2.80 (ddd, J = 12.9, 6.9, 3.6 Hz, 2H), 2.57 (ddd, J = 12.6, 7.5, 4.3 Hz, 2H), 2.20 
– 2.06 (m, 2H), 1.80 – 1.70 (m, 3H), 1.70 – 1.51 (m, 9H), 1.33 – 1.13 (m, 3H), 1.05 – 
0.86 (m, 2H). 13C NMR (151 MHz, CDCl3) δ 131.8, 128.3, 127.6, 124.1, 89.1, 85.0, 77.4, 
76.9, 65.4, 52.8, 41.0, 31.3, 30.8, 29.4, 27.3, 27.0, 26.4, 26.2. MS (LCMS) m/z: ([M + 
H]+) calcd for C21H30N, 296.2; found, 296.2, Rt = 2.47 min.  




Propargylamine C4Pada was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.47 – 
7.41 (m, 2H), 7.33 – 7.27 (m, 3H), 3.79 – 3.69 (m, 4H), 3.13 (d, J = 9.8 Hz, 1H), 2.75 – 
2.67 (m, 2H), 2.52 (ddd, J = 11.2, 6.3, 2.9 Hz, 2H), 2.14 – 2.01 (m, 2H), 1.81 – 1.56 (m, 




CDCl3) δ 131.8, 128.4, 128.0, 123.6, 86.9, 86.8, 67.4, 64.1, 50.1, 39.3, 31.5, 31.1, 30.5, 
29.6, 26.9, 26.3, 26.2. MS (LCMS) m/z: ([M + H]+) calcd for C19H26NO, 284.1; found, 
284.1, Rt = 2.60 min.  (Method C4A) isolated yield = 272 mg, 96%, (methods C4B and 




Propargylamine C4Pafa was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 
1H NMR (600 MHz, CDCl3) δ 7.34 (dd, J = 6.8, 2.9 Hz, 2H), 7.25 (dd, J = 5.2, 1.9 Hz, 
3H), 7.09 (t, J = 7.2 Hz, 2H), 6.68 (t, J = 7.3 Hz, 1H), 6.58 (d, J = 8.0 Hz, 1H), 4.15 (d, J 
= 10.0 Hz, 1H), 3.55 – 3.43 (m, 2H), 3.00 (tt, J = 15.2, 10.8 Hz, 2H), 2.22 (dtd, J = 12.4, 
4.0, 2.2 Hz, 1H), 2.11 (dtd, J = 13.6, 4.6, 4.1, 2.3 Hz, 1H), 1.88 – 1.69 (m, 4H), 1.40 – 
1.13 (m, 5H). 13C NMR (151 MHz, CDCl3) δ 151.8, 131.9, 130.2, 128.2, 128.0, 127.3, 
124.5, 123.4, 118.0, 107.8, 87.1, 85.3, 55.4, 48.4, 41.2, 31.6, 31.1, 30.3, 29.6, 28.5, 26.7, 
26.2, 26.1. MS (LCMS) m/z: ([M + H]+) calcd for C23H26N, 316.2; found, 316.0, Rt = 
3.64 min.  (Method C4A) isolated yield = 230 mg, 73%, (method C4B) isolated yield = 277 




Propargylamine C4Pbaa was obtained by each method as a yellow oil. Method C4B 




7.38 (m, 2H), 7.27 (dd, J = 5.1, 2.0 Hz, 3H), 3.65 (dd, J = 8.8, 6.0 Hz, 1H), 2.75 (qd, J = 
6.7, 3.2 Hz, 2H), 2.67 (qd, J = 7.0, 6.5, 2.9 Hz, 2H), 1.81 – 1.77 (m, 4H), 1.75 – 1.65 (m, 
3H), 1.57 (dddd, J = 12.0, 8.4, 6.5, 3.5 Hz, 1H), 1.50 – 1.45 (m, 1H), 1.32 (ddd, J = 7.6, 
5.7, 3.5 Hz, 3H), 0.90 – 0.89 (m, 3H).  13C NMR (151 MHz, CDCl3) δ 131.9, 128.3, 127.9, 
123.7, 88.5, 85.4, 55.3, 54.7, 49.9, 46.7, 45.7, 35.2, 31.8, 26.6, 23.7, 22.7, 14.2. MS 
(LCMS) m/z: ([M + H]+) calcd for C18H26N, 256.2; found, 256.2, Rt = 2.41 min.  (Method 
C4A) isolated yield = 202 mg, 79%, (method C4B) isolated yield = 202 mg, 79%.  
 
1-(1-Phenyloct-1-yn-3-yl)azepane (C4Pbca)  
 
Propargylamine C4Pbca was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.44 – 
7.39 (m, 2H), 7.32 – 7.23 (m, 3H), 3.52 (dd, J = 8.5, 6.5 Hz, 1H), 2.82 (ddd, J = 12.7, 7.1, 
3.6 Hz, 2H), 2.63 (ddd, J = 12.5, 7.8, 3.9 Hz, 2H), 1.75 – 1.57 (m, 9H), 1.56 – 1.40 (m, 
2H), 1.33 (tt, J = 6.0, 2.7 Hz, 4H), 0.90 (t, J = 6.9 Hz, 3H). 13C NMR (151 MHz, CDCl3) 
δ 131.7, 128.1, 127.6, 123.7, 89.5, 84.2, 59.0, 52.5, 50.8, 34.3, 31.6, 29.0, 27.0, 26.4, 
25.3, 25.1, 22.6, 14.0. MS (LCMS) m/z: ([M + H]+) calcd for C20H30N, 284.1; found, 
284.1, Rt = 2.55 min. HRMS (ESI-FTMS) m/z: ([M + H]
+) calcd for C20H30N, 284.2378; 
found, 284.2378. (Method C4A) isolated yield = 224 mg, 79%, (method C4B and C5A) 
isolated yield = 255 mg, 90%.  
 





Propargylamine C4Pbda was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.46 – 
7.39 (m, 2H), 7.29 (q, J = 2.8 Hz, 3H), 3.76 (s, 4H), 3.50 (s, 1H), 2.76 (s, 2H), 2.58 (s, 
2H), 1.60 – 1.50 (m, 2H), 1.46 (tt, J = 16.6, 8.8 Hz, 2H), 1.36 – 1.30 (m, 4H), 0.93 – 0.86 
(m, 3H).  13C NMR (151 MHz, CDCl3) δ 131.9, 130.1, 128.4, 85.6, 85.2, 83.0, 41.0, 34.0, 
31.6, 28.6, 26.4, 24.0, 22.7, 20.9, 17.6, 17.4, 14.8, 14.2, 8.1. MS (LCMS) m/z: ([M + H]+) 
calcd for C18H26NO, 272.2; found, 272.0, Rt = 2.40 min. HRMS (ESI-FTMS) m/z: ([M + 
H]+) calcd for C18H26NO, 272.2014; found, 272.2016. (Methosd C4A and C5A) isolated 
yield = 255 mg, 94%, (method C4B) isolated yield = 269 mg, 99%.  
 
N,N-Diallyl-1-phenyloct-1-yn-3-amine (C4Pbea)  
 
Propargylamine C4Pbea was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.49 – 
7.44 (m, 2H), 7.36 – 7.28 (m, 2H), 5.90 (dddd, J = 17.6, 10.1, 7.9, 4.7 Hz, 2H), 5.28 (dq, 
J = 17.1, 1.7 Hz, 2H), 5.16 (dd, J = 10.1, 1.9 Hz, 2H), 3.76 (t, J = 7.6 Hz, 1H), 3.38 (ddd, 
J = 14.2, 4.5, 2.1 Hz, 2H), 3.04 (dd, J = 14.2, 7.9 Hz, 2H), 1.79 – 1.68 (m, 2H), 1.58 – 
1.46 (m, 2H), 1.36 (dddd, J = 12.6, 9.2, 6.7, 3.7 Hz, 4H), 0.94 (t, J = 7.0 Hz, 2H). 13C 
NMR (151 MHz, CDCl3) δ 136.8, 131.8, 128.3, 127.9, 123.7, 117.1, 88.5, 85.1, 76.9, 
54.1, 53.2, 34.0, 31.7, 26.4, 22.7, 14.2. MS (LCMS) m/z: ([M + H]+) calcd for C20H28N, 
272.2; found, 282.1, Rt = 2.56 min. HRMS (ESI-FTMS) m/z: ([M + H]
+) calcd for 
C20H28N, 282.2014; found, 282.2223. (Method C4A) isolated yield = 247 mg, 91%, 







Propargylamine C4Pcaa was obtained by each method as a yellow oil. Method B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.64 – 
7.60 (m, 2H), 7.51 – 7.47 (m, 2H), 7.36 (dd, J = 8.3, 6.8 Hz, 2H), 7.33 – 7.28 (m, 4H), 
4.94 (s, 1H), 2.73 (tq, J = 7.0, 3.0 Hz, 4H), 1.82 (pd, J = 5.2, 4.2, 3.1 Hz, 4H).  13C NMR 
(151 MHz, CDCl3) δ 139.3, 131.9, 131.6, 129.8, 128.5, 128.4, 128.3, 128.1, 127.8, 123.3, 
87.2, 86.6, 59.2, 50.3, 23.6. MS (LCMS) m/z: ([M + H]+) calcd for C19H20N, 262.2; found, 
261.9, Rt = 2.23 min.  (Method C4A) isolated yield = 165 mg, 63%, (method C4B) isolated 




Propargylamine C4Pdaa was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.50 
(dd, J = 6.7, 3.0 Hz, 2H), 7.42 (d, J = 7.7 Hz, 1H), 7.38 (dd, J = 9.9, 2.1 Hz, 1H), 7.38 – 
7.30 (m, 4H), 7.00 (td, J = 8.4, 2.6 Hz, 1H), 5.01 (s, 1H), 2.82 – 2.72 (m, 4H), 1.87 – 1.79 
(m, 4H). 13C NMR (151 MHz, CDCl3) δ 162.8 (d, 
1JF,C= 245.5 Hz), 141.2, 131.8, 129.8 
(d, 3JF,C= 8.0 Hz), 128.4, 128.3, 123.9 (d, 
4JF,C= 3.1 Hz),  122.7, 115.3, (d, 
2JF,C= 22.4 
Hz),  114.8 (d, 2JF,C= 20.8 Hz), 87.8, 85.0, 58.5 (d, 
4JF,C= 2.2 Hz), 55.8, 50.1, 24.0. MS 
(LCMS) m/z: ([M + H]+) calcd for C19H19NF, 280.2; found, 280.0, Rt = 2.26 min. (Method 
C4A) isolated yield = 170 mg, 61%, (method C4B) isolated yield = 237 mg, 85%. (Method 







Propargylamine C4Pdba was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.55 – 
7.49 (m, 2H), 7.44 (d, J = 7.7 Hz, 1H), 7.39 (dt, J = 10.2, 2.0 Hz, 1H), 7.35 – 7.32 (m, 
4H), 6.98 (td, J = 8.4, 2.5 Hz, 1H), 4.80 (s, 1H), 2.56 (s, 4H), 1.69 – 1.41 (m, 6H). 13C 
NMR (151 MHz, CDCl3) δ 162.8 (d, 
1JF,C= 244.4 Hz), 141.5, 131.8, 129.4 (d, 
3JF,C= 8.0 
Hz), 128.3, 128.2, 124.0, 123.0, 115.3 (d, 2JF,C= 23.1 Hz), 114.3 (d, 
2JF,C= 19.9 Hz), 88.2, 
85.2, 61.9 (d, 4JF,C= 1.8 Hz), 50.6, 26.1, 24.3.  MS (LCMS) m/z: ([M + H]
+) calcd for 
C20H21NF, 294.2; found, 294.0, Rt = 2.43 min. (Method C4A) isolated yield = 173 mg, 





Propargylamine C4Pdca was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.51 
(dd, J = 6.6, 3.1 Hz, 2H), 7.49 (d, J = 6.7 Hz, 1H), 7.44 (d, J = 10.0 Hz, 1H), 7.36 – 7.27 
(m, 4H), 6.97 (s, 1H), 4.88 (s, 1H), 2.72 (s, 4H), 1.68 (d, J = 12.5 Hz, 2H), 1.61 (s, 6H).  
13C NMR (151 MHz, CDCl3) δ 162.8 (d, 
1JF,C= 245.5 Hz), 131.8, 129.4 (d, 
3JF,C= 9.1 Hz), 
128.3, 128.2, 123.8 (d, 4JF,C= 2.6 Hz), 123.1, 115.2 (d, 
2JF,C= 22.1 Hz), 114.3 (d, 
2JF,C= 
20.5 Hz), 87.6, 86.1, 62.3, 62.3 (d, 4JF,C= 1.8 Hz), 52.7, 28.8, 26.9. MS (LCMS) m/z: ([M 




([M + H]+) calcd for C21H23NF, 308.1814; found, 308.1817. (Method C4A) isolated yield 
= 190 mg, 62%, (method C4B) isolated yield = 215 mg, 70%. 
 
 1-(1-(3-Fluorophenyl)-3-phenylprop-2-yn-1-yl)pyrrolidine (C4Peaa)  
 
Propargylamine C4Peaa was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.64 – 
7.58 (m, 2H), 7.51 (dd, J = 6.6, 3.0 Hz, 2H), 7.34 (p, J = 3.7 Hz, 3H), 7.10 – 7.03 (m, 
2H), 4.89 (s, 1H), 2.70 (ddt, J = 9.4, 6.2, 3.3 Hz, 4H), 1.86 – 1.77 (m, 4H). 13C NMR (151 
MHz, CDCl3) δ 162.3 (d, 
1JF,C= 246.0 Hz), 136.9, 135.5 (d, 
4JF,C= 3.2 Hz), 131.9, 129.9 
(d, 3JF,C= 7.9 Hz), 128.4, 128.3, 123.2, 117.2, 15.1 (d, 
2JF,C= 21.5 Hz), 87.3, 86.5, 58.4, 
54.1, 50.3, 23.6. MS (LCMS) m/z: ([M + H]+) calcd for C19H19FN, 280.1; found, 280.0, 
Rt = 2.26 min.  (Method C4A) isolated yield = 53 mg, 19%, (method C4B) isolated yield = 




Propargylamine C4Peca was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.74 – 
7.68 (m, 2H), 7.58 – 7.53 (m, 2H), 7.40 – 7.34 (m, 3H), 7.11 – 7.04 (m, 2H), 4.91 (s, 1H), 
2.76 (ddd, J = 7.1, 4.6, 2.3 Hz, 6H), 1.76 – 1.70 (m, 1H), 1.71 – 1.58 (m, 5H). 13C NMR 
(151 MHz, CDCl3) δ 162.2 (d, 
1JF,C= 245.5 Hz), 135.7 (d, 
4JF,C= 3.1 Hz), 131.9, 129.9 (d, 
3JF,C= 7.8 Hz), 128.4, 128.2, 123.4, 114.8, 114.8 (d, 
4JF,C= 21.3 Hz), 87.4, 86.6, 62.2, 




Rt = 2.39 min. HRMS (ESI-FTMS) m/z: ([M + H]
+) calcd for C21H23NF, 308.1814; found, 
308.1820. (Method C4A) isolated yield = 49 mg, 16%, (method C4B) isolated yield = 92 




Propargylamine C4Paab was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.40 – 
7.33 (m, 2H), 6.86 – 6.79 (m, 2H), 3.80 (s, 2H), 3.33 (d, J = 8.3 Hz, 1H), 2.72 (t, J = 7.0 
Hz, 2H), 2.64 (p, J = 5.8 Hz, 2H), 2.11 – 2.04 (m, 1H), 1.98 – 1.91 (m, 1H), 1.78 (q, J = 
4.1, 2.6 Hz, 4H), 1.71 – 1.64 (m, 1H), 1.57 (tdt, J = 11.6, 8.2, 3.4 Hz, 1H), 1.32 – 1.04 
(m, 4H). 13C NMR (151 MHz, CDCl3) δ 159.3, 133.2, 116.0, 114.0, 86.4, 85.7, 61.5, 55.4, 
50.2, 41.5, 30.9, 30.4, 26.9, 26.4, 26.4, 23.7. MS (LCMS) m/z: ([M + H]+) calcd for 
C20H28NO, 298.2; found, 298.1, Rt = 2.42 min.  (Method C4A) isolated yield = 288 mg, 
97%, (method C4B) isolated yield = 288 mg, 97%. (Method C5A) isolated yield = 282 mg, 




Propargylamine C4Padb was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.38 – 
7.34 (m,2H), 6.84 – 6.79 (m, 2H), 3.80 (s, 3H), 3.78 – 3.68 (m, 4H), 3.10 (d, J = 9.7 Hz, 




– 1.99 (m, 2H), 1.76 (td, J = 12.1, 11.4, 5.6 Hz, 2H), 1.58 (d, J = 14.3 Hz, 2H), 1.32 – 
1.14 (m, 3H), 1.08 – 1.00 (m, 1H), 0.95 (d, J = 12.1 Hz, 1H). 13C NMR (151 MHz, CDCl3) 
δ 159.4, 133.2, 115.7, 114.0, 110.2, 86.7, 85.1, 67.4, 64.2, 55.4, 50.1, 39.3, 31.1, 30.6, 
26.9, 26.3, 26.2. MS (LCMS) m/z: ([M + H]+) calcd for C20H28NO2, 314.2; found, 314.0, 
Rt = 2.33 min. HRMS (ESI-FTMS) m/z: ([M + H]
+) calcd for C20H28NO2, 314.2119; 
found, 314.2119. (Method C4A) isolated yield = 298 mg, 95%, (methods C4B and C5A) 




Propargylamine C4Pbab was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.37 – 
7.34 (m, 2H), 6.85 – 6.81 (m, 2H), 3.81 – 3.79 (m, 3H), 2.97 (s, 1H), 1.95 – 1.84 (m, 4H), 
1.75 – 1.66 (m, 2H), 1.46 (s, 2H), 1.36 – 1.25 (m, 6H), 0.93 – 0.81 (m, 5H).  13C NMR 
(151 MHz, CDCl3) δ 159.9, 133.4, 114.1, 56.0, 55.5, 50.3, 49.9, 39.6, 34.2, 31.5, 26.4, 
23.9, 22.6, 14.1. MS (LCMS) m/z: ([M + H]+) calcd for C19H28NO, 286.2; found, 286.0, 
Rt = 2.43 min. HRMS (ESI-FTMS) m/z: ([M + H]
+) calcd for C19H28NO, 286.2170; 
found, 286.2171. (Method C4A) isolated yield = 225 mg, 79%, (method C4B) isolated yield 







Propargylamine C4Pbdb was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.38 – 
7.33 (m, 2H), 6.85 – 6.79 (m, 2H), 3.80 (s, 3H), 3.68 (s, 4H), 3.48 (s, 1H), 2.74 (s, 2H), 
2.57 (s, 2H), 1.62 – 1.50 (m, 3H), 1.45 (dp, J = 14.4, 7.6 Hz, 1H), 1.33 (dt, J = 8.5, 4.0 
Hz, 4H), 0.93 – 0.84 (m, 3H). 13C NMR (151 MHz, CDCl3) δ 133.3, 114.0, 67.2, 58.5, 
55.5, 49.9, 33.0, 31.7, 26.4, 22.7, 14.2. MS (LCMS) m/z: ([M + H]+) calcd for C19H28NO2, 
302.2; found, 301.9, Rt = 2.40 min. HRMS (ESI-FTMS) m/z: ([M + H]
+) calcd for 
C19H28NO2, 302.2119; found, 302.2119. (Method C4A) isolated yield = 271 mg, 90%, 




Propargylamine C4Pfda was obtained by each method as a yellow oil. Method C4B 
provided the sample whose purity is documented. 1H NMR (600 MHz, CDCl3) δ 7.54 – 
7.52 (m, 2H), 7.50 – 7.47 (m, 2H), 7.45 – 7.27 (m, 16H), 4.64 (d, J = 5.9 Hz, 1H), 4.58 
(d, J = 5.3 Hz, 1H), 4.02 – 3.92 (m, 6H), 3.60 (p, J = 6.9 Hz, 1H), 3.53 (td, J = 7.0, 5.3 
Hz, 1H), 1.60 (d, J = 6.9 Hz, 3H), 1.52 (d, J = 7.1 Hz, 3H). 13C NMR (151 MHz, CDCl3) 
δ 141.2, 140.6, 132.1, 131.9, 130.1, 130.0, 129.2, 129.0, 128.8, 128.8, 128.6, 128.2, 128.2, 
127.3, 120.6, 120.6, 93.5, 93.4, 78.3, 78.0, 66.0, 65.4, 63.9, 54.4, 42.4, 41.4, 40.2, 20.3, 
19.5. MS (LCMS) m/z: ([M + H]+) calcd for C21H24NO, 306.2; found, 306.1, Rt = 2.32 
min. HRMS (ESI-FTMS) m/z: ([M + H]+) calcd for C21H24NO, 306.1857; found, 
306.1855. (Method C4A) isolated yield = 217 mg, 71%, (method C4B) isolated yield = 262 
mg, 62%.  
 





Propargylamine C5Paga was obtained as yellow oil. 1H NMR (600 MHz, CDCl3) δ 7.38 
– 7.34 (m, 2H), 7.27 – 7.23 (m, 4H), 7.23 – 7.19 (m, 2H), 6.83 (dd, J = 24.1, 13.6 Hz, 
3H), 4.16 (d, J = 5.6 Hz, 1H), 2.00 (d, J = 12.4 Hz, 1H), 1.92 (d, J = 9.5 Hz, 1H), 1.84 – 
1.76 (m, 3H), 1.69 (d, J = 12.5 Hz, 1H), 1.35 – 1.21 (m, 5H). (LCMS) m/z: ([M + H]+) 
calcd for C21H24N, 290.2; found, 290.0, Rt = 3.32 min. (Method C5A) isolated yield = 269 
mg, 93%. 
 
N-(1-Cyclohexyl-3-phenylprop-2-ynyl)-4-fluorobenzenamine (C5Paha)  
 
Propargylamine C5Paha was obtained as yellow oil. 1H NMR (600 MHz, CDCl3) δ 7.35 
(dd, J = 6.7, 3.0 Hz, 2H), 7.29 – 7.23 (m, 3H), 6.91 (t, J = 8.7 Hz, 2H), 6.70 (dd, J = 8.9, 
4.5 Hz, 2H), 4.07 (d, J = 5.8 Hz, 1H), 2.04 – 1.88 (m, 2H), 1.81 (ddd, J = 10.2, 6.5, 2.9 
Hz, 2H), 1.72 (t, J = 10.9 Hz, 2H), 1.42 – 1.19 (m, 5H). 13C NMR (151 MHz, CDCl3) δ 
156.5 (d, 1JF,C = 235.7 Hz), 143.4, 131.8, 128.3, 128.2, 123.2, 115.7 (d, 
2JF,C = 22.2 Hz), 
115.5, 89.0, 84.3, 53.1, 42.6, 30.2, 28.9, 26.5, 26.3, 26.1. HRMS (ESI-FTMS) m/z: ([M 
+ H]+) calcd for C21H23NF, 308.1814; found, 308.1809. MS (LCMS) m/z: ([M + H]
+) 
calcd for C21H23FN, 308.2; found, 308.1, Rt = 3.30 min. (Method C5A) isolated yield = 
288 mg, 94%.   
 





Propargylamine C5Pcga was obtained as yellow oil. 1H NMR (600 MHz, CDCl3) δ 7.66 
(dd, J = 7.2, 1.8 Hz, 2H), 7.59 (s, 1H), 7.41 (ddd, J = 7.6, 4.9, 2.0 Hz, 4H), 7.37 – 7.32 
(m, 1H), 7.31 – 7.26 (m, 2H), 7.25 – 7.19 (m, 2H), 6.82 – 6.76 (m, 3H), 5.50 (s, 1H). 




Propargylamine C5Pcia was obtained as yellow oil. 1H NMR (600 MHz, CDCl3) δ 7.65 
– 7.61 (m, 2H), 7.50 – 7.44 (m, 2H), 7.44 – 7.38 (m, 4H), 7.37 – 7.27 (m, 4H), 6.60 (d, J 
= 8.2 Hz, 2H), 5.46 (s, 1H). 13C NMR (151 MHz, CDCl3) δ 137.9, 131.9, 129.0, 128.7, 
128.5, 128.4, 127.6, 122.6, 51.1. HRMS (ESI-FTMS) m/z: ([M ‒ H]+) calcd for C21H15NI, 
408.0249; found, 408.0244. MS (LCMS) m/z: ([M + H]+) calcd for C21H17NI, 410.0; 




Propargylamine C5Pcja was obtained as yellow oil. 1H NMR (600 MHz, CDCl3) δ 7.66 




6.47 (d, J = 13.6 Hz, 3H), 5.49 (s, 1H), 2.26 (s, 6H). 13C NMR (151 MHz, CDCl3) δ 139.0, 
131.9, 128.9, 128.4, 128.4, 128.2, 127.6, 123.0, 121.1, 112.5, 88.6, 85.3, 51.0, 21.7. 
HRMS (ESI-FTMS) m/z: ([M + Na]+) calcd for C23H20NNa, 334.1572; found, 334.1576. 
MS (LCMS) m/z: ([M + H]+) calcd for C23H22N, 312.0; found, 311.9, Rt = 3.26 min. 











8 Chapter 8: Crystallographic Data  
Chapters 2-5 
Table 8-1. Crystal data and structure refinement for 2.1. 
Identification code 1891851  
Empirical formula C82H100Dy2F6N12Ni2O26S2 
Formula weight 2290.27 
Temperature/K 173 
Crystal system monoclinic 













Crystal size/mm3 0.15 × 0.1 × 0.03 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 9.38 to 143.714 
Index ranges -16 ≤ h ≤ 20, -17 ≤ k ≤ 22, -19 ≤ l ≤ 16 
Reflections collected 14643 
Independent reflections 8755 [Rint = 0.0473, Rsigma = 0.0708] 
Data/restraints/parameters 8755/0/595 
Goodness-of-fit on F2 1.063 
Final R indexes [I>=2σ (I)] R1 = 0.0563, wR2 = 0.1529 
Final R indexes [all data] R1 = 0.0645, wR2 = 0.1655 






Table 8-2. Crystal data and structure refinement for C2P3a HCl 
Identification code 1891852  
Empirical formula C17H17ClN2O 
Formula weight 300.77 
Temperature/K 100.01(10) 
Crystal system orthorhombic 













Crystal size/mm3 0.07 × 0.03 × 0.03 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 7.17 to 140.126 
Index ranges -20 ≤ h ≤ 25, -11 ≤ k ≤ 11, -35 ≤ l ≤ 36 
Reflections collected 31394 
Independent reflections 5857 [Rint = 0.0438, Rsigma = 0.0378] 
Data/restraints/parameters 5857/12/422 
Goodness-of-fit on F2 1.239 
Final R indexes [I>=2σ (I)] R1 = 0.0754, wR2 = 0.1657 
Final R indexes [all data] R1 = 0.0851, wR2 = 0.1694 





Table 8-3. Crystal data and structure refinement for 4.1S 
Identification code 1954036  
Empirical formula C36H52CuN2O2 
Formula weight 608.33 
Temperature/K 100(2) 
Crystal system triclinic 













Crystal size/mm3 0.15 × 0.02 × 0.02 
Radiation MoKα (λ = 0.71075) 
2Θ range for data collection/° 5.9 to 54.97 
Index ranges -12 ≤ h ≤ 12, -17 ≤ k ≤ 17, -18 ≤ l ≤ 19 
Reflections collected 31262 
Independent reflections 14276 [Rint = 0.0751, Rsigma = 0.1274] 
Data/restraints/parameters 14276/747/763 
Goodness-of-fit on F2 1.014 
Final R indexes [I>=2σ (I)] R1 = 0.0655, wR2 = 0.1097 
Final R indexes [all data] R1 = 0.1108, wR2 = 0.1276 
Largest diff. peak/hole / e Å-3 0.55/-0.80 





Table 8-4. Crystal data and structure refinement for 4.1RS 
Identification code 1954037  
Empirical formula C36H52CuN2O2 
Formula weight 608.33 
Temperature/K 100(2) 
Crystal system triclinic 













Crystal size/mm3 0.24 × 0.03 × 0.03 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 6.854 to 136.502 
Index ranges -11 ≤ h ≤ 11, -16 ≤ k ≤ 16, -17 ≤ l ≤ 17 
Reflections collected 19916 
Independent reflections 19916 [Rint = ?, Rsigma = 0.0240] 
Data/restraints/parameters 19916/3/764 
Goodness-of-fit on F2 1.008 
Final R indexes [I>=2σ (I)] R1 = 0.0645, wR2 = 0.1669 
Final R indexes [all data] R1 = 0.0687, wR2 = 0.1711 
Largest diff. peak/hole / e Å-3 0.60/-0.79 





Table 8-5. Crystal data and structure refinement for 5.1. 
Identification code 1891851  
Empirical formula C28H22CuF6N10O6S2 
Formula weight 836.21 
Temperature/K 173 
Crystal system triclinic 













Crystal size/mm3 0.2 × 0.1 × 0.03 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 7.566 to 143.358 
Index ranges -9 ≤ h ≤ 7, -10 ≤ k ≤ 11, -14 ≤ l ≤ 12 
Reflections collected 4355 
Independent reflections 3025 [Rint = 0.0292, Rsigma = 0.0380] 
Data/restraints/parameters 3025/0/242 
Goodness-of-fit on F2 1.044 
Final R indexes [I>=2σ (I)] R1 = 0.0391, wR2 = 0.1046 
Final R indexes [all data] R1 = 0.0429, wR2 = 0.1098 
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1 Chapter 1 
2 Chapter 2 
2.1 Characterization spectra for compound 2.1  
 
 
Figure S 2-1. FT-IR of the coordination compound 2.1.  
 
 
Figure S 2-2. UV-Vis of 2.1 (green) and the corresponding H2L20 (yellow) in concentration10‒
3 M, in MeOH. 
3 
 




Figure S 2-3. TGA of the coordination compound 2.1. 
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+ (lower) fragments.  
 
SXRD 
Structures 2.1 and C2P3aHCl have been given CCDC deposition numbers 1891851-1891852, 
respectively. 
 
Crystal Data for C82H100Dy2F6N12Ni2O26S2 (M =2290.27 g/mol): monoclinic, space group 
P21/c (no. 14), a = 16.7112(6) Å, b = 18.8566(7) Å, c = 15.7900(6) Å, β = 110.115(4)°, V = 
4672.2(3) Å3, Z = 2, T = 173 K, μ(CuKα) = 10.071 mm-1, Dcalc = 1.628 g/cm3, 14643 
reflections measured (9.38° ≤ 2Θ ≤ 143.714°), 8755 unique (Rint = 0.0473, Rsigma = 0.0708) 
which were used in all calculations. The final R1 was 0.0563 (I > 2σ(I)) and wR2 was 0.1655 
(all data).  
5 
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Figure S 2-6. Crystal structure for 2.1 with 40% thermal ellipsoids. The crystal structure is 
obtained from vapour diffusion of Et2O into DMF solution.  
 
Crystal Data for C17H17ClN2O (M =300.77 g/mol): orthorhombic, space group Pbca (no. 61), 
a = 21.6654(4) Å, b = 9.6032(2) Å, c = 29.9888(7) Å, V = 6239.4(2) Å3, Z = 16, T = 
100.01(10) K, μ(CuKα) = 2.162 mm-1, Dcalc = 1.281 g/cm3, 31394 reflections measured 
(7.17° ≤ 2Θ ≤ 140.126°), 5857 unique (Rint = 0.0438, Rsigma = 0.0378) which were used in all 
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Figure S 2-7.  Crystal structure for C2P3aHCl with 40% thermal ellipsoids. Short-living light 
red needle-shaped crystals are formed when dilute HCl is added directly to the NMR tube 
(CDCl3) of the crude product. 
 
2.2 Theoretical Calculations  
 
Computational details and results 
Geometry optimizations and EDA analysis were carried out using and as implemented in the 
Amsterdam Density Functional (ADF)1–3 program at the OLYP/TZ2P4–8 level of theory. To 
obtain the singlet state, spin-restricted calculations were performed constraining the projection 
of the total electronic spin along a reference axis to 0. Frequency calculations were conducted 
to determine if each stationary point corresponds to a minimum.9–11 Reported bond orders are 
of the Mayer bond order type12,13 and atomic charges were determined according to the 
Hirshfeld charge analysis.14,15 The Graphical User Interface (ADF-GUI) – a part of the ADF 
package – was used for visualisation purposes. 
 
 
Table S 2-1. Selected calculated bond lengths and Mayer bond orders (MBO). 
 
Entries  3aCl 3a+ 3a 3aTS 
7 
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1 N1-C1 1.401 (1.01) 1.412 (1.14) 1.393 (1.03) 1.393 (1.04) 
2 N1-C7 1.358 (1.13) 1.338 (1.23) 1.365 (1.10) 1.368 (1.08) 
3 N2-C11 1.324 (1.31) 1.333 (1.24) 1.334 (1.22) 1.326 (1.27) 
4 N2-C12 1.406 (1.03) 1.410 (0.98) 1.391 (1.04) 1.422 (0.89) 
5 C7-C8 1.375 (1.44) 1.388 (1.35) 1.375 (1.44) 1.372 (1.46) 
6 C8-C9 1.408 (1.24) 1.399 (1.29) 1.403 (1.26) 1.407 (1.23) 
7 C9-C10 1.401 (1.34) 1.396 (1.37) 1.426 (1.22) 1.419 (1.25) 
8 C10-C11 1.421 (1.26) 1.400 (1.33) 1.447 (1.15) 1.450 (1.14) 
9 C10-O1 1.331 (1.04) 1.370 (0.87) 1.267 (1.50) 1.271 (1.48) 
 
 
Table S 2-2. Hirshfeld charge at selected centres. 
Entries  3aCl 3a+ 3a 3aTS 
1 N1 -0.054 -0.030 -0.060 -0.065 
2 N2 -0.033 -0.025 -0.041 -0.052 
3 C1 0.049 0.049 0.047 0.047 
4 C7 0.030 0.059 0.015 0.010 
5 C8 -0.067 -0.067 -0.069 -0.073 
6 C9 -0.046 -0.029 -0.066 -0.073 
7 C10 0.065 0.056 0.035 0.029 
8 C11 0.040 0.046 0.017 0.029 
9 C12 0.052 0.051 0.050 0.048 
10 O -0.174 -0.156 -0.342 -0.342 
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Figure S 2-9. Molecular electrostatic potential mapped on density of C2P3a (bottom) and 
C2P3aTS (top). 
 
Coordinates of C2P3a, C2P3aTS and Stenhouse salt 
 
Coordinates of C2P3a; total energy: -5189.75 kcal/mol; no imaginary frequencies 
N   16.512786    1.176104   12.364854 
H   15.592710    0.806535   12.563694 
N   15.867172    5.045410   18.421794 
H   14.979133    4.521719   18.367478 
C   16.296786    2.463325   14.393515 
C   16.996671    2.070286   13.276476 
H   17.985728    2.466648   13.075597 
C   15.975611    3.743743   16.489014 
C   17.098459    0.694197   11.195313 
C   16.757525    3.377710   15.352850 
H   17.741094    3.830756   15.237378 
C   18.366427    1.101333   10.740345 
H   18.952693    1.826173   11.294457 
C   16.608578    4.705794   17.366068 
H   17.590845    5.132552   17.209419 
C   16.087389    5.918761   19.482840 
C   16.378515   -0.247950   10.433647 
H   15.396160   -0.573972   10.771923 
C   17.271319    6.664803   19.627531 
10 
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H   18.071536    6.580200   18.899434 
C   18.885041    0.572922    9.560101 
H   19.866862    0.901046    9.225289 
C   16.412282    7.654918   21.670121 
H   16.540125    8.327010   22.514778 
C   15.071216    6.053497   20.448073 
H   14.153588    5.478897   20.341890 
C   16.909210   -0.764913    9.258057 
H   16.332500   -1.491004    8.689246 
C   18.169152   -0.360048    8.808778 
H   18.584128   -0.764276    7.889343 
C   17.421936    7.521941   20.714431 
H   18.342557    8.092906   20.813981 
C   15.236029    6.913561   21.527454 
H   14.439510    7.004802   22.262587 
H   15.303358    2.049018   14.570939 
O   14.818293    3.319858   16.785370 
 
Coordinates of C2P3a TS; total energy: -5184.09 kcal/mol; one imaginary: -74.022 cm-1 
N   16.445558    1.433217   12.195269 
H   15.438402    1.456503   12.111920 
N   15.671862    5.289695   18.245221 
H   14.695764    5.163909   17.924122 
C   16.184533    2.721265   14.219176 
C   16.960714    2.077882   13.287564 
H   18.040326    2.056111   13.385365 
C   15.811399    4.043662   16.279220 
C   17.102806    0.748654   11.176146 
C   16.671724    3.395007   15.354978 
H   17.743677    3.428734   15.542932 
C   18.502361    0.609667   11.111786 
H   19.141535    1.041592   11.873976 
C   16.487256    4.687975   17.388591 
H   17.559540    4.710041   17.555922 
11 
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C   16.009434    6.013321   19.422968 
C   16.321685    0.166933   10.156642 
H   15.237701    0.264425   10.190010 
C   16.240660    7.392199   19.354431 
H   16.183496    7.895578   18.392851 
C   19.085593   -0.090695   10.057830 
H   20.169009   -0.185919   10.027736 
C   16.594199    7.449759   21.747926 
H   16.819515    8.009100   22.652909 
C   16.067964    5.354636   20.656623 
H   15.878169    4.285348   20.700432 
C   16.918672   -0.527953    9.111990 
H   16.291159   -0.966484    8.339108 
C   18.308311   -0.664668    9.050930 
H   18.775194   -1.208096    8.233886 
C   16.533401    8.105162   20.517080 
H   16.710729    9.176715   20.459176 
C   16.361556    6.075127   21.814528 
H   16.404973    5.559217   22.771050 
H   15.100930    2.726963   14.093431 
O   14.543119    4.119676   16.240345 
 
Coordinates of Stenhouse salt; total energy: -5175.45 kcal/mol; one imaginary: -53.982 cm-1  
N  20.233217    3.341454   17.368225 
H  20.260394    2.352910   17.573358 
N  15.730302    5.991542   18.169819 
H  15.157757    6.382644   17.405203 
C  18.114180    3.005260   16.233745 
C  19.086838    3.815052   16.784932 
H  18.971558    4.891900   16.762342 
C  16.178138    4.618857   16.322468 
C  21.384714    4.050489   17.710104 
C  16.837686    3.447377   15.842524 
H  16.318524    2.895744   15.059111 
12 
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C  21.603224    5.385269   17.321983 
H  20.883826    5.905644   16.698865 
C  16.431048    4.954769   17.719303 
H  17.016516    4.364933   18.412590 
C  15.545113    6.381611   19.527894 
C  22.369623    3.400277   18.479489 
H  22.215364    2.367307   18.787581 
C  16.358284    7.374239   20.085568 
H  17.139280    7.827341   19.480559 
C  22.767896    6.042379   17.714455 
H  22.920277    7.073165   17.401466 
C  15.145838    7.193915   22.172336 
H  14.989838    7.510680   23.200887 
C  14.528700    5.798277   20.293790 
H  13.896360    5.034172   19.849196 
C  23.530233    4.066390   18.855053 
H  24.275381    3.541862   19.449174 
C  23.738196    5.397239   18.482109 
H  24.645216    5.918026   18.777170 
C  16.157968    7.774948   21.406825 
H  16.794002    8.545588   21.836368 
C  14.331919    6.207601   21.612723 
H  13.538574    5.754088   22.202652 
H  18.371464    1.959555   16.046126 
O  15.301850    5.296432   15.708443 
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Figure S 2-10.  HRMS of C2P4a.  
 
 
Figure S 2-11. HRMS of C2P4b.  
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Figure S 2-12. HRMS of C2P4c.  
 
 
Figure S 2-13. HRMS of C2P4d.  
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Figure S 2-14. HRMS of C2P5a.  
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Figure S 2-16. 1H NMR of compound C2P4a 
 
Figure S 2-17. 13C NMR of compound C2P4a 
5 
 
S5 | P a g e  
 
 
Figure S 2-18. 1H NMR of compound C2P4b 
 
Figure S 2-19. 13C NMR of compound C2P4b 
6 
 
S6 | P a g e  
 
 
Figure S 2-20. 1H NMR of compound C2P4c 
 
Figure S 2-21. 13C NMR of compound C2P4c 
7 
 




Figure S 2-22. 1H NMR of compound C2P4d 
 
Figure S 2-23. 13C NMR of compound C2P4d 
8 
 




Figure S 2-24. 1H NMR of compound C2P5a.  
 
Figure S 2-25. 13C NMR of compound C2P5a   
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Figure S 2-26. 1H NMR of compound C2P5b 
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3 Chapter 3 
 
3.1 Characterization spectra for compound 3.1‒HYFNIF 
 
CD of HYFNIF fibrils in water 
 
Figure S 3-1.  (a) The CD spectra of 2.4 x10-3 HYFNIF at 0 and 90 deg. (insert) The signal at 
275 nm (CD spectra) is attributed to the tyrosine residue. (b) Transmission electron microscopy 
images of HYFNIF amyloid fibres in water. 
 
Circular dichroism (CD) 
CD spectra were collected for samples AI - EI. The peptide solution in H2O-MeOH (1.26 mM), 
with and without metal sources, was monitored after one day incubation at 25 °C, using a Jasco 
J-715 spectropolarimeter with a Peltier temperature control system at 21 °C. Peptide samples 
(30 μl) were placed into 0.1-mm path length quartz cuvettes (Hellma), and scanned from 180-
320 nm.  The parameters were set as the following: a pitch of 0.1 nm, a scan speed 50 nm 
min−1, response time 4 s, slit widths 1 nm and with standard sensitivity. Each set of data was 
collected in triplicate. Spectrum of the blanks, H2O-MeOH with and without metal sources was 
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Figure S 3-2.  CD spectra of 1.26x10-3 M HYFNIF untreated (black) and treated with metal 
sources: 3.1 (red), Zn(NO3)2.6H2O (grey), Dy(NO3)3.6H2O (blue), Zn(NO3)2.6H2O-
Dy(NO3)3.6H2O (yellow), in Milli-Q H2O-MeOH and incubated for 24 h at room temperature. 
The CD signals reveal HYFNIF fibrils treated with Zn2Dy2 maintain the β-sheet secondary 
structure with significantly enhanced contribution from Tyrosine residues at 230 and 275 nm.  
 
 
Figure S 3-3. Figure S3.3. CD spectrum of the Coordination Compound 3.1 (Zn2Dy2) shows 
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NanoDrop UV-Vis spectroscopy 




-3 M in H2O-MeOH) using NanoDrop 




Table S 3-1. FESEM/EDX analysis showing the material composition of the film.  
 
Sample C N O Na Zn[a] Dy[a] 










0.27 ± 0.04 
wt%,  
0.15 At% 




0.08  wt%, 
0.01 At% 
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Figure S 3-4. Tyr-fluorescence plots for fibrils HYFNIF, 3.1‒HYFNIF, Zn‒Dy‒HYFNIF 
(upper) and 3.1 and plain metal salts Zn(NO3)2.6H2O and Dy(NO3)3.5H2O (lower) showing 
almost zero intensity.  
 
 
Scheme S 3-1. Possible coordination modes of the fibril. 
 
3.2 Monitoring catalysis 
To determine the catalytic ability of 3.1‒HYFNIF (AI), the procedure described below was 
applied to the synthesis of trans-4,5-diaminocyclopent-2-enones from 2‑furaldehyde and 
primary or secondary amines. The solvent mixture - H2O/MeOH - was evaporated (at 36◦C) 
from each peptide solution AI-DI, and the remaining precipitates (3.1‒HYFNIF, Zn‒HYFNIF, 
Dy‒HYFNIF, Zn‒Dy‒HYFNIF) were tested as catalysts. Three stock solutions, one of each 
substrate [S] in MeCN (2‑furaldehyde (0.5 M), morpholine (1.2 M) and aniline (1.2 M)) were 
used to prepare fresh working solutions of [S] 4.8 mM for 2-furaldehyde and 10.6 mM for each 
amine in MeCN-MeOH. Specifically, MeCN (dry, 200 μL), MeOH (50 μL), furfural (1.2 μmol, 
2.4 μL from the stock solution), amine (2.64 μmol, 2.4 μL from the stock solution) and the 
appropriate amount of catalyst (1 mol %), were added. 1H NMR spectra of the products were 
14 
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recorded in Chloroform-d for the reactions of 2-Furaldehyde ‒ Morpholine and 2-Furaldehyde 
‒ Aniline, catalysed by 3.1‒HYFNIF. The latter, shows the co-existence of both trans-4,5-
bis(phenylamino)cyclopent-2-enone and (1E,2Z,4E)-5-(phenylamino)-1-(phenyliminio)penta-
2,4-dien-2-olate in the solution. 
 
1 H NMR and HRMS Spectra for the purified Compounds C3P2a and C3P2b employing 
3.1‒HYFNIF as catalyst. 
 




S15 | P a g e  
 
 





S16 | P a g e  
 
 
Figure S 3-7. 1H NMR of C2P3a catalysed by 3.1‒HYFNIF (1 mol%).  
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4 Chapter 4 
4.1 Characterization spectra for compounds 4.1S, 4.1RS and 4.2 
 
 
Figure S 4-1. FT-IR of the ligand (H2L
22-S). 
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Figure S 4-3. ESI-FTMS of the catalyst (4.1S). m/z: ([M + H]+) calcd for CuC36H53N2O2, 
608.3402; found, 608.3409. 
 
 
Figure S 4-4. The CD spectrum of H2L
22-S in DCM (1 mM) at 0˚.  
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Figure S 4-5. The CD spectrum of 4.1S in DCM (1 mM) at 0˚. 
   
 
TGA  
Thermal studies for 4.1S and recovered 4.1RS, were conducted up to1000 and 800 °C 
respectively. For 4.1S.CH3CN (Figure S7) a continuous mass loss occurs from room 
temperature up to 140 °C, corresponding to the loss of the lattice solvent molecule. The 
remaining core is then immediately subjected to a further mass loss. The analysis for 1S (Figure 
S7) shows an initial mass loss which begins from 300˚C and agrees to one acetonitrile molecule 
(calc.: 4.7%, theor.: 4.8%). Decomposition of 4.1S to CuO follows at 330˚C (CuO residue calc.: 
12.2%, theor.: 12.2%). The recovered compound 4.1S.2CH2Cl2 shows an initial mass loss 
which occurs at 212 °C and corresponds in good agreement to the loss of two lattice 
dichloromethane molecules (calc.:9.8%, theor.: 10.2%). Subsequently, the complex undergoes 
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Figure S 4-7. UV-Vis time study of the catalyst (4.1S) (0.1 mM) upon addition of 
phenylacetylene (PA) in DCM, in the region of 280-750 nm. The ratio of 4.1S:PA is equal to 
1:50. The maxima at 381 nm correspond to MLCT, and the maxima at 562 nm are attributed 
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Figure S 4-8. UV-Vis time study of the recovered catalyst (4.1RS) (0.1 mM), after the first 
catalytic cycle, upon addition of phenylacetylene (PA) in DCM, in the region of 280-750 nm. 
The ratio of 4.1RS:PA is equal to 1:50. The maxima at 562 nm are attributed to the Cu(II) centre 
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Figure S 4-9. TGA of the recovered compound 4.1S after the fifth catalytic cycle (20-800˚C).  
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Figure S 4-11.  (upper) The redox CV of 4.1S in the presence of phenylacetylene. 4.1RS gave 
a similar pattern.  (lower)  
 
 
Figure S 4-12. ESI-FTMS of the compound [4.2]. m/z: ([M+H]+) calcd for CuC36H57N2O2, 
612.3715; found, 612.3655. 
 
  
-0.6 -0.4 -0.2 0 0.2 0.4 0.6 0.8 1 1.2
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Table S 4-1. Bond distances of Cu based compounds build with similar salen frameworks and 
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Table S 4-2. Bond distances comparison of 4.1S prior and post catalysis (4.1RS) 
 
 
Bond 4.1S 4.1RS 
Cu – N1 1.916(8) 1.920(8) 1.940(6) 1.920(5) 
Cu – N2 1.935(8) 1.928(8) 1.935(6) 1.926(5) 
Cu – O1 1.902(7) 1.896(7) 1.900(5) 1.889(5) 
Cu – O2 1.893(7) 1.879(7) 1.910(5) 1.882(5) 
1 1.307(13) 1.332(12) 1.300(9) 1.328(9) 
2 1.445(14) 1.420(13) 1.447(10) 1.439(10) 
3 1.359(15) 1.372(14) 1.400(10) 1.384(11) 
4 1.406(14) 1.409(14) 1.414(10) 1.395(10) 
5 1.370(14) 1.375(14) 1.361(10) 1.378(10) 
6 1.402(15) 1.432(15) 1.401(11) 1.436(10) 
7 1.434(14) 1.418(14) 1.440(10) 1.405(10) 
8 1.432(14) 1.409(14) 1.468(8) 1.443(10) 
9 1.297(12) 1.305(12) 1.292(10) 1.296(9) 
10 1.255(13) 1.265(12) 1.284(10) 1.292(9) 
11 1.451(14) 1.453(14) 1.472(8) 1.440(10) 
12 1.444(15) 1.424(14) 1.433(10) 1.419(10) 
13 1.462(14) 1.430(14) 1.438(9) 1.435(9) 
14 1.397(15) 1.399(15) 1.395(11) 1.377(10) 
15 1.419(14) 1.429(14) 1.407(10) 1.416(10) 
16 1.359(14) 1.365(15) 1.352(10) 1.380(10) 
17 1.393(15) 1.418(15) 1.421(11) 1.413(11) 
18 1.287(13) 1.305(13) 1.308(9) 1.326(9) 
19 1.477(10) 1.483(9) 1.468(8) 1.482(7) 
20 1.531(10) 1.516(10) 1.529(7) 1.518(9) 
21 1.490(9) 1.487(10) 1.472(8) 1.481(7) 
22 1.535(14) 1.533(14) 1.538(9) 1.535(10) 
23 1.535(16) 1.529(14) 1.535(10) 1.538(10) 
24 1.529(14) 1.550(14) 1.548(10) 1.545(9) 
25 1.537(15) 1.524(15) 1.541(9) 1.545(10) 
26 1.551(13) 1.540(12) 1.542(10) 1.526(11) 
27 1.548(14) 1.549(13) 1.536(9) 1.533(9) 
28 1.513(14) 1.547(14) 1.536(10) 1.551(10) 
29 1.557(13) 1.538(13) 1.539(10) 1.530(10) 
30 1.520(14) 1.508(15) 1.518(11) 1.533(10) 
31 1.543(15) 1.558(13) 1.549(9) 1.554(10) 
32 1.539(13) 1.526(12) 1.552(9) 1.545(9) 
33 1.546(14) 1.536(14) 1.537(10) 1.528(10) 
34 1.541(13) 1.534(14) 1.532(10) 1.523(10) 
35 1.530(13) 1.546(14) 1.540(10) 1.541(10) 
36 1.534(13) 1.536(13) 1.542(9) 1.535(9) 
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Table S 4-3. Bond Valence Sum analysis for 4.1S prior and post catalysis (4.1RS).20 
 
 






a 9.8640(2) 9.8842(2) 9.8778(2) 9.8707(4) 9.8532(4) 9.8859(4) 
b 13.6012(4) 13.5926(3) 13.5731(2) 13.5816(6) 13.589(10)5 13.5894(5) 
c 14.8446(3) 14.8655(4) 14.8563(2) 14.8795(8) 14.8669(7) 14.8650(4) 
Alpha 62.802(3) 62.813(2) 62.862(2) 62.815(5) 62.901(6) 62.850(3) 
Beta 73.297(2) 73.287(2) 73.333(2) 73.314(4) 73.467(4) 73.292(4) 
Gamma 78.658(2) 78.682(2) 78.744(2) 78.760(3) 78.768(5) 78.707(4) 





S29 | P a g e  
 
 
Figure S 4-13. Crude 1H NMR spectrum of the test reaction in the presence of TEMPO. The 
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4.2 Theoretical Calculations 
 
Figure S 4-14. Geometrical structures of all reactants, intermediates and products directly 
optimised in solution phase employing the PBE0/Def2-TZVP/PCM computational protocol. 
 
 
Table S 4-5.  Cartesian coordinates and energies of ll reactants, intermediates and products 









































Sum of electronic and zero-point Energies=           -561.020927 
 Sum of electronic and thermal Energies=              -561.007929 
 Sum of electronic and thermal Enthalpies=            -561.006985 








































Sum of electronic and zero-point Energies=           -485.102753 
 Sum of electronic and thermal Energies=              -485.091229 
 Sum of electronic and thermal Enthalpies=            -485.090285 

























































Sum of electronic and zero-point Energies=          -2673.307896 
 Sum of electronic and thermal Energies=             -2673.287347 
 Sum of electronic and thermal Enthalpies=           -2673.286403 
 Sum of electronic and thermal Free Energies=        -2673.357758 
 
[Cu(Salen)(HC≡CPh] 
Cu                    0.5942    0.01044  -0.8066  
 O                    -1.09572  -0.35696  -1.63645  
 O                     1.19078  -1.76932  -1.20937  
 N                     0.03031   1.76775  -0.16721  
 N                     2.36056   0.56919  -0.18007  
 C                    -2.09913   0.44737  -1.75666  
 C                    -3.23372   0.01788  -2.48882  
 C                    -4.33642   0.82105  -2.65497  
 H                    -5.18162   0.44879  -3.22504  
 C                    -4.38698   2.10744  -2.10188  
 C                    -3.30483   2.55289  -1.38367  
 H                    -3.31774   3.54468  -0.9412  
 C                    -2.15735   1.75926  -1.19504  
 C                    -1.0962    2.32658  -0.41928  
 H                    -1.29575   3.32146  -0.01809  
 C                     1.04761   2.38912   0.67671  
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 H                     0.98127   1.89338   1.65629  
 C                     0.9383    3.88921   0.88534  
 H                    -0.00941   4.13882   1.3691  
 H                     0.94805   4.39296  -0.08875  
 C                     2.09126   4.39403   1.74426  
 H                     2.01741   5.47913   1.85238  
 H                     2.0024    3.97196   2.75208  
 C                     3.43883   4.01168   1.15381  
 H                     4.24929   4.35173   1.80351  
 H                     3.57318   4.52105   0.19241  
 C                     3.55175   2.50679   0.94426  
 H                     4.51203   2.27556   0.47599  
 H                     3.53011   1.99207   1.9125  
 C                     2.40799   2.00486   0.08122  
 H                     2.47147   2.49367  -0.90165  
 C                     3.35944  -0.20837   0.02621  
 H                     4.27922   0.20729   0.44063  
 C                     3.3956   -1.61196  -0.25419  
 C                     4.57846  -2.30047   0.07609  
 H                     5.38314  -1.73828   0.541  
 C                     4.73298  -3.64129  -0.17506  
 C                     3.67709  -4.33173  -0.7855  
 H                     3.78068  -5.3913   -0.99637  
 C                     2.50974  -3.69131  -1.12495  
 C                     2.31272  -2.31074  -0.87098  
 H                    -3.20155  -0.97717  -2.91842  
 H                    -5.26019   2.7335   -2.2362  
 H                     5.64947  -4.15396   0.08889  
 H                     1.69654  -4.23109  -1.59734  
 C                    -3.38801  -0.97236   2.82472  
 C                    -4.75366  -1.14679   2.67626  
 C                    -5.24631  -2.04517   1.73849  
 C                    -4.36606  -2.77126   0.94669  
 C                    -2.99892  -2.60302   1.08828  
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 C                    -2.49628  -1.70031   2.03051  
 C                    -1.09035  -1.52285   2.17484  
 C                     0.09921  -1.3726    2.28925  
 H                    -3.00069  -0.27206   3.55509  
 H                    -5.43712  -0.57791   3.29589  
 H                    -6.31581  -2.17867   1.62419  
 H                    -4.74636  -3.47232   0.21282  
 H                    -2.30959  -3.16462   0.4696  
 H                     1.15272  -1.24736   2.39408  
 
Sum of electronic and zero-point Energies=          -2981.328467 
 Sum of electronic and thermal Energies=             -2981.299990 
 Sum of electronic and thermal Enthalpies=           -2981.299045 







































































Sum of electronic and zero-point Energies=          -2981.295048 
 Sum of electronic and thermal Energies=             -2981.265980 
 Sum of electronic and thermal Enthalpies=           -2981.265036 




4.3 Characterisation spectra of selected isolated the A3 Coupling products - 1H NMR, 
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Figure S 4-15. 1H NMR spectrum of propargylamine (C4Paaa) 
 
Figure S 4-16. 13C NMR spectrum of propargylamine (C4Paaa) 
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Figure S 4-18. 1H NMR spectrum of propargylamine C4Paba 
 
Figure S 4-19. 13C NMR spectrum of propargylamine C4Paba 
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Figure S 4-21. 1H NMR spectrum of propargylamine C4Paca 
 
Figure S 4-22. 13C NMR spectrum of propargylamine C4Paca 
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Figure S 4-24. 1H NMR spectrum of propargylamine C4Pada 
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Figure S 4-25. 13C NMR spectrum of propargylamine C4Pada 
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Figure S 4-27. 1H NMR spectrum of propargylamine C4Pafa 
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Figure S 4-28. 13C NMR spectrum of propargylamine C4Pafa 
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Figure S 4-30. 1H NMR spectrum of propargylamine C4Pbaa 
 
Figure S 4-31. 13C NMR spectrum of propargylamine C4Pbaa 
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Figure S 4-33. 1H NMR spectrum of propargylamine C4Pbca 
 
 
Figure S 4-34. 13C NMR spectrum of propargylamine C4Pbca 
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Figure S 4-35. HRMS (ESI-FTMS) m/z: ([M + H]+) calcd for C20H30N, 284.2378; found, 


















Figure S 4-37. 1H NMR spectrum of propargylamine C4Pbda.  
 
Figure S 4-38. 13C NMR spectrum of propargylamine C4Pbda. 
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Figure S 4-39. HRMS (ESI-FTMS) m/z: ([M + H]+) calcd for C18H26NO, 272.2014; found, 
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N,N-diallyl-1-phenyloct-1-yn-3-amine (C4Pbea) 
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Figure S 4-42. 13C NMR spectrum of propargylamine C4Pbea.  
 
Figure S 4-43. HRMS (ESI-FTMS) m/z: ([M + H]+) calcd for C20H28N, 272.2014; found, 
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Figure S 4-44. LCMS spectrum of propargylamine C4Pbea.  
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Figure S 4-45.  1H NMR spectrum of propargylamine C4Pcaa 
 
Figure S 4-46. 13C NMR spectrum of propargylamine C4Pcaa.  
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Figure S 4-47. LCMS spectrum of propargylamine C4Pcaa. 
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Figure S 4-49. 13C NMR spectrum of propargylamine C4Pdaa.  
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Figure S 4-50. LCMS spectrum of propargylamine C4Pdaa.  
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Figure S 4-51. 1H NMR spectrum of propargylamine 5dba.  
 
 
Figure S 4-52. 13C NMR spectrum of propargylamine C4Pdba   
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Figure S 4-54. 1H NMR spectrum of propargylamine C4Pdca 
 
 
Figure S 4-55. 13C NMR spectrum of propargylamine C4Pdca 
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Figure S 4-56. HRMS (ESI-FTMS) m/z: ([M + H]+) calcd for C21H23NF, 308.1814; found, 
308.1817 for C4Pdca. 
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Figure S 4-58. 1H NMR spectrum of propargylamine C4Peaa 
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Figure S 4-59. 13C NMR spectrum of propargylamine C4Peaa 
74 
 




Figure S 4-60. LCMS spectrum of propargylamine C4Peaa.  
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1-(1-(4-fluorophenyl)-3-phenylprop-2-yn-1-yl)azepane (C4Peca)  
 
 
Figure S 4-61. 1H NMR spectrum of propargylamine C4Peca 
 
 
Figure S 4-62. 13C NMR spectrum of propargylamine C4Peca 
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Figure S 4-63. HRMS (ESI-FTMS) m/z: ([M + H]+) calcd for C21H23NF, 308.1814; found, 
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Figure S 4-66. 13C NMR spectrum of propargylamine C4Paab 
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Figure S 4-67. LCMS spectrum of propargylamine C4Paab   
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4-(1-cyclohexyl-3-(4-methoxyphenyl)prop-2-yn-1-yl)morpholine (C4Padb) 
   
 
Figure S 4-68. 1H NMR spectrum of propargylamine C4Padb 
 
Figure S 4-69. 13C NMR spectrum of propargylamine C4Padb 
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Figure S 4-70. HRMS (ESI-FTMS) m/z: ([M + H]+) calcd for C20H28NO2, 314.2119; found, 
314.2119 for  C4Padb 
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1-(1-(4-methoxyphenyl)oct-1-yn-3-yl)pyrrolidine (C4Pbab) 
   
 
Figure S 4-72. 1H NMR spectrum of propargylamine C4Pbab 
 
Figure S 4-73. 13C NMR spectrum of propargylamine C4Pbab 
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Figure S 4-74. HRMS (ESI-FTMS) m/z: ([M + H]+) calcd for C19H28NO, 286.2170; found, 
286.2171 for C4Pbab. 
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Figure S 4-77. 13C NMR spectrum of propargylamine C4Pbdb 
 
 
Figure S 4-78. HRMS (ESI-FTMS) m/z: ([M + H]+) calcd for C19H28NO2, 302.2119; found, 

















Figure S 4-80. 1H NMR spectrum of propargylamine C4Pfda 
 
Figure S 4-81. 13C NMR spectrum of propargylamine  C4Pfda 
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Figure S 4-82. HRMS (ESI-FTMS) m/z: ([M + H]+) calcd for C21H24NO, 306.1857; found, 
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5 Chapter 5 
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Figure S 5-2. ESI-FTMS of the 5.1 in methanol. The main fragments accurately measured by 
ESI-MS at 604.0338 m/z and 407.9566 m/z show the presence of [Cu(L7)2(CF3SO3)]
+ and 
[Cu(L7)(CF3SO3)]
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Figure S 5-3. Experimental (upper) and theoretical (lower) accurately measured ESI-MS 
patterns at 407.9566 m/z show the presence of [Cu(L7)(CF3SO3)]
+ in solution. 
 
 
Figure S 5-4. Experimental (upper) and theoretical (lower) accurately measured ESI-MS 
patterns at 604.0338 m/z show the presence of [Cu(L7)2(CF3SO3)]









Figure S 5-5. UV-Vis of 5.1 (0.1 mM) in DCM, in the region of 250-900 nm shows a very 
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Figure S 5-7. Thermogravimetric analysis of 5.1 under N2 atmosphere. The initial loss of 
10.39% corresponds to two CH3CN lattice molecules (theoretical value 9.83%), while the final 
residue corresponds to Cu2O residue (theoretical value 17.12%).  
 
Cyclic Voltammetry 








Figure S 5-8. (upper) The cyclic voltammogram of 5.1 and 5.2. (lower) The cyclic 
voltamogram of 5.1 in the presence of phenylacetylene. 
 
Synthesis and characterization of 5.2.  
[CuII(bpy)2(CF3SO3)]
+ (5.2) was synthesized according to the reported procedure.21 ESI-FTMS 
of the 6 in methanol m/z: ([M]+) calcd for [CuC21H16N4F3O3S]
+, 524.0191; found, 524.0218.  
 
 
Figure S 5-9.  ESI-FTMS of the 5.2 in methanol. The main fragment accurately measured by 
ESI-MS at 524.0218 m/z show the presence of [CuII(bpy)2(CF3SO3)]
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5.2 Theoretical Calculations 
Geometry optimizations and further analysis were carried out using the Amsterdam Density 
Functional (ADF)1-3 program at the OLYP/ZORA/TZP 4-8 level of theory.  To obtain the singlet 
state, spin-restricted calculations were performed constraining the projection of the total 
electronic spin along a reference axis to 0. Frequency calculations were conducted to determine 
if each stationary point corresponds to a minimum.9-11 
 
 
5.3 Characterisation spectra of selected isolated the A3 Coupling products - 1H NMR, 






Figure S 5-10. 1H NMR spectrum of propargylamine C5Paga.      
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Figure S 5-11.  LCMS of propargylamine C5Paga 
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Figure S 5-12. 1H NMR spectrum of propargylamine C5Paha 
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Figure S 5-13. 13C NMR spectrum of propargylamine C5Paha 
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N-(1,3-diphenylprop-2-ynyl)benzenamine  (C5Pcga) 
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N-(1,3-diphenylprop-2-ynyl)-4-iodobenzenamine (C5Pcia) 
   
 
 
Figure S 5-16. 1H NMR spectrum of propargylamine C5Pcia 
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Figure S 5-17. 13C NMR spectrum of propargylamine C5Pcia 
 
 
Figure S 5-18. HRMS (ESI-FTMS) spectrum of the propargylamine C5Pcia in methanol.  
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Figure S 5-20. 1H NMR spectrum of propargylamine C5Pcja 
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Figure S 5-21. 13C NMR spectrum of propargylamine C5Pcja 
 
 










S110 | P a g e  
 
 








S111 | P a g e  
 
5.4 Mechanistic evidence  
Reaction with TEMPO 
 
Figure S 5-24. Crude 1H NMR spectrum in Chloroform-d, after catalyst removal, of the test 
reaction for C4Pcaa in presence of TEMPO. The spectrum shows the formation of the product 
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Experimental data supporting ligand dissociation during catalysis.  
 
 
Figure S 5-25. (upper) Crude 1H NMR in Chloroform-d spectrum of C5Paga reaction at 25°C 
after the catalyst (5.1) withdrawal. (lower) 1H NMR spectrum of the ligand L7. The crude 
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Figure S 5-26. LCMS spectrum of the crude reaction mixture for the synthesis of C5Paga by 
1, taken before reaction completion, shows the presence of dissociated L, ([M + H]+) C11H9N4 
at 197.1 m/z with Rt = 2.64 min along with propargylamine 5aaa,  ([M - H]
+) calcd for C21H22N, 
288.3, Rt = 3.32 min (for LCMS of the L and the purified propargylamine 5aaa (see Fig. S5-1 
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